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2. List of Abbreviations 
ABD Agonist-binding domain 
AKT Protein kinase B 
BFU-e Burst-forming unit-erythroids 
BMP-4 Bone morphogenic protein-4 
Ca2+ Calcium 
Ca2+-CaM Ca2+-calmodulin 
CaM K Ca2+/calmodulin-dependent protein kinase 
CaM KII CaM kinase II 
CFU-e Colony-forming unit-erythroids 
CFU-GEMM Colony-forming unit-granulocyte, erythrocyte, 
monocyte/macrophage, megakaryocyte 
CREB Cyclic-AMP response element binding protein 
CTA Clinical trial approval 
CTD Carboxyl-terminal domain 
DAG Diacylglycerol 
DAPK-2 Death associated protein kinase-2 
EPCs Erythroid precursor cells 
Epo Erythropoietin 
EpoR Erythropoietin receptor 
ER Endoplasmic reticulum 
Flt-3 Fms-like kinase-3 
FOG-1 Friend of GATA-1 
GCs Glucocorticoids 
GM-CSF Colony-stimulating factor 
Hb Hemoglobin 
HDAC Histone deacetylase 
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HU Hydroxyurea 
IGF-1 Insulin-like growth factor-1 
IL Interleukin 
IP3 Inositol(1,4,5)P3 
JAK2 Janus kinase 2 
Klf-1 Krüppel-like factor-1 
koff Dissociation rate constant 
NSCC Non-selective cation channel 
NMDAR N-methyl-D-aspartate receptor 
NO Nitric oxide 
NTD Amino-terminal domain 
PI3-kinase Phosphatidylinositol 4,5-bisphosphate 3-kinase 
PIP2 Phosphatidylinositol 4,5-bisphosphate 
PKC Protein kinase C 
PLC-ɣ1 Phospholipase C ɣ1 
PoC Proof of concept 
Pu.1 Putative oncogene Spi-1  
RBCs Red blood cells 
SCD Sickle cell disease 
STAT-5 Signal Transducer and Activator of Transcription-5 
TDM Transmembrane domain 
TFs Transcription factors 
TRPC Transient receptor potential channel 
VCAM-1 Vascular cell-adhesion molecule-1 
VDAC Voltage-dependent anion channel 
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2. Summary 
This project was based on a pilot study indicating that N-methyl-D-aspartate receptors 
(NMDARs) are expressed in rat erythroid precursor cells (EPCs) and present in both, 
circulating rat and human red blood cells (RBCs). Furthermore, assessment of this 
receptor’s activity in RBCs of sickle cell disease (SCD) patients revealed that calcium 
(Ca2+) overload is likely to be due to the pathological up-regulation of receptor 
abundance and activity in them. The present study was focused on the characterization 
of NMDARs on the molecular and functional level during erythropoietic maturation. 
EPCs of healthy humans and SCD patients were studied ex vivo. These findings were 
then bridged with the data obtained from the NMDARs in mature RBCs. The data 
revealed the changes in the NMDAR subunit composition mirrored by the change of 
the functional properties during differentiation. Functional NMDARs were shown to be 
required for survival of the erythroid precursor cells. They prevented cells from undergo 
apoptosis. In particular, this protecting effect was present at the proerythroblastic 
stage. Furthermore, no significant difference was observed in the expression of 
NMDAR subunits during differentiation of the precursor cells of healthy humans and 
SCD patients. However, in the circulating RBCs of asymptomatic patients, the number 
of active receptors exceeded that in cells of healthy donors by 5 to 10-fold. Inhibition 
of the receptors with pore-targeting antagonist Memantine substantially reduced the 
dehydration of RBCs and decreased the risk of sickle cell transformation. At the same 
time, EPCs of SCD patients were less sensitive to Memantine than proerythroblasts of 
healthy humans. These results suggested that inhibition of the NMDARs in RBCs of 
SCD patients may be beneficial. The reduction of Ca2+ uptake could decrease 
dehydration, increase RBC life span, and reduce the risk of thrombosis. Based on 
these findings, a clinical trial in which Memantine is to be used for treatment of a small 
cohort of patients is in preparation. 
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3. Zusammenfassung 
Das Projekt basiert auf einer Pilotstudie die zeigte, dass N-methyl-D-aspartat 
Rezeptoren in erythropoietischen Zellen von Ratten und Menschen zu finden sind. 
Zudem wurde festgestellt, dass Patienten mit einer erhöhten intrazellulären Kalzium 
Konzentration in den Erythrozyten eine gesteigerte Aktivität der Rezeptoren 
aufweisen. Das Ziel der vorliegenden Arbeit war es, die Zusammensetzung und die 
Eigenschaften der Rezeptoren während der Erythropoiese von gesunden Probanden 
und Sichelzellenanämie-Patienten zu untersuchen. Die Ergebnisse wurden 
anschliessend mit den Daten über die Struktur und die Funktion des Rezeptors aus 
den roten Blutkörperchen verknüpft. 
Die Ergebnisse zeigten, dass sich die Zusammensetzung der Rezeptoruntereinheiten 
während der Differenzierung der Erythrozyten verändert. Es konnte gezeigt werden, 
dass die N-methyl-D-aspartat Rezeptoren vor allem für das Überleben der 
Proerythroblasten und der basophilen Erythroblasten entscheidend sind. Ebenfalls 
wurde gezeigt, dass sich die Rezeptorexpression während der Erythropoiese in 
gesunden Probanden nicht massgeblich von Sichelzellenanämie-Patienten 
unterscheidet. Nichtsdestotrotz wurde klar beobachtet, dass in roten Blutkörperchen 
von Patienten die Anzahl von aktiven Rezeptoren fünf bis zehn mal grösser ist als im 
Vergleich zu gesunden Probanden. Die Inhibition dieser aktiven Rezeptoren mit dem 
Antagonisten Memantin bewirkte eine Reduktion der Dehydration und die damit 
assoziierte typischen Verformung der Erythrozyten. Gleichzeitig wurde gezeigt, dass 
die erythropoietischen Vorläuferzellen von Patienten, im Gegensatz zu den Zellen von 
gesunden Probanden, weniger sensitiv auf Rezeptorantagonisten reagieren. 
Diese Ergebnisse legen nahe, dass sich die Inhibition dieser N-methyl-D-aspartat 
Rezeptoren in Erythrozyten positiv auf den Kalziumspiegel der roten Blutkörperchen 
auswirkt und damit nicht nur die Lebensdauer der Zellen, sondern auch die 
gesundheitliche Situation der Patient erheblich verbessert werden kann. Basierend auf 
diesen Resultaten ist eine klinische Studie mit den Rezeptorantagonisten Memantin 
als neue Therapie für Sichelzellenanämie in Planung. 
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4. Introduction 
Red blood cells (RBCs) are responsible for oxygen transport in multiple invertebrate 
species and all vertebrates. 1 In humans, erythrocytes deliver oxygen highly efficient 
from the lungs to the hypoxic periphery. On the way back to the lungs, erythrocytes 
transport carbon dioxide as bicarbonate. In addition, RBCs have recently shown to play 
an active role in the regulation of vascular tone. In mammals, unlike other species, 
mature RBCs are deprived of essential organelles, including nucleus, endoplasmic 
reticulum (ER), and mitochondria. This terminal transformation of erythroid precursor 
cells (EPCs) occurs at the final stage of their differentiation, namely before 
reticulocytes are released into the circulation. Despite the inability to synthesize new 
proteins, these remarkable cells are able to tolerate stressful conditions such as shear 
stress, oxidative stress, and resist to a rather broad range of pH and osmolality 
change. 2 They can rapidly adapt to a harsh environment, which would seriously 
damage most other cells in the body. The adaption to those stress conditions is 
mediated by the release of several hormones (such as catecholamines, insulin, and 
erythropoietin), inflammatory factors, and gasotransmitters. These signals are sensed 
by the erythrocytes and trigger adjustments in cell volume, metabolic rate, production 
of free radicals (radical oxygen species: ROS) and antioxidants including nitric oxide 
(NO). Finally, those adjustments can modulate the oxygen carrying capacity of 
hemoglobin (Hb). 
Recent studies revealed the presence of N-methyl-D-aspartate receptors (NMDARs) 
in membranes of rat and human RBCs making these cells responsive to changes in 
glutamate and glycine concentrations. 3-5 These ligand-gated ion channels exhibit a 
high permeability to Ca2+ ions. NMDARs are voltage, pH, mechano-sensitive and 
require both, glutamate and glycine for full activation. A change in any of these factors 
may generate Ca2+-driven signals in erythroid cells. The number of NMDAR in 
circulating RBCs of rats and humans is low (4-30 per cell on average), which does not 
allow to investigate the subunit composition of the receptor, but enabling receptor 
activity measurements, however. 
As most of the receptors, NMDARs appeared to be highly abundant in the Epo-
dependent human erythroleukemia cell line UT7. 6 These data suggested that the 
NMDAR-driven signaling might be actively involved in the differentiation of erythroid 
cells. Thus, EPCs are the cells to choose for studies of the origin and diverse 
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physiological roles of any channels including the NMDA receptors in the formation of 
RBCs and their adaptation to varieties of conditions when in the circulation. 
 
 
4.1. Ex vivo erythropoiesis systems 
In adult humans around 1010 erythrocytes are produced and released into the 
circulation every hour. 7 Prenatal hematopoiesis appears first with precursor cells in 
the yolk sac, followed by the blood formation in the fetal liver and the spleen. During 
the prenatal development the bone marrow takes progressively over the entire RBCs 
production. Postnatal, the hematopoiesis occurs in the columna vertebralis, pelvis, 
sternum, ribs, tibia, and femur. While in adults, erythrocyte formation only takes place 
in the pelvis, cranium, vertebrae, and sternum. 8 Due to the poor accessibility of the 
EPCs for research, several ex vivo cell culture systems were developed within the past 
years. This made it much easier to study the process of erythropoietic maturation. 9-11 
These systems include isolation of CD34+ cells and the differentiation under 
humanized in vitro cell culture conditions as described elsewhere. 3,5,9 EPCs undergo 
gradual transformation from CD34 expressing burst-forming unit-erythroids (BFU-e) to 
enucleated reticulocytes representing a robust and reproducible ex vivo erythropoietic 
maturation system (Figure. 1A, B).  
These differentiation steps correspond to most of the stages that pluripotent stem cells 
undergo within the bone marrow where a relatively small number of pluripotent stem 
cells generate all the different lineages of hematopoietic cells. In the erythroid lineage, 
the multipotential myeloid stem cells differentiate into BFU-e and further differentiate 
into the rapidly proliferating colony-forming unit-erythroids (CFU-e) (Figure 1A). CFU-e 
cells undergo three to five cell divisions before they differentiate into proerythroblasts, 
basophilic erythroblasts, and polychromatic erythroblasts. Morphologically 
erythroblasts at various differentiation stages differ from each other in their hemoglobin 
content and the size of their nucleus (Figure 1A, 1B). 12 Polychromatic erythroblasts, 
which are still capable for proliferation, are turning into orthochromatic erythroblasts. 
They undergo enucleation and lose other cell organelles during the differentiation to 
reticulocytes. The latter are released into the circulation where they turn into mature 
erythrocytes within the next few days. Complex processes associated with 
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differentiation of EPCs are coordinated by growth factors, hormones, and miRNAs. 
These signals are sensed by receptors, transcription factors, cofactors, second 
messengers and target proteins. 7,13 
 
Figure 1A: Erythropoietic maturation with expression of selected receptors and membrane-
bound proteins (adapted from Spivak JL, 2005. 14). Hematopoietic stem cells (HSC) (CD34+ and 
CD117+) differentiate gradual to CFU-GEMM (CD38+ and CD34+) and to the most immature BFU-e 
(CD34+, CD117+, CD71+, and low EpoR expression) from the erythroid linage. BFU-e further differentiate 
to CFU-e (CD34-, CD117+, CD71+, and high EpoR expression) and proerythroblasts (CD117+, CD71+, 
and EpoR+). Only HSC and proerythroblasts are shown. During proceeding maturation proerythroblasts 
differentiated to basophilic erythroblasts (CD117+, EpoR+, CD71+, and CD235a+), polychromatic 
erythroblasts (CD117-, EpoR-, CD71+, CD235a+, and hemoglobin accumulation), and the first non-
dividing EPC-type polychromatic erythroblasts (CD71+ and CD235a+). After enucleation reticulocytes 
(CD71+ and CD235a+) differentiate to fully mature erythrocytes (CD71- and CD235a+). B: Ex vivo 
erythropoietic maturation. Mononuclear cells (CD34+) were isolated from peripheral blood samples, 
cultured and differentiated in a 2-phase liquid system up to 21 days until they reached the stage of 
enucleated and mature erythrocytes. Detailed protocol is described elsewhere. 3,5,15 
 
At various stages differentiation of erythroid cells is controlled by the downstream 
signaling cascades of a number of receptors. Those receptors found to be essential 
and sufficient to drive ex vivo erythropoiesis are listed in Table 1.  
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Table 1: Selection of downstream signaling cascades during erythropoietic 
maturation 13,16,17 
Differentiation 
stage/cell type 
Markers 
expressed 
Factors 
required 
Receptors 
involved 
Ex vivo 
erythropoiesis 
system 
equivalents 
LT-HSC (long-
term 
hematopoietic 
stem cell) 
 Wnt, Notch-L 
(Jagged 1 and 2, 
Delta1), Shh and 
BMP-4, SCF, 
Tpo, IGF-2, 
FGF-1 
Glutamate? 
CD117 (c-Kit), 
MPL, 
Flt3, 
IL receptors, 
Notch, 
Frizzled, 
BMP-R, 
NMDAR?  
 
 
 
 
 
 
 
ST-HST (Short-
term 
hematopoietic 
stem cell) 
IL-7R-, 
c-mp1+ 
SCF, IL-6, Flt3L, 
G-CSF, Tpo, IL-
1, IL-11, IL-12, 
LIF (?) 
Glutamate? 
CD117 (c-Kit), 
Flt3R, LR6, MLP, 
IL11R, 
NMDAR? 
(UT7/Epo) 
CMP (common 
myeloid 
precursor) or 
CFU-GEMM  
CD34+, CD38+, 
IL-3Rα, CD45RA- 
 
 
 
 
 
Epo, SCF, IL-6, 
IGF-1, Tpo, IL-9, 
IL-3, Epo, TNFα, 
Glutamate? 
 
 
 
 
 
EpoR, c-Kit, 
IL3R, IL6R, 
IGF-R, c-MPL,  
EpoR, IL3R, 
NMDAR? 
(UT7/Epo) 
BFU-E CD71+, CD117+ Flt-3 Ligand, SCF, 
IL-3, IL-6, 
dexamethasone, 
estradiol 
Erythroblasts CD71+, CD235a+ Epo, IL-3, SCF, 
glutamate/glycine 
Reticulocytes  Glutamate NMDAR Glutamate/glycine 
RBCs  Glutamate NMDAR 
 
Table legend: SCF stem cell factor, BMP-4 bone morphogenic protein, CSF colony-stimulating factor, 
Tpo thrombopoietin, EpoR erythropoietin receptor, IL interleukin, IGF-1/2 insulin-like growth factor 1/2, 
Flt3L Fms-related tyrosine kinase 3 ligand, Shh sonic hedgehog, Wnt Wingless, FGF fibroblast growth 
factor, MPL thrombopoietin receptors/myeloproliferative leukemia protein or CD110  
Receptor (Ligand): Notch (Jagged/Delta), c-Kit (SCF), Frizzled (WNT proteins), Flt3R (Flt3L), IGFR 
(IGF2), FGFR (FGF), gp130/IL6R (IL6), β-chain/IL3R (IL3), c-MPL (Tpo), G-CSF-R/CD114 (CSF), EpoR 
(Epo) 
 
In the first step a 100-1000-fold expansion of CD34+ cells is achieved in the presence 
of IL-3, IL-6, SCF, Flt3L, dexamethasone, and estradiol in the culturing medium. Within 
the first five days most of cells reach the proerythroblastic stage. Within the next ~15 
days, the cells undergo further differentiation steps, turning from proerythroblasts into 
basophilic, polychromatic, and orthochromatic erythroblasts and finally to enucleated 
reticulocytes in the presence of SCF, IL-3, and erythropoietin (Epo). In the culture 
media, both glutamate and glycine are present along with other essential amino acids. 
Whether glutamate and/or glycine are involved in proliferation and differentiation of 
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EPCs is unknown. To answer this question the information on temporal expression 
pattern and the subunit composition of the receptor is required. The channel properties 
including the current amplitude, deactivation time and ion preferences are determined 
by the subunit composition. Most of the receptor subtypes are showing high Ca2+ 
selectivity and their activation results in Ca2+ uptake. 
The presence of NMDAR in erythroid cells therefore would imply that glutamate release 
within bone marrow and the erythroblastic islands triggers induction of Ca2+-sensitive 
signaling pathway(s). Extracellular Ca2+ was reported to be required to support 
survival, proliferation and differentiation of EPCs. 18,19 However, molecular 
mechanisms of Ca2+-dependent signaling have not yet been identified and the 
molecular identity of Ca2+ transport pathways, including ion channels, remains largely 
unknown. In the following, chapters the current state of research in the field are 
presented in more detail. They will cover some aspects of regulation of erythropoiesis, 
updates of ion channels in erythroid cells in health and diseases, and finally, some 
insights into the NMDAR properties and their possible physiological role. 
 
 
4.2. Receptors in erythroid cells and their role in 
erythropoiesis 
Most of the findings on the role of Ca2+ in control of erythropoiesis cover erythropoietin 
receptor-driven erythropoiesis. Therefore, these differentiation stages are covered 
below in more detail. 20,21 Epo (humoral erythropoietic factor 'hémopoïétine') was 
discovered to stimulate erythropoiesis in rabbits after bleeding in 1905 by Paul Carnot 
and Clotilde Deflandre. 22 Following the Epo gene identification in 1985 the first 
recombinant Epo was licensed and produced by Amgen Inc., Thousand Oaks, USA. 
Since then, Epo has been used both to treat anemia and illegally to improve sport 
performance, particularly by endurance athletes. At present Epo is viewed as a 
pleiotropic glycoprotein hormone that interacts with homodimeric (classical) and most 
probably also heterodimeric (non-classical) receptors in multiple locations. 23 However, 
its main function in concordance with other growth factors (Tpo, SCF, IL-3, and IL-6, 
see Table 1) is associated with stimulation of erythrocyte production. Even after 70 
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years of intensive research, the mechanism of erythropoiesis is still hiding many 
secrets including the role of amino acids in it. 24 
 
4.2.1. Erythropoietin and erythropoietin receptor 
Erythropoietin and its homodimeric erythropoietin receptor (EpoR) are the main 
hormonal regulators of erythrocyte production. Each receptor subunit consists of a 
single transmembrane domain. The EpoR dimerizes upon the interaction with Epo and 
triggers several signaling cascades essential for cell survival, proliferation, and 
differentiation. 25,26 The highest expression levels of EpoR was shown in CFU-e and 
proerythroblasts (up to 1100 receptors per cells) decreasing steadily thereafter. 27,28 It 
was long believed that reticulocytes and mature RBCs are completely deprived of the 
EpoR and therefore insensitive to the plasma-borne Epo. However, recent data 
suggest that the circulating RBCs, particularly reticulocytes, may retain several copies 
of the receptor. 29 These retaining receptors are most likely involved in regulation of 
clearance of young RBCs, a process known as neocytolysis. 30,31 
 
4.2.2. Epo-activated signaling pathways and calcium 
The dimerized receptor undergoes auto-phosphorylation of tyrosine residues within the 
cytosolic domain. These steps are followed by activation of Janus kinase 2 (JAK2), 
Signal Transducer and Activator of Transcription 5 (STAT5), RAS, phosphatidylinositol 
4,5-bisphosphate 3-kinase (PI3-kinase), and Ca2+ channels (Figure 2). 26 Thus, Ca2+ 
uptake is initiated by Epo binding its receptor. Table 2 summarizes Ca2+-dependent 
processes involved at various stages of differentiation, proliferation and protection from 
apoptosis. 
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Table 2: Ca2+-dependent processes during erythropoietic maturation 
Process Target regulation Physiological role Erythropoiesis 
Metabolism 
 
Mitochondria 
 
 
Glycolytic enzymes 
Transmembrane potential, 
reactive oxygen species 
generation, oxidative 
phosphorylation efficiency 
Epo stimulates 
oxidative 
phosphorylation (32) 
Cell cycle 
(proliferation) 
 
c-fos, c-Jun expression 
(Ca2+ ?) 
cyclin D expression 
(CaM K), CDK2 and 
CDK4 (CaM K) 
nuclear translocation of 
transcription factors (33) 
Stimulation of proliferation 
 
 
G1->S phase in cell cycle 
(34) 
Proliferation of 
erythroid precursor 
cells 
Cell fate 
(differentiation)  
Apoptosis 
c-myb expression, 
Hemoglobin/β-globin 
production CREB and 
NFAT phosphorylation 
(CaM-calcineurin) 
 
Ca2+-sensitive 
endonuclease 
Differentiation Differentiation 
 
 
 
 
 
Apoptosis 
Proteolysis Ca2+-dependent 
proteases (μ-calpain) 
Multiple targets 
(cytoskeleton, metabolic 
proteins, ion transporters, 
signaling proteins…) (35-
37) → Differentiation 
Differentiation 
Signaling PKC-α (38) 
calciueurin 
Differentiation Differentiation 
Iron metabolism Transferrin endocytosis 
and iron uptake (Ca2+-
CaM) 
Hemoglobin synthesis Ca2+-CaM is 
required to support 
Fe uptake into 
erythroid precursors 
(39)  
Epo-driven signaling 
cascades 
Opening of TRP 
channels 
IP3-kinase → PLC → 
DAG cascade (Ca2+-
CaM) 
Differentiation  Differentiation 
 
References are given in brackets ().  
One of the pathways, which is essential for erythropoiesis, is the JAK2 signaling 
cascade. 40 After the trans-phosphorylation of JAK2, the kinase phosphorylates the 
tyrosine residues of the EpoR. STAT5 binds to the phosphorylated EpoR and gets 
phosphorylated by JAK2. The transcription factor then dissociates from the receptor, 
dimerizes, and translocates to the nucleus. 26 
A second downstream pathway of the EpoR is the Ras cascade. The binding of the 
cytoplasmic adaptor protein Grb2 and the Ras guanine nucleotide exchange factor 
SOS, leads to the translocation of SOS and the associated activation of 
Shc/Ras/Mitogene-activated kinase (MAPK) pathway. 26,41-43  
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Figure 2: Schematic overview of the major erythropoietin signaling pathways in erythroid cells. 
After Epo-EpoR binding, dimerization, and tyrosine phosphorylation, the JAK2 tyrosine kinase gets 
activated and induces (blue arrows) several downstream pathways including MAPK pathway, STAT5, 
PLC-ɣ1, PI3-kinase, and transient receptor potential channel (TRPC) activation (green arrows).  
 
A third pathway which gets activated by Epo is the PI3-kinase pathway: 44 PI3-kinase 
generates phosphatidylinositol 3-phosphate, phosphatidylinositol 3,4-bisphosphate, 
and phosphatidylinositol (3,4,5)-trisphosphate. 45 Theses second messengers activate 
the serine/threonine-specific protein kinase B (AKT) and p70s6k which mediate mRNA 
transcription and translation by phosphorylation of ribosomal proteins. 26,46,47 Binding 
of Epo to its receptor in EPCs results in activation of several other signaling cascades 
and turns on a variety of transcription factors (TFs). One of these signaling cascades 
is initiated by the activation of the phospholipase C-ɣ1 (PLC-ɣ1). 26 PLC-ɣ1 triggers 
cleavage of phosphatidylinositol 4,5-bisphosphate (PIP2) to diacylglycerol (DAG) and 
inositol(1,4,5)P3 (IP3). Binding of IP3 to its receptor causes a release of Ca2+ from 
endoplasmic reticulum (ER), followed by the activation of downstream Ca2+-sensitive 
cytosolic targets, including classic and novel protein kinase C (PKC) isoforms and 
Ca2+-calmodulin-sensitive processes. 44,45,48 Release of Ca2+ from the ER storage was 
shown to control apoptosis of CD34+-derived EPCs. 49 This occurs partially due to the 
mitochondrial Ca2+ overload as well as via the regulation of Ca2+-calmodulin- (Ca2+-
CaM) dependent death associated protein kinase-2 (DAPK-2). 21 The Ca2+-CaM 
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complex can interact with 4.1R protein, a major structural element of the cytoskeleton 
in erythrocyte. This interaction causes the binding of 4.1R protein to the anion transport 
protein band 3 and the transmembrane protein glycophorin C. Thereby, Ca2+ and its 
signaling cascades are taking part in RBC membrane biogenesis during terminal 
erythroid differentiation. 50 Ca2+-CaM binding to the CaM kinase II (CaM KII) results in 
phosphorylation of IP3-kinase, which in turn phosphorylate multiple targets including 
IP3 to IP4. Ca2+-signaling originating from the ER regulates amongst other cellular 
processes, the regulation of the expression of the transient receptor potential channel 
3 and 6 (TRPC). 51 These channels were shown to be involved in regulation of the 
intracellular Ca2+ in precursor cells during erythropoietic maturation. 18 After the Epo-
Epo receptor dependent activation, the channels cause the required Ca2+ influx in 
CFU-e cells and proerythroblasts. 52,53  
 
4.2.3. Growth factors and membrane-bound proteins 
Besides the Epo-Epo receptor interaction, several other interactions of cytokines and 
growth factors with membrane-bound receptors are essential for erythropoietic 
maturation. The expression of surface receptors and membrane-bound proteins are 
quite specific for the different stages of maturation (Figure 1). 
Although the antigen CD34 is regularly used to identify hematopoietic stem cells, its 
function is still not fully understood. This glycoprotein is only expressed in erythroid 
cells until BFU-e stage; it contributes to self-renewal and inhibits differentiation of early 
stage EPCs. 54 SCF binds to the c-kit receptor (CD117) and promotes proliferation and 
self-renewal of CD34+ cells, CFU-e cells, proerythroblasts, and basophilic 
erythroblasts by induction of Myc. 55,56 Similar to the Epo-EpoR signaling, the binding 
of SCF to CD117 promotes dimerization of the receptor subunits and 
autophosphorylation of the receptor. Moreover, the activated c-kit receptor has a highly 
similar downstream signaling cascade, which includes PLC-ɣ, PI-3 kinase, Grb2, and 
the MAPK pathway. 55,57,58 Both signaling pathways have synergetic effects, are 
potentially Ca2+-dependent, and are required for erythropoiesis. Nonetheless, the 
interaction of Epo and SCF signaling is not fully understood. 59,60 
The transferrin receptor protein 1 (CD71) is expressed in EPCs during the whole 
erythropoietic maturation. CD71 expression is highest in basophilic, polychromatic, 
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and orthochromatic erythroblasts and decrease in reticulocytes. CD71 is essential for 
the uptake of the iron-transferrin complex. 61 The heavily glycosylated glycophorin A 
(CD235a) provides erythroid cells with hydrophilic surface. The surface expression of 
CD2351a increases in proerythroblasts and remains high even in mature 
erythrocytes. 62 Interleukin-3 (IL-3), Granulocyte macrophage colony-stimulating factor 
(GM-CSF), and SCF contribute to the early differentiation steps from a colony-forming 
unit-multipotential myeloid stem cell (CFU-GEMM) cell to a BFU-e and CFU-e 
cell. 13,20,63,64 Another factor that triggers self-renewal of BFU-e over terminal 
differentiation is the bone morphogenic protein-4 (BMP-4), which induces the 
expression of Smad5, SCL/Tal-1, and GATA-2. This member of the TGF-β family is 
essential for the stress-induced erythropoiesis and enhanced production of 
erythrocytes by increasing the number of BFU-e cells. 65-67 Thrombopoietin is neither 
limited to megakaryocyte differentiation nor platelets production. 68,69 Together with 
Fms-like tyrosine kinase-3 (Flt-3) ligand, thrombopoietin are important for maintenance 
of common myeloid progenitors and CFU-GEMM. 70,71 Insulin and insulin-like growth 
factor-1 (IGF-1) are required for the differentiation of BFU-e and CFU-e and they 
stimulate the maturation of polychromatic erythroblasts. 72-74 This overlapping 
expression stage with the EpoR, might suggest some interaction with the Epo signaling 
pathway, but the exact mechanism of possible co-regulation remains unclear. Even 
less is known about the role of Fas ligand receptor in erythroid cells. The receptor of 
the tumor necrosis factor family is a known trigger of caspase activation and apoptosis 
in other cell types. However, recent studies imply that in the EPCs, the Fas ligand 
induce positive signals for erythropoietic maturation. 75 
While the early stages of terminal erythropoietic maturation (BFU-e cells to 
polychromatic erythroblasts) is highly Epo-dependent, the later differentiation stages 
are integrin-dependent. The interaction of integrin with the extracellular matrix protein 
fibronectin is required for the last cell divisions of polychromatic erythroblasts and 
triggers enucleation of reticulocytes. 13,76 Furthermore glucocorticoids (GCs) stimulate 
the stress-induced erythropoiesis by increasing the number of CFU-e cells and protect 
the BFU-e cells. 13 GCs enhance the expression of the transcription factors involved in 
self-renewal of BFU-e cells (Myb and LMO-2) and impair GATA-1 expression, which 
promotes terminal differentiation. 77,78 
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4.3. Transcriptional and posttranscriptional regulation of 
erythropoietic maturation 
Several transcription factors (TFs) involved in erythropoietic maturation have been 
described extensively in the literature. Some of them maintain the self-renewal of the 
erythropoietic cells, while others induce the various differentiation steps. Nevertheless, 
analogue to the functions of growth factors and their complex interplay, the 
transcriptional regulation with all of the posttranscriptional modifications are only 
partially understood. 
 
4.3.1. Transcriptional regulation 
The regulation and the complex interplay of transcription factors, cofactors, miRNAs, 
and post-translational histone modifications have been studied for years. The number 
of crucial transcriptional regulators is relatively small, but arrangement with various 
cofactors and the mechanism of how those multiprotein complex regulate gene 
expression is far less understood (Figure 3). 
 
 
Figure 3: Transcriptional and posttranscriptional regulation of the erythropoietic maturation 
(adapted from Hattangadi et al. 13). Selection of transcription factors, DNA-binding factors (both in 
green), microRNAs (in red), and growth hormones/factors (in blue) which influence erythroid maturation. 
The pentameric complex of GATA-1, LMO-2, SCL/Tal-1, Ldb-1, and E2A triggers terminal maturation, 
while the GATA-2 variant of this complex activates c-kit transcription and self-renewal. At various stages, 
microRNAs (miRs) trigger the self-renewal of EPCs or differentiation, including the enucleation and 
formation of the condensed nucleus embedded in a cytoplasmic layer (pyrenocyte), respectively. 12 
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Two of the best studied TFs involved in erythropoiesis are GATA-1 and GATA-2. The 
two homologues zinc-finger domains of those TFs bind to the DNA consensus 
sequence ((A/T)GATA(G/A)) in many erythroid genes, including the genes of band 3 
protein, globins, and EpoR. GATA-2 is expressed in early EPCs and contributes to the 
expansion and cell survival of those cells. 79 If GATA-2 expression is high and GATA-1 
is low, the terminal maturation of EPCs is blocked and early EPCs proliferation is 
increased. Next to GATA-2 the proto-oncogene c-Myb and putative oncogene Spi-1 
(Pu.1) block terminal differentiation and promote self-renewal of early EPCs. 
Furthermore, for the differentiation of pluripotent hematopoietic stem cells in to 
erythroid linage, the relative ration of Pu.1 and GATA-2 is crucial. Low expression of 
GATA-2 and high expression of Pu.1 lead to the formation of myeloid precursor cells, 
while only high GATA-2 and low Pu.1 expression results in EPCs formation.  
In the course of switching from self-renewal of BFU-e cells to induction of terminal 
erythropoiesis GATA-2, c-Myb, and Pu.1 need to be down-regulated while GATA-1 
and several cofactors need to be up-regulated. 79-82 The increased expression of 
GATA-1 leads together with the co-regulators SCL/Tal-1, E2A, and LIM domain 
containing factors LMO-2 and Ldb-1, to the formation of a major activating complex for 
terminal maturation. LMO-2 and Ldb-1 act in this complex as bridging factors between 
the DNA binding SCL/Tal-1 and GATA-1. It has been assumed that the zinc-finger 
protein friend of GATA (FOG-1) contributes to erythropoiesis in a GATA-1 independent 
and GATA-1 dependent manner. The repressor complex is formed by binding of 
FOG-1 and Gfi-1b to GATA-1. In contrast to the activation complex, less is known 
about the composition and the mechanism of the action of the GATA-1 repressor 
complex, which enables the down-regulation of GATA-2. 2,13,79,82 The CACC 
consensus binding sites for the zinc finger protein Krüppel-like factor-1 (Klf-1) are often 
located closely to the GATA binding sites in erythroid genes. The interaction of GATA-1 
and Klf-1 promotes gene expression. One of the target genes is the β-globin. In Klf-1 
knock-out mice embryonic erythropoiesis (ε- and ζ-globin) occurs normally, but they 
suffer from a lethal β-globin deficiency. Klf-1 deficient mice show, besides the β-globin 
deficiency, up-regulated ɣ-globin expression. This indicates that Klf-1 is required for 
terminal erythropoiesis, hemoglobin switch, and especially β-globin expression. 2,83-86 
Besides the balance between self-renewal, proliferation, and differentiation, cell 
survival is another crucial factor of successful erythopoietic maturation. The 
transcription factor STAT5 is essential to prevent apoptosis of EPCs. Upon binding to 
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the activated EpoR, STAT5 gets phosphorylated and activated. The dimerized STAT5 
translocates to the nucleus and up-regulates the expression of the antiapoptotic gene 
Bcl-x. 79,87  
 
4.3.2. MicroRNAs 
During the entire erythropoietic maturation, microRNAs (miRs) are important regulators 
of differentiation, proliferation, and enucleation. The small non-coding RNA molecules 
can silence genes by interfering with their mRNA (Figure 3). For example, at the early 
stage of CFU-GEMM cells, the down-regulation of miR-150 is a trigger for 
differentiation towards erythropoietic linage by reducing the Myb expression. 88 During 
further maturation of CFU-e cells to erythroblasts, the down-regulation of miR-223 is 
critical for the enhanced expression of the zinc finger domain containing LMO-2 and 
terminal differentiation. 89 The expression of majority of miRs is down-regulated during 
normal erythropoiesis. Two exceptions are the miR-144 and miR-451. They are 
transcriptional targets of GATA-1 and are highly up-regulated during terminal 
differentiation and chromatin condensation. 90 Another crucial regulator for terminal 
maturation is miR-191. The miR-191 inhibits the expression of Riok3 and Mix1, two 
genes essential for chromatin condensation and enuclation. In EPCs over-expressing 
miR-191 enuclation was abundant. 28 There are several additional microRNAs that are 
involved in the regulation of erythropoietic maturation, but to determine the exact 
mechanism further investigation is needed. 13 
 
4.3.3. Epigenetic modifications during differentiation and enuclation 
Mature mammalian RBCs are enucleated. For this enucleation during erythropoiesis, 
chromatin condensation is required. By the interaction with a macrophage, the 
orthochromatic erythroblast extrudes his nucleus and divides asymmetrically into a 
reticulocyte, containing most of the cytoplasm, and the condensed nucleus embedded 
in a cytoplasmic layer (pyrenocyte). 12 While reticulocytes get released into the 
circulation and further differentiate to erythrocytes, pyrenocytes get degraded by 
macrophages. This asymmetric cell division enables an enrichment of reticulocytes 
with hemoglobin. Condensation and inactivation of the nucleus appears in all 
vertebrates, but the enuclation is limited to mammals. 12,13,91,92  
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Crucial for enucleation is the completed chromatin condensation. Depending on the 
acetylation status of the histones (H3 and H4), chromatin can occur in an open 
(euchromatin) and a closed (heterochromatin) conformation. 12,93 The switch from 
euchromatin to heterochromatin is mainly regulated by histone deacetylases (HDAC). 
If the histones get deacetylted by a HDAC, both the chromatin shifts to its closed 
conformation and the polymerase complex can no longer bind, thereby the genes are 
getting silenced. 12 HDAC function is precisely regulated by the Ca2+ signal exchange 
between the ER and the nuclear compartment. The activation of the inositol 3 
phosphate receptors within the ER membrane leads to phosphorylation of HDACs 
mediated by nuclear Ca2+-calmodulin-sensitive kinases (CaM Ks). 94 In erythropoiesis, 
several HDAC isoforms (HDAC1, HDAC2, and HDAC3) have been identified that 
induce terminal differentiation, regulate the globin switch, and cause chromatin 
condensation, respectively. When BFU-e differentiate to CFU-e, GATA-1 suppresses 
GATA-2 by binding to a HDAC1 containing complex and down-regulates its 
expression. 12,95 The HDAC3 complex represses the ɣ-globin expression and 
contributes to the switch from fetal to adult hemoglobin. 96 In polychromatic 
erythroblasts, the HDAC2 complex induces the chromatin condensation and triggers 
the terminal differentiation to orthochromatic erythroblasts. 12,97 
 
4.3.4. Stress-induced erythropoiesis 
Hematocrit and erythrocyte production is under precise regulation by Epo. In healthy 
adults, Epo concentrations are relatively low (20-50 mU/L), but under stress conditions, 
an enhanced Epo release triggers production of new red blood cells. This 
Epo-mediated increase of erythrocytes production is limited by a fixed number of 
divisions (3 to 5 cell divisions) of the CFU-e, proerythroblasts, basophilic, and 
polychromatic erythroblasts. Under conditions of severe chronic anemia, the 
Epo-mediated increase is not sufficient and enhanced Epo-independent formation of 
BFU-e and CFU-e is required. 13,98 
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4.4. Ion homeostasis and ion channels 
Considerably fewer studies have been focusing on the identification and 
characterization of the physiological role of ions and ion channels in erythroid cells. 
Transient receptor potential cation channels (TRPCs) have been studied in EPCs in 
more detail by Miller and colleagues. 99,100 By now, TRPCs remain the only channels 
studied during erythropoiesis, including their expression patterns, functions, or 
interactions. Although a number of other channels - including Gardos channels, non-
selective cation channels (NSCC), voltage-dependent anion channels (VDAC) and 
several others - have been reported in mature red cells, none of them were studied in 
the EPCs and their physiological function remain largely unclear. 101 In this section 
more emphasis will therefore be given to the literature on ion channels in mature RBCs. 
As no de novo protein synthesis occurs in enucleated circulating RBCs, all of these 
channels are obviously expressed in not yet released erythroid cells, at least during 
the late differentiation stages. 
 
4.4.1. Ion homeostasis and cell hydration 
The changes in cell ion content and cell volume occur in a variety of differentiating 
cells. Especially in EPCs are those changes during the transformation from BFU-e to 
the orthochromatic erythroblasts easy to follow (Figure 1A, B). Cell volume and 
hydration in erythroid cells are mainly determined by cation concentration (Na+, K+, 
Ca2+, and Mg2+). Various ion channels and electroneutral ion transporters control this 
homeostasis in erythrocytes, including the K+-Cl- and Na+-K+-2Cl- co-transporters, the 
Na+/H+ exchanger, the gradient-forming Na+,K+-ATPase, and plasma membrane Ca2+ 
pump. 102,103 However, acute dehydration of RBCs may result from the activation of 
Ca2+-sensitive K+ channel (Gardos channel, KCNN4, K(Ca)3.1). Anion concentration 
(Cl-, HCO3-, hemoglobin, and 2,3-BPG) is pretty fixed, with a strong increase of 
hemoglobin concentration in reticulocytes and red blood cells, respectively (Donnan 
effect). Mutations in the anion exchanger (band 3 protein) however, are believed to be 
associated with an increase in cation permeability and abnormalities in cell ion and 
water content e.g. in patients with cryohydrocytosis. 104,105 Disturbances in cell volume 
regulation lead to the compromised hemorheology and premature clearance of 
RBCs. 106 Dehydration of erythrocytes has particularly fatal consequences in patients 
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with SCD, as it promotes irreversible sickle cell transformation. 107,108 Dehydrated 
erythrocytes have a much higher probability for hemoglobin S (HbS) polymer formation 
and cell adhesion. 109,110 
In contrast to erythrocytes, there is less known about ion homeostasis in EPCs. Mainly 
K+-Cl- co-transporters and TRPCs have been studied during erythropoietic maturation. 
K+-Cl- co-transporters are taking part in regulation of cell volume, 111,112 and TRPCs 
are essential for the regulation of Ca2+ signaling during the EPC differentiation. 49,96 
4.4.1.1. Calcium 
Calcium is a master-regulator of multiple processes in any living cell. 113 Relative small 
changes in the intracellular Ca2+ or its re-distribution between the intracellular 
compartments are sensed by numerous Ca2+ sensors. 114 In contrast to other ions, 
there is a large concentration gradient between free intracellular Ca2+ (20-50 nM) and 
extracellular Ca2+ (~2 mM). Furthermore, the divalent ion is essential for several 
cellular processes, including gene transcription and regulation of cell survival (Figure 
4). 113  
 
 Figure 4: Schematic overview of Ca2+ signaling in erythroid cells and effects of enhanced Ca2+ 
influx. The Ca2+ influx through ion channels (TRPC, NMDAR, and non-selective cation channel (NSCC)) 
(in green) leads to activation of a variety of proteins (in blue). Enhanced intracellular Ca2+ influx can 
trigger several processes (in red), which can induce the removal of the RBC from the circulation or even 
hemolysis.  
 
Calmodulin is one of the intracellular Ca2+ sensors. After the binding of Ca2+, the 
messenger protein can interact with hundreds of different proteins. 113,115 These 
interactions can lead from gene expression to the regulation of apoptosis. 115 Ca2+ 
signaling can appear very locally within a cell, and the intracellular Ca2+ concentration 
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can increase by 100-fold over 10 nm. 116,117 In the dendritic spine, the localization of 
Ca2+ signaling produces an increase of intracellular Ca2+ concentration up the 1 µM 
within a few milliseconds. 113,118-120 In contrast to almost any other cell type, the release 
of intracellular Ca2+ from organelles such as mitochondria or endoplasmic reticulum, is 
due the lack of those compartments marginal.  
During the erythropoietic maturation, Ca2+ signaling is one of the major regulators for 
cell survival, proliferation, and differentiation. Two of the essential proteins of this 
signaling cascade are the protein phosphatase-calcineurin and the serine/threonine-
specific protein kinase Ca2+/calmodulin-dependent protein kinase (CaM K). 33,121 The 
inhibition of CaM KIV causes the differentiation of hematopoietic stem cells to myeloid 
cells over erythroid cells. 122 On the other hand, over-activation of Ca2+ signaling in the 
non-hematopoietic tissues surrounding erythroblastic islands leads to apoptosis. 121 
Besides the co-regulation of various transcription factors, including c-myb and c-fos, 
Ca2+-signaling triggers the activation of hemoglobin synthesis, the endothelial NO-
synthase, and the type I adenylylcyclase. 121,123,124 These findings indicate that precise 
regulation of intracellular Ca2+ in erythroid cells as well as in adjacent non-
hematopoietic cells are crucial for successful erythropoiesis. 
4.4.1.2. Potassium 
Transmembrane Na+/K+ gradient in human EPCs and in mature red blood cells is 
mediated by the Na+,K+-ATPase, 125,126 whereas passive K+ loss occurs via several 
types of ion channels (TRPCs, Gardos channels, non-selective cation 
channels 101,127,128) and co-transporters (such as the Na+-K+-2Cl- co-transporter and 
K+-Cl- co-transporter 129-132). These transporters and channels are responsible for the 
maintenance of the steady state intracellular potassium levels. The expression levels 
and the activity of these proteins vary, depending on the differentiation state, cell age 
and various pathologies. 106,111,112 A number of factors, including intracellular Ca2+, pH, 
cell volume changes, shear stress, oxidative stress, and Hb oxygenation, control their 
activity precisely.  
Nonetheless in the pathophysiology of SCD at least two of those proteins exhibit 
enhanced expression or activity. In patients the hyper-activation of the Gardos channel 
and the K+-Cl- co-transporter lead to cell dehydration, further deoxygenation, and 
facilitated sickling of RBCs. 133 Whereas the K+-Cl- co-transporter is particularly up-
regulated in the RBCs, forming medium density fraction, abnormally high activity of the 
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Gardos channel is more pronounced in the cells forming dense fraction on 
Percoll/Ficoll gradient. 134,135 
4.4.1.3. Sodium 
Low intracellular Na+ levels are maintained by the Na+,K+-ATPase. A fraction of high 
density irreversible sickled erythrocytes exhibits an abnormal high sodium 
concentration. 136 The exact mechanism and the significance of high Na+ concentration 
in a subpopulation are still not fully understood. Some studies have shown alteration 
in cation permeability and the impaired activity contributes to increased intracellular 
Na+ levels. 108,137,138 Nevertheless, in the pathophysiology of sickle cell anemia, Ca2+ 
and K+ are much more important. 
 
4.4.2. Ion channels in erythroid cells 
There is still an ongoing discussion about the role of ion channels in mature RBCs. 
The presence of a variety of ion channels has been demonstrated on a molecular and 
function level. However, their physiological role in precursors, and in particular in 
circulating RBCs, remains obscure. Researchers argue if these channels are just relics 
of differentiation or if they are take actively part in the regulation of ion 
homeostasis. 52,100,101,139-145 Pathophysiological conditions associated with malfunction 
of these ion channels indicate that they are required for survival, differentiation, and 
proliferation of erythroid cells. 52,100,101,141,142,146-148 
4.4.2.1 Gardos channel and dehydration 
Gardos channels received particular attention in RBCs of patients with SCD. These 
channels were chosen as a potential pharmacological target for treatment of the 
hereditary disorder. 149-151 Activation of Gardos channels by enhanced intracellular 
Ca2+ levels result in a transient shrinkage of cells, due to the net loss of K+-Cl- and 
water. The dehydration triggers the irreversible polymerization of the deoxygenated 
HbS. This process is responsible for the characteristic changes in cells morphology of 
erythrocytes known as sickling. 135,144,152 Therefore, inhibition of the Gardos channel 
was suggested to be a beneficial pharmacological strategy for the treatment of SCD. 
The inhibitor Senicapoc (ICA-17043, 2,2-bis(4-fluorophenyl)-2-phenylacetamide) 
entered the phase II trial and was shown to reduce hemolysis in patients, but it did not 
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affect the frequency of pain crisis. 149 The physiological function of the Gardos 
channels in healthy RBC is currently unclear, but is probably related to the upstream 
up-regulation of Ca2+, as activation of this channel requires a local increase in free Ca2+ 
from 20-50 nmol l-1 above 150 nmol l-1. 101,153 
4.4.2.2. Voltage-dependent anion channel 
The Voltage-dependent anion channel (VDAC) has been described first and studied 
intensively as a mitochondrial protein. 101,154,155 Later, the presence in the plasma 
membrane of human B-lymphocytes and RBCs was shown. 101,156-158 In artificial 
membrane systems, VDACs were still open in the range of from -10 mV to +10 mV. 156 
With a resting membrane potential of RBCs (around -10 mV) the channel should 
remain in the open conformation, but it is actually inactive under physiological 
conditions. This indicates a different gating and activation mechanism in the 
erythrocyte membrane compared to artificial systems. 101 Moreover, Ca2+ and reactive 
oxygen species (ROS) influence the function of VDAC, but the exact mechanisms of 
its physiological regulation in erythroid cells remain unknown. 154 
4.4.2.3. Peripheral benzodiazepine receptor complex 
Another receptor of the VDAC conductive pathway present in erythrocytes is the 
peripheral benzodiazepine receptor. Just like most of the channels in the RBC 
membrane, these receptors are dormant under physiological conditions but get 
activated in cells infected by Plasmodium falciparum. 159 The maxi-anion channel 
contributes to a band 3-independet anion transport. 143,148,159 Two proteins of this 
peripheral benzodiazepine receptor complex are the translocator protein and the 
adenine nucleotide transporter. They interact with VDAC and might be involved in the 
regulation of apoptosis. 101,160 
4.4.2.4. Transient receptor potential cation channels 
During erythropoietic maturation, the temporary rise of intracellular Ca2+ is essential 
for differentiation and proliferation. 18,19,161 It has been demonstrated that Epo 
stimulates a dose-dependent increase in free intracellular Ca2+ levels by modulating 
the TRPC. TRPCs are non-selective, voltage-independent cation channels with the 
highest permeability to Ca2+ ions. 52,53,140,162-165 A complex interplay of different proteins 
and the receptor is needed to change the conformation in the open state. The activated 
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EpoR-PLCɣ complex interacts directly with several sites of the TRPCs. Next to PLCɣ, 
activated IP3-receptor is needed for full activation of the receptor and induces the 
enhanced Ca2+ influx in EPCs. 52 Together with EpoRs, TRPCs are relevant during the 
first stage of maturation up to the stage of basophilic erythroblasts (Figure 2). 
4.4.2.5. Small conductance chloride channel 
Even less is known about the Zinc-sensitive small conductance chloride channel. The 
channel might contribute to the basal conductance and the regulation of cell volume. 
Typical properties of these channels are long opening, followed by long closing 
intervals and a conductance of 5 pS. 148,166 
 
 
4.5. The N-methyl-D-aspartate receptor 
N-methyl-D-aspartate receptors (NMDARs) have been studied intensively since they 
were first discovered in neurons in the late 70s in spinal cord of a frog. 167,168 As they 
appeared to be of pivotal importance in synaptic transmission, electrophysiology, 
pharmacology, and molecular biology of these receptors were mainly studied by 
researchers in basic and clinical neuroscience. Within the past decades, these 
receptors were characterized in a variety of non-neuronal tissues as well. 169 In 2010, 
Makhro et al. 4 from our laboratory showed the presence of functional NMDARs in rat 
erythrocytes for the first time. Earlier these receptors were found in cells originating 
from the hematopoietic lineage (lymphocytes, platelets, macrophages, and 
megakaryocytes). 170-174 This discovery created great curiosity about their relevance in 
human erythroid cells and if they could possibly be involved in the pathophysiology of 
red blood cell-related disorders. 
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4.5.1. Properties, structure, and downstream signaling cascade of 
the N-methyl-D-aspartate receptors 
Together with the AMPA and kainate receptors, the voltage-dependent NMDARs 
belong to the family of ionotropic glutamate receptors. 175-182 The heteromeric ion 
channels are composed of four subunits (Figure 5).  
 
Figure 5: Model of the N-methyl-D-
aspartate receptor (by Witt et al. 183). The 
tetrameric channel requires for full activation 
glutamate and glycine. The naturally 
occurring antagonist Mg2+ can block the Ca2+ 
influx in a voltage-dependent manner. The 
different NMDAR subunits have several 
binding sites for allosteric modulators e.g. 
GluN2A for Zinc. 
 
 
 
By now, seven different subunit types have been described. There are the glycine or 
D-serine binding subunits GlunN1 and GluN3 (A-B) and the L-glutamate or 
N-methyl-D-aspartate binding subunits GluN2 (A-D). 167,184-187 Some subunits have 
additional splicing variants and isoforms. Such as from the GluN1 subunit eight 
functional splicing variants have been described so far. 188-191 These subunits variants 
are highly pH-dependent and may therefore function as a pH sensor. 180,192-194 For full 
activation of classical NMDARs, L-glutamate and glycine binding subunits are required. 
However, recently NMDARs composed of glycine binding subunits (GluN1 and GluN3) 
only have also been described. 192,195,196 In neuronal cells, the presynaptic release of 
glutamate is taking the function of a neurotransmitter, while glycine acts as a 
modulator. 197 The pharmacological and electrophysiological properties of NMDARs 
highly depend on their subunit composition. 198,199 NMDARs containing GluN2A-B 
subunits have high conductance and fast decay time while GluN2C-D show low 
conductance and slow deactivation. 196,200-211 GluN3 (A-B) subunits exhibit dominate 
negative properties, referring to their current response and permeability to divalent 
ions. 192,195,212-220 Intensive structural and functional studies during the last years have 
led to better understanding of the subunit assembly. All subunits are encoded by seven 
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different genes and their length varies from 900 to 1480 amino acids. The different 
sizes of the subunits are mainly attributed to the variations in intracellular carboxyl-
terminal domain (CTD). This domain is coupled to the downstream signaling 
pathway. 199,221 NMDAR subunits are structured in four domains: the amino-terminal 
domain (NTD), the agonist-binding domain (ABD), the transmembrane domain (TDM) 
and the CTD. The NTD is composed of two clamshell-like regions and is taking part in 
allosteric modulation and subunit assembly. The ABD is made of the segments (S1 
and S2) that are binding either glutamate or glycine. The TMD is formed of three 
transmembrane helices and one re-entrant pore loop, which is responsible for the 
selectivity to ions. Depending on the subunit composition, NMDARs have a different 
permeability of Ca2+ Na+, K+, and Cs+ ions. 222 They have the highest permeability for 
Ca2+ and Na+ ions. 177,178,188,199,202,221,223-225 Analogue to conductance and deactivation 
time, NMDARs have subunit-dependent sensitivity to magnesium block. 178,179,226-228 
Di-heteromeric channels containing GluN1 together with GluN2A or GluN2B have a 
lower half-maximal inhibitory concentration than NMDAR containing GluN2C or 
GluN2D. These characteristics are primarily controlled by one amino acid in the M3 
transmembrane region. 221,229 Besides magnesium, there are several endogenous 
modulators of NMDAR, such as Zn2+, H+, and polyamines. 180,189,198,207,230 GluN3A or 
GluN3B containing receptors show, beside the lower conductance a reduced 
sensitivity to Mg2+ as well. 212,217,231 Apart from agonist or antagonist binding, 
phosphorylation and dephosphorylation of the CTD are a crucial mechanism for the 
regulation of NMDARs. Varieties of different kinases are interacting with the CTD and 
trigger the downstream signaling cascade. The PDZ-binding domains of GluN2 
subunits can interact with several membrane-associated guanylate kinase scaffolding 
proteins, such as SAP-102 and PSD-95. 232-237 Several other kinases - including 
protein kinase A, protein kinase C, and Ca2+/calmodulin-dependent protein kinase - 
are participating in the NMDAR trafficking. Further downstream the cascade, NMDAR 
signaling affects the MAPK and cyclic-AMP response element binding protein (CREB) 
mediated pathway and regulates multiple gene activation and cell survival. 221,238  
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4.5.2. Plasticity and function in neuronal cells 
The NMDAR is involved in a lot of molecular and functional processes from memory 
formation to inflammation. 199 Expression patterns for the different NMDAR subunits 
change greatly during the development from embryonic to adult brain. 221 While 
expression of the GluN1 isoforms is pronounced and ubiquitous in the brain, GluN2 
and GluN3 subunits expression is more likely to be associated with specific 
development stages, areas, and functions of the receptor. 239-241 This plasticity of 
NMDAR is not limited to the development stage. Alterations in the number and activity 
of receptors in adult neurons may occur within minutes. Relatively little is known about 
the regulation of this subtype plasticity. 221 Besides the subunit composition, the 
function of NMDARs is highly influenced by the localization. Activation of synaptic 
NMDARs triggers neuronal cells survival by activation of CREB and inhibition of pro-
apoptotic genes. In contrast to that activation of extrasynaptic NMDARs causes 
dephosphorylation of CREB, inactivation of the serine/threonine kinase ERK1/2, and 
triggers cell death by mitochondrial dysfunction. 238,242 NMDARs contribute decisively to 
the long term potentiation, synaptic plasticity, learning, memory formation, and 
neuronal communication. 221 
 
4.5.3. Pathophysiology and the potential as a drug target in neuronal 
cells 
Since the receptor is crucial for neuronal development and memory formation, it is 
associated with several neuronal disorders and damages. 242 In Alzheimer’s disease it 
has been shown that a constant over-activation of extrasynaptic NMDARs and a 
decreased GluN2B expression are affecting the progress of the disease. 243,244 In the 
brain of patients with Parkinson’s disease, location of the GluN2B-containing receptor 
shifts from the synaptic to the extrasynaptic site, and the GluN2A levels get up-
regulated. 242,245 In Alzheimer’s and Huntington’s diseases, an increase in 
extrasynaptic NMDAR activity has been described by Gladding and Raymond. 246 In 
contrast to these neurodegenerative disorders, schizophrenia is associated with a 
decrease in NMDAR activity. 247 During both acute and chronic alcohol/cocaine abuse, 
alteration in the receptor expression and properties occur as well. 248-250 Taken 
together, over-stimulation of the NMDARs leads to sever increased intracellular Ca2+ 
30 
 
levels, which causes excitotoxicity, while under-stimulation can cause cognitive 
dysfunction. This turns the use of the NMDAR as a drug target into a balancing act. 
The NMDAR modulators D-serine and glycine are used to stimulate the receptors in 
patients with schizophrenia 251 and multiple synthetic blockers (competitive and non-
competitive antagonists) were designed to compensate for the hyper-activation of the 
NMDARs in the brain. 197,252 In addition to the receptor channel pore and 
glycine/glutamate binding sites, the receptors containing GluN2A and 2B subunits are 
equipped with several binding sites for allosteric modulators, including Zinc, ifenprodil, 
and polyamines (Figure 5). Even through these extracellular allosteric modulatory 
binding sites offer novel opportunities for therapy approaches, many compounds have 
failed in clinical trials because of their side effects. The most promising candidates are 
those with subunit selectivity (e.g. GluN2B subunit), reversible channel blockers (e.g. 
Memantine), and activity–dependent blockers. 197 
 
4.5.4. Keep dementia in mind - Memantine 
Over-activation of NMDARs is associated with a variety of neurodegenerative 
disorders, such as dementia, Huntington’s, and Parkinson diseases. 253-255 Therefore, 
NMDARs have been of interest as a promising drug target for years. Unfortunately, 
attempts to use NMDARs antagonists in multiple clinical trials have often failed 
because of their deleterious and repressive side effects. 253,256,257 One of the inhibitors 
with approval in the US and in Europe is Memantine (1-amino-3,5-dimethyl-
adamantane) (Figure 6). It is clinically used for the treatment of moderate to severe 
forms of Alzheimer’s disease. 183,254,258 Originally, Memantine was synthesized as a 
precursor molecule for a compound (N-arylsulfonyl-N’-3,5-dimethyladamantylurea) to 
lower blood sugar levels by Eli Lilly. 255,259 Nine years later, in 1972, Merz and Co. 
reported that Memantine may be used for the treatment of diseases of the central 
nervous system and they filed a patent. 255,260,261 After another ten years of research 
several groups showed that the therapeutic effects of the compound were caused from 
the NMDAR antagonism. 262-266 Besides the pathological over-activation present in 
various diseases, exceeding inhibition also affects the glutamate-mediated synaptic 
transmission, thereby critically affecting cognitive function, memory formation, and 
synaptic plasticity. 257 Compared to the other non-competitive NMDAR antagonists as 
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dizocilpine ((5S,10R)-(+)-5-Methyl-10,11-dihydro-5H-dibenzo[a,d] cyclohepten-
5,10imine), the open channel blocker Memantine has special binding properties: the 
binding site of Memantine is at the asparagine-residues in the M2 loop region of GluN1 
and GluN2 subunits. The channel needs to be open to bind and block the NMDAR. 
After the agonist dissociates from its binding site, the receptor gets deactivated and 
Memantine remains partial trapped inside the channel pore. The naturally occurring 
NMDAR antagonist Mg2+ has a highly similar mechanism of action. 254 The advantage 
of Memantine over the other open channel blockers is mainly based on its 
pharmacological properties and not the partial trapping: it has a low affinity and a fast 
dissociation rate constant (koff) of around 0.2 s-1. Furthermore, the affinity is NMDAR 
subunit specific and the degree of inhibition depends on agonist concentration. At a 
high agonist concentration and receptor activity, the probability of a Memantine 
molecule staying inside the channel pore increases. 255 As a result, Memantine does 
not affect normal synaptic transmission under physiologically conditions, but inhibits 
receptors only when pathological over-activated. 254 Furthermore pharmacokinetics of 
Memantine contributes to its clinical efficiency and the oral application improves the 
compliance. The bioavailability is almost 100% and plasma levels reach the peak 
concentration three to eight hours after the intake. It is eliminated mainly by the kidneys 
as uncharged substance with a total clearance of 170 ml/min/1.73 m2 (glomerular 
filtration rate at normal kidney function). Cytochrome P450 interactions have not been 
described so far and the half-life is between 60-100 hours. 254,267 
 
 
 
Figure 6: Structure of Memantine. Structure of the non-
competitive channel blocker Memantine with the same binding 
site inside the pore loop as magnesium. 
 
Memantine got the approval for the treatment of mild to severe Alzheimer’s disease in 
Europe (2002) and the US (2003) after successful clinical trials demonstrated the 
neuroprotective efficacy. 255,257,268 Usually, it is administrated at 10-20 mg per day, 
which results in concentrations of < 1 µM in the cerebrospinal fluid. Those levels are 
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far below the effective level at any other target (low off-target toxicity). 183,265,269,270 
Because of the pharmacological properties and the neuroprotective effects, 
Memantine was used as a potential candidate for clinical trials in both 
neurodegenerative and psychiatric disorders. Even in child and adolescent psychiatry 
studies for the off-label use have been performed, including the fields of autism 
spectrum disorder, attention deficit hyper-activity syndrome, and obsessive compulsive 
disorder. 271,272 
 
4.5.5. Forget memory formation - NMDARs in non-excitable tissues 
as potential drug targets 
Although NMDARs are mostly studied in neuronal cells, it has been shown that the 
receptors are present in several other tissues, including osteoclasts and osteoblasts 
as well as in kidney tissue. 169,273,274 Furthermore, functional NMDARs were reported 
to be present in various cells originating from hematological lineages, such as 
leucocytes, platelets, and red blood cells. 3,172,275 
The presence of NMDARs was shown in rat erythrocytes in 2010 by our laboratory, 4 
while Eaton et al. 276 have already demonstrated in the 1970s that sickle cell 
erythrocytes exhibit elevated Ca2+. These two findings laid the foundation for the study 
of the NMDAR in SCD patients’ erythrocytes. As enhanced Ca2+ influx is a major trigger 
in the pathophysiology of sickle cell anemia, the possible involvement of NMDAR in 
Ca2+ homeostasis, the potential as a novel drug target, and the preclinical safety-
assessment of Memantine, making it a candidate for clinical trials to treat SCD will be 
one of the main parts of this study. Therefore the following chapters will cover some 
aspects of sickle cell anemia, its pathophysiology, epidemiology, and therapeutic 
strategies for its treatment. 
 
 
4.6. Sickle cell anemia 
Sickle cell anemia is one of the most common inherited disorders worldwide. 277 The 
physician James Herrick 278 described the typically sickle-shaped red blood cells 
33 
 
(Figure 7) for the first time in 1910. In 1942, Linus Pauling and colleagues 279 
introduced the term molecular disease for SCD. Thirteen years, later Vernon Ingram 280 
showed that a single point mutation in the hemoglobin gene is responsible for the 
devastating disease. However, even after decades of intensive research, no sufficient 
therapy for this severe disease has been developed. 277  
 
 
 
Figure 7: Typical sickle-shape erythrocyte. 
Red blood cells of a sickle cell anemia patient.  
 
 
 
As gene therapy is not available and bone marrow transplantation is expensive, finding 
a potential target that may relieve the symptoms of SCD offers great opportunities for 
the development of new therapeutic strategies. Especially, if the new treatment would 
be a drug, that is already on the market for several years (new indication/off-label use). 
 
4.6.1. Genotypes and phenotypes of sickle cell anemia 
The term “sickle cell anemia” includes all genotypes with at least one HbS gene. Next 
to the most common homozygous HbS/S genotype, there are several other genotypes 
(most common listed in Table 3 277,281). The different genotypes and mutations affect 
severity of the disease. Furthermore it has been shown that there is heterogeneity in 
both the manifestation and the progress of SCD. 282 Several polymorphisms have been 
linked to the severity and complications (such as polymorphism in the promoter of the 
ɣ-globin or in the BCL11A gene). 283,284 Even less characterized than the influence of 
polymorphisms are the effects of environmental factors on the SCD progression. 
 
Table 3, Most common genotypes of sickle cell anemia 
©2013 Georgia Regents University 
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Genotype Phenotype Characteristics 
HbS/S Severe Most common form, β6Glu>Val/β6Glu>Val  
Severe HbS/β+ thalassemia Severe 
Highest prevalence in Eastern Mediterranean and India, small amount of 
HbA, 
HbS/β0 thalassemia Severe Highest prevalence in Eastern Mediterranean and India 
HbS/O Arab Severe 
Relatively rare, present in north Africa and Middle East, 
β6Glu>Val/β121Glu>Lys 
HbS/D Punjab Severe Highest prevalence in Northern India, β6Glu>Val/β121Glu>Gln 
HbC/S Antilles Severe Very rare, β6Glu>Lys/β6Glu>Val, β23Val-Ile 
HbS/C Moderate 25-30% of all cases in Africa, β6Glu>Val/β6Glu>Lys 
Moderate HbS/β+ 
thalassemia 
Moderate Highest prevalence in Eastern Mediterranean 
HbA/S Oman Moderate Very rare double mutation, βA/β6Glu>Val/β121Glu>Lys 
Mild HbS/β++ thalassemia Mild 16-30% HbA present 
HbS/HbE Mild Highest prevalence in South East Asia, β6Glu>Val/β26Glu>Lys 
HbS/HPFH Mild Large deletions in β-globin 
 
4.6.2. Pathophysiology 
A mutation in the β-globin gene causes the monogenic disorder. The 17th nucleotide is 
exchanged from thymine to adenine, leading to the replacement of a glutamic acid by 
a hydrophobic valine. 285 During deoxygenation of erythrocytes, the hydrophobic 
pockets are exposed to each other and the polymerization of β1- and β2-globin chains 
is initiated. The probability to induce irreversible polymerization of HbS in a RBC 
depends on the cell volume, the HbS concentration, the amount of fetal hemoglobin 
(HbF), and the extent of deoxygenation. The HbS polymers promote further 
dehydration, endothelial dysfunction, impair cytoskeletal stability, and decrease cell 
flexibility. 277,285,286 
Accumulation of sickled erythrocytes leads to a variety of severe pathophysiological 
processes and complications. Two of the main triggers of all complications are 
hemolysis and vaso-occlusion. They can lead to such complications as acute chest 
syndrome, pulmonary hypertension, acute pain crisis, leg ulceration, priapism, renal 
damage, and stroke. 277,287 Next to the rigid and sickled erythrocytes, inflammation is 
the second factor that drives vaso-occlusion. The inflammatory meditated aggregation 
of RBCs and leucocytes leads to an enhanced RBC-leucocyte-endothelial adhesion, 
resulting in vascular obstruction. 288-290 The episodic occlusion mainly affects the 
microcirculation and leads to ischemia and endothelial dysfunction after 
reperfusion. 277 The tissue damage produces oxidative stress and a further release of 
inflammatory cytokines that increases expression of adhesion molecules and the 
vaso-occlusion. 286 The consequence of those repetitive vaso-occlusion crises can 
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provoke, among others, acute chest syndrome or fat embolization in lung and bone 
marrow. 277,282 Enhanced hemolysis in SCD patients leads not only to chronic anemia, 
oxidative stress, and fatigue, it also affects the progressive vasculopathy. 277,291-293 
Free hemoglobin is another factor which has an important role in the pathophysiology. 
The potent NO binder hemoglobin, disrupts not only the cytoskeleton, it decreases NO, 
and produces free radicals (ROS). 294 Furthermore, free iron increases ROS 
production (H2O2 and hydroxyl radicals), that further decreases NO bioavailability and 
therefore inhibits the NO-signaling in endothelial cells. 295,296 As NO acts as a 
vasodilator, inhibits platelets activation, and suppresses the transcriptional expression 
of adhesion molecules (such as spectrins and vascular cell-adhesion molecule-1 
(VCAM-1)); the depletion of NO is crucial for the progression of SCD. Furthermore, 
during hemolysis, the substrate for NO production (arginine) is depleted by the release 
of the enzyme arginase. 297-300 
 
4.6.3. Cell heterogeneity 
RBC heterogeneity is more pronounced in sickle cell anemia patients than in healthy 
subjects. 301 Blood of patients is enriched with both very dense and low-density RBCs. 
Part of this difference is due to the low activity of K+-Cl- co-transporter in low density 
RBCs and the high activity in dense RBCs. 132,302 In contrast, in healthy cells, 
reticulocytes along with old cells are found in the dense RBC fraction, suggesting that 
young RBCs are prone to dehydration. 303 The mechanism of the rapid dehydration 
assumes the activation of either K+-Cl- co-transporter or the Gardos channel and an 
enhanced Ca2+ influx into to young cells. 
 
4.6.4. Epidemiology 
Over 275’000 children are born with the HbS mutation every year and millions of people 
are affected worldwide. 304-306 Besides the genetic advantage in malaria-endemic 
regions, migration is the second factor for the global distribution of SCD. 277 In 1954, 
A.C. Allison 307 suggested for the first time that HbS carrier have a survival advantage 
after a Plasmodium falciparum infection. By now, the hypothesis of a balanced 
polymorphism has been confirmed in various studies. 308-310 High frequency of the HbS 
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allele appears in three regions in Africa (Senegal, Benin, and Bantu) and the Arab-India 
region (Figure 8). 287  
 
 
Figure 8: Map of the estimated sickle cell allele frequency 315 
(©2010 Malaria Atlas Project). Distribution of the sickle cell allele 
(HbS) frequency. Due to migation, the HbS/S frequency is further 
increased during the next decades in Europe and North America. 
 
About 80% of all births with HbS/S worldwide have been born in the sub-Saharan 
region. 277,311 The number of affected births in the US (around 1800) and in Europe 
(around 1300) every year has been increasing steadily over the past years, and SCD 
gets more and more attention. 305,306,312-314 
 
4.6.5. Therapeutic strategies 
Even after intensive years of research, there is still no therapy on the market that 
targets specifically the pathophysiology of SCD. By now, blood transfusion and iron 
chelation, the treatment with hydroxyurea, and the management of the complications 
are the main therapeutic options. 
4.6.5.1. Blood transfusion and iron chelation 
Blood transfusion is one of the major therapeutic options for acute and chronic 
complications in SCD (Table 4). 277 Besides the reduction of the HbS percentage and 
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the anemic condition, transfusions can improve health conditions and prolong the 
patient’s life span. 277,316 Iron chelation and erythocytapheresis have increased the 
efficacy of transfusion and reduced the risks of complications. 316 Iron overload is one 
major complication in SCD patients with sporadic and frequent blood transfusions: 317 
Intermittent transfusions and increased hemolysis are the causes of this iron overload. 
In contrast to thalassemia major patients, SCD patients tend to show a lower risk for 
iron overload because of the different transfusion schemata and decreased basal iron 
levels. 318 Furthermore, through hemolysis, a substantial amount of the iron gets 
extracted via urine (15 mg/d). 318-320 If Iron accumulation occurs it affects mainly the 
liver and can lead to cirrhosis. 321,322 To avoid the adverse effects of iron overload under 
transfusion therapy, iron chelators, such as Deferiprone or Deferoxamine are used 
additionally. 323,324 Alloimmunisation to erythrocyte antigens is the other main 
complication of transfusion therapy. 325 Blood group genotyping for better antigen-
matched erythrocytes will probably decrease alloimmunisation in the near 
future. 316,325-327 
 
Table 4. Indication for blood transfusion 277 
Acute transfusion Repetitive transfusion 
Acute chest syndrome Recurrent acute chest syndrome 
Acute exacerbation of anemia Progressive organ damage 
Stroke or multiorgan failure Stroke prevention 
Pre-operative Failure of Hydroxyurea treatment 
 
4.6.5.2. Hydroxyurea 
Hydroxyurea (HU) is still the only drug approved in the US and Europe for SCD 
treatment. Although the complete mechanism of action is still not fully understood yet, 
it has been shown that HU up-regulates HbF and thereby reduces the hemoglobin 
polymerization. The cytotoxic drug inhibits the ribonucleotide reductase and arrests the 
cell cycle in the G1-S phase. 328,329 Compared to other cytotoxic drugs, HU has a much 
lower toxicity with short-term myelosuppression as the main adverse effect. 330 It has 
been demonstrated in several studies and meta-analyses that HU reduces the 
frequency of pain crises, hospitalization, and transfusions. But there are two major 
concerns with HU: the long-term toxicity is not yet fully understood and HU has not 
been efficient enough in all SCD patients. 110,282,287,330-333 
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4.6.5.3. Management of complications 
Sickle cell anemia and irreversible sickled erythrocytes lead to a wide range of 
complications, morbidity and a higher mortality. 277,282,334 Vaso-occlusion and acute 
pain crises are the most frequent complications and causes of hospitalizations. The 
management of acute pain crisis is quite limited and opiate analgesia is mainly 
used. 335-337 Acute chest syndrome is caused by vaso-occlusion, fat embolism, and 
infarction in the lung. Besides acute pain crises, acute chest syndrome causes second 
most hospitalization. 338 During the alveolar pulmonary infiltration, respiratory failure 
occurs and can lead to death. 339 Transfusions, bronchodilators, and antibiotics are 
used to treat those patients. 340 Elevated pulmonary artery systolic pressure and 
pulmonary hypertension can be observed 20-30% of patients, which increase the risk 
of death significantly. 341 Several approaches have been used in clinical trials for 
pulmonary hypertension, including phosphodiesterase-5 inhibitors, prostaglandin 
analogues, and endothelin receptor antagonists. 277 Another cardiopulmonary risk 
factor for high mortality is diastolic dysfunction. Preventive echocardiographic 
screenings to assess the risk factors is recommended in adult SCD patients. 342 
Especially in developed countries, infection increases morbidity and mortality of 
children with SCD. Antibiotic prophylaxis and vaccination against H influenza or S 
pneumonia can reduce the risk of death in children. 277,343 Neurological complications 
and strokes are mostly associated with vaso-occlusive events in the distal internal 
carotid and middle cerebral arteries. They occur in 7-8% of all children with SCD. 277,344 
Regularly blood transfusions (reduction of HbS to < 30%) and preventive transcranial 
doppler screenings reduce this frequency significantly. 345 The physiological conditions 
occurring in the kidneys (low pH, high osmolality, and low oxygen partial pressure 
highly) favor induction of sickling and lead to vaso-occlusive crises, papillary necrosis, 
and renal complications. 277,346 Sickle cell anemia manifests itself with plenty of other 
complications, including priapism, leg ulcers, and retinitis proliferans. Taken all of these 
complications together, SCD causes chronic organ damage and reduces the patient’s 
life span. Therefore several general and specific therapeutic approaches have been 
used for the management and treatment (selection is listed in Table 5). Despite all of 
the efforts and progress made during the last years, there is still a strong need for new, 
efficient, and inexpensive therapies. 
Table 5. Therapeutic approaches for the treatment of sickle cell anemia 277,287,347 
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Target or 
complication  
Approach Examples 
Inflammatory response 
Corticosteroids, phospholipase 
A2 inhibitors 
Dexamethasone, varespladib 
Blood rheology 
Inhibition of adhesion, inhibition of 
endothelin receptors 
Bosentan, GMI-1070, Poloxamer-188, herparin, 
sulfasalazine 
Tissue damage  Reduce oxidative stress N-acetyl cysteine, glutamnie 
HbF Increase of HbF Pomalidomide, Decitabine, butyrate 
Dehydration (RBC) Cation channel inhibition Senicapoc, magnesium, zinc, dipyridamole 
Nitric oxide Increase NO Nitric oxide, arginine, sildenafil, statins 
Priapism Adrenergic agonists Phosphodiesterase-5 inhibitors, Finasteride 
Retinitis proliferans 
Screening and laser 
photocoagulation 
- 
Hyposplenism Screening, prophylaxis Prophylactic antibiotics 
General 
Stem-cell transplantation, gene 
therapy 
- 
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5. Aim and Publications 
5.1. Aim of the work 
The main focus of the study was to characterize the expression and the function of 
NMDAR in erythropoietic precursor cells of both healthy subjects and sickle anemia 
patients. After the ex vivo erythropoiesis system was established, the mRNA 
expression pattern (GRIN genes) and the protein expression (GluN) of the NMDAR 
subunits was studies first. Nonetheless, it was crucial to verify the expression pattern 
during erythropoietic maturation of the NMDAR on functional level as well. Therefore 
the second part of the study was focused on the function of NMDARs in erythroid cells 
and the validation of the expression pattern on the functional level by measuring NMDA 
induced whole-cell currents and NMDA mediated Ca2+ influx. 
The three key findings of the work are: 
(i) Characterization of the temporal expression pattern for the GRIN genes in 
differentiating EPCs and monitoring the function of the NMDARs in the 
erythroid precursor cells of healthy humans and SCD patients; 
(ii) Assessment of the impact of the NMDAR on the regulation of intracellular 
Ca2+ and the functional plasticity of the receptor during erythropoietic 
maturation, including inter-individual variability in the receptor expression 
pattern; 
(iii) Safety assessment for the use of the NMDAR antagonist Memantine for the 
treatment of sickle cell anemia. 
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The presence of N-methyl-D-aspartate receptor (NMDAR) was previ-
ously shown in rat red blood cells (RBCs) and in a UT-7/Epo human
myeloid cell line differentiating into erythroid lineage. Here we have
characterized the subunit composition of the NMDAR and monitored
its function during human erythropoiesis and in circulating RBCs.
Expression of the NMDARs subunits was assessed in erythroid
progenitors during ex vivo erythropoiesis and in circulating human
RBCs using quantitative PCR and flow cytometry. Receptor activity
was monitored using a radiolabeled antagonist binding assay, live
imaging of Ca2 uptake, patch clamp, and monitoring of cell volume
changes. The receptor tetramers in erythroid precursor cells are
composed of the NR1, NR2A, 2C, 2D, NR3A, and 3B subunits of
which the glycine-binding NR3A and 3B and glutamate-binding
NR2C and 2D subunits prevailed. Functional receptor is required for
survival of erythroid precursors. Circulating RBCs retain a low
number of the receptor copies that is higher in young cells compared
with mature and senescent RBC populations. In circulating RBCs the
receptor activity is controlled by plasma glutamate and glycine.
Modulation of the NMDAR activity in RBCs by agonists or antago-
nists is associated with the alterations in whole cell ion currents.
Activation of the receptor results in the transient Ca2 accumulation,
cell shrinkage, and alteration in the intracellular pH, which is associ-
ated with the change in hemoglobin oxygen affinity. Thus functional
NMDARs are present in erythroid precursor cells and in circulating
RBCs. These receptors contribute to intracellular Ca2 homeostasis
and modulate oxygen delivery to peripheral tissues.
NMDA receptors; calcium; red blood cells; erythroid precursors
INTRACELLULAR CALCIUM IS A regulator of multiple processes in
mammalian red blood cells (RBCs; Ref. 6). Functions of key
glycolytic enzymes are calcium sensitive (e.g., Refs. 2, 36, 75).
Increase in the intracellular calcium to 1 M and more causes
activation of Ca2-dependent K channels (Gardos channels),
loss of KCl from the cells, cell shrinkage, and dehydration
(37). Along with the changes in cell volume and cation content,
accumulation of Ca2 was shown to facilitate intercellular
adhesion (60). Upregulation of the intraerythrocytic Ca2 re-
sults in activation of calpain and promotes cleavage of cyto-
skeletal proteins (actin, spectrin, ankyrin, and band 4.1 protein)
as well band 3 protein and the plasma membrane Ca2 pump
(PMCA; Ref. 6). Thus the cell membrane becomes destabilized
in RBCs upon Ca2 overload. The changes in rheology asso-
ciated with cell dehydration and proteolysis of cytoskeletal
proteins are followed by the alteration of hemodynamics.
Uncontrolled Ca2 accumulation upon treatment of RBCs with
Ca2 ionophore A23187 was reported to cause phosphatidyl-
serine (PS) exposure to the outer membrane leaflet (16). This
process may contribute to enhanced RBC clearance by macro-
phages in patients with a number of diseases. Apart of PS
exposure, high intracellular Ca2 may promote oxidative stress
due to the activation of NADPH oxidase and nitric oxide
synthase in its uncoupled mode (20, 51). Whereas extracellular
Ca2 concentration in the plasma reaches 1.8 mM, the intra-
cellular free Ca2 level is precisely controlled and does not
exceed 50–100 nM in healthy human RBCs (64). This impres-
sive transmembrane gradient is maintained by an active Ca2
extrusion via the PMCA and low passive permeability of the
RBC plasma membrane for Ca2 which is mainly mediated by
ion channels (28). PMCA in RBCs has been well characterized,
whereas our knowledge on the ion transport systems mediating
Ca2 uptake in human RBCs is rather limited. Among the
transport systems contributing to Ca2 uptake into human
RBCs are several classes of cation channels (28). An increase in
Ca2 “leak” and the concomitant elevation of intracellular Ca2
concentrations are typical for RBCs of patients with phosphofruc-
tokinase deficiency (75), thalassemia (7), and sickle cell disease
(7, 70). The importance of electrogenic Ca2 uptake pathway
(Psickle) in promoting sickle cell transformation upon deoxygen-
ation has been acknowledged (8, 70, 72). The molecular
identity of the nonselective cation channels, including those
mediating Psickle, remains unknown.
Recently, we have reported the presence of N-methyl-D-
aspartate receptors (NMDARs) in the plasma membrane of rat
RBCs and in the human erythroid precursor cell (EPC) line
UT-7/Epo (38). These receptors are ligand-gated, nonselective
cation channels showing a 10-fold preference for Ca2 over
Na or K (12).
These receptors are comprised of four subunits of which
eight different isoforms coded by independent genes have been
described (68). Subunits NR1 and NR3A and B are binding
glycine or D-serine whereas NR2A, B, C, and D interact with
glutamate and its homologues homocysteine, homocysteic acid
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(HCA), or NMDA. Subunit composition defines gating prop-
erties and ion preferences of the channel, as well as its affinity
to the agonists and antagonists. Whereas channels composed of
NR1-NR2A/B generate large currents and deactivate quickly,
the channels built up by the NR1-NR2D generate smaller
currents and are slow-deactivating (10). Physiological role of
the “inhibitory” NR3 subunits making the receptors in the brain
glutamate insensitive are not well defined (52). Local expres-
sion pattern vary within the brain (21, 40). Apart of that in the
brain NMDARs have been shown to be expressed in a number
of nonneuronal tissues including the bone and the kidney (42,
57). Subunit composition, physiological function, and regula-
tion of activity of these “atypical glutamate receptors” in
megakaryocytes (19, 24) and in rat RBCs (38) have been
reported. In rat RBCs activation of the NMDARs by adminis-
tration of agonists triggered Ca2 accumulation whereas ex-
posure of the cells to antagonists on the contrary reduced the
intracellular Ca2 levels (38). Furthermore, activation of the
receptor by glutamate, NMDA, or HCA triggered opening of
the Gardos channel followed by cell shrinkage as well as
activation of the endothelial nitric oxide synthase (38).
Herein we report the presence of NMDARs in membranes of
EPCs and circulating RBCs of healthy human subjects. We
characterize subunit composition of the receptor and explore its
function and contribution to the maintenance of intracellular
Ca2 homeostasis and in regulation of hemoglobin oxygen
affinity.
DESIGN AND METHODS
Human subjects. Our subject pool consisted of 36 adult subjects
(Caucasians, both genders, median age 32.5; range 25–49) with no
history of hematological disorders. Five to ten milliliters of venous
heparinized blood were obtained after informed, written consent, in
accordance with the Declaration of Helsinki, at the Divisions of Hema-
tology of the University Hospital and the Children’s Hospital Zurich as
well as at the Medical Faculty, Saarland University, Homburg/Saar,
Germany and processed immediately. The Institutional Ethics Board of
the University Hospital in Zurich and that of the Canton of Zurich as well
as the Ethics committee of the medical association of the Saarland
approved the study protocol.
RBC purification for flow cytometry and quantitative real-time
PCR. Blood was washed three times with 10 ml of PBS containing 2
mM EDTA and separated in a Ficoll-Hypaque gradient (GE Health-
care, Glattbrug, Switzerland) to remove mononuclear cells and plate-
lets. Reticulocytes were then filtered through a leuco-depletion filter
(Purecell Neo; Pall, Basel, Switzerland). The leuco-depleted reticulo-
cytes were washed and resuspended in PBS/EDTA. The purity grade
of reticulocytes was assessed by an automated blood cell analyzer
(Sysmex Digitana, Horgen, Switzerland), as well as by flow cytometry
for surface expression of CD45 with fluorescence-labeled antibodies
(Becton Dickinson, Rotkreuz, Switzerland). In addition, depletion of
leukocytes and platelets and enrichment of late EPCs and reticulo-
cytes were analyzed by quantitative real-time PCR (qPCR). The
pan-leukocyte marker CD45 was used as a white blood cell (WBC)
marker, and mRNAs encoding hemoglobin subunits were chosen to
detect late EPCs and reticulocytes.
Ex vivo hematopoiesis. EPCs were cultured using a two-phase
liquid system as described elsewhere (41, 42). At phase I mononuclear
cells were isolated from peripheral blood according to the protocol
provided by the GE Healthcare producing Ficoll-Paque PLUS and seeded in
StemSpan SFEM Medium supplemented with a cytokine mix supplements
CC100 StemSpan (StemCell Technologies, Grenoble, France) and peni-
cillin/streptomycin. Cells were maintained in phase I medium at a
density of 0.1–1  106 cells/ml for 5 days. Thereafter, nonadherent
cells were reseeded in StemSpan SFEM Medium with 2% penicillin/
streptomycin, 20 ng/ml SCF, 1 U/ml Epo, 5 ng/ml IL-3, 2 M
dexamethasone, and 1 M -estradiol and maintained in it for 6, 12,
or 18 days.
mRNA isolation and qPCR. Total RNA was purified from cells by
the TRIzol/glycogen/osopropanol. GRIN1, GRIN2A, GRIN2C,
GRIN2D, GRIN3A, GRIN3B, and CD45 mRNAs, as well as control
GAPDH mRNA, were quantified using the TaqMan Gene Expression
Kits acquired from Applied Biosystems (Rotkreuz, Switzerland). The
following primers were used: Hs02758991_g1 Gapdh: GTC-
CCCATCCCAACTCAGCCCCCAA; Hs00609557_m1 Grin1: TCA-
TCTCCAGCCAGGTCTACGCCAT; Hs00168219_m1 Grin2a: GGAA-
TGGGAAAAGGTGGGCAAGTGG; Hs00168230_m1 Grin2b: TGG-
GAAAGGGTGGGGAAGTGGAAAG; Hs01016626_m1 Grin2c:
TGGCTTTCAGCAGGGGCATCTACAG; Hs00367969_m1 Grin2d:
CAGCTCAAGGCAGGGAAGCTGGACG; Hs00370290_m1 Grin3a:
ACATGACCCCAAGTTACATCATCCT; and Hs00367969_m1 Grin3b:
GCTTCTTGGCACGGTTCCTGGCCAA.
Flow cytometry for detection of NMDAR abundance and distribu-
tion in EPCs. Staining of EPCs for the NMDAR subunit-specific
antibodies was performed as follows. Cells were washed once with
working solution (PBS supplemented with 0.1% BSA) and centri-
fuged for 30 s at 3,000 rpm. The supernatant was discarded and the
cells resuspended in working solution and fixed with 0.05% glutarald-
hyde solution prepared in PBS for 9 min. Cells were washed twice,
supernatant was discarded, and cells were resuspended in Tween
solution (working solution supplemented with 0.1% of NaN3 and
0.1% of Tween20) to permeabilize them. Before the primary antibody
was added, the EPCs were washed once and resuspended in working
solution.
After incubation with primary antibodies for 15 min in the darkness
at room temperature, the cells were washed once and exposed to the
allophycocyanin-conjugated secondary antibodies for 15 min in the
darkness. The following antibodies were used: IgG1 mouse anti
human Anti-CD45 PerCP, clone 2D1 (BD, San Jose, CA) as a marker
of WBCs; IgG2a mouse anti-human CD71, clone M-A712 FITC-
conjugated (BD) as a marker of reticulocytes; anti-NMDAε3 (NR2C),
goat polyclonal IgG, no. sc-1470; anti-NMDAε4 (NR2D), mouse
monoclonal IgG, no. sc-178221; anti-NR3A (NR3A), goat polyclonal
IgG no. sc-51160; and anti-NR3B, goat polyclonal IgG, no. sc-55731.
All primary antibodies against the NMDAR subunits used were
provided by Santa Cruz Biotechnology (Dallas, TX) and used at a
final concentration of 0.2 g/ml. Allophycocyanin-cojugated Affini-
Pure F(ab’)2 Fragment Donkey Anti-Goat IgG, Code 705–136-147,
and allophycocyanin-cojugated AffiniPure F(ab=)2 Fragment Goat
Anti-Mouse IgG, Code 155–136-146 were used as secondary anti-
bodies at 1:625 and 1:2500 dilutions, respectively.
Stained cells were washed once with the working solution supple-
mented with 1% formaldehyde and resuspended in an appropriated
volume of the working solution, and fluorescence intensity was
measured using the BD Biosciences FACSCalibur flow cytometer
(BD Biosciences). Cells stained with the secondary antibodies alone
were used as a negative control. Data were analyzed by using FCS
express software (De Novo Software, Los Angeles, CA). All chemi-
cals were provided by Sigma-Aldrich (St. Louis, MO).
Fractionation of RBCs on Percoll density gradient. Fractionation
of RBCs into light (L), medium (M), and dense (D) fractions was
performed in 90% isotonic Percoll solution prepared by mixing a
90-ml aliquot of sterile Percoll (GE Healthcare; density 1.130 g/ml)
with 10 ml  10 PBS (Sigma-Aldrich) and 11 ml  1 PBS (Sigma-
Aldrich). Blood or RBC suspension was prefiltered on cellulose filter
to remove WBCs, platelets were as described elsewhere (5), and
1.0–1.5 ml was overlaid then over 12.5 ml isotonic Percoll and
centrifuged using Sorvall RC 5C plus centrifuge equipped with a
SM-24 rotor at 4°C for 30 min at 45,000 g. The obtained L, M, and
D fractions of RBCs were collected and washed three times with the
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incubation medium containing the following (mM): 145 NaCl, 4 KCl,
10 glucose, 10 Tris·HCl, 0.1 EDTA, and 0.1% BSA (pH 7.4 at room
temperature). Therefore, the obtained RBCs were used for detection
of the number of [3H]MK-801 binding sites or for fluorescence live
imaging. The amount of reticulocytes in L, M, and D fractions was
18.1  8.2, 1.5  4, and 0.89  0.08% respectively, with mean
reticulocyte counts of 1.9  0.6%. Mean cell volume (MCV) of cells
in fractions was 103.6  1.9, 90.9  0.7, and 82.6  1.5 fl for the L,
M, and D fraction, respectively, mean MCV being 86.5  1.4 fl
(means  SD; Sysmex Digitana, Horgen, Switzerland).
Percoll solutions of lower density (82–86% Percoll) were used to
monitor rapid changes in volume occurring within the M fraction
containing the majority of mature RBCs in response to the NMDAR
stimulation. Final ion composition in Percoll solution was adjusted to
145 mM NaCl, 5 mM KCl, 20 mM HEPES (pH 7.4 at room
temperature), 10 mM glucose, and 2 mM CaCl2. Control samples
were agonists free. Stimulation of the NMDARs was performed by
supplementation of Percoll solution with 200 M of 1:1 NMDA-
glycine mixture. Washed RBCs (0.5 ml packed cells per 12 mM of
Percoll solution) were added to the Percoll solution, mixed with it and
centrifuged for 2 min at 48,000 g at room temperature. Due to the
interindividual variability in basal cell density and in the amplitude of
responses, Percoll density was slightly adjusted for each of five
healthy subjects tested to achieve better separation of the M fraction.
In four out of five donors, the agonists-induced changes in RBC
density developed within 2 min and were reversed already after 5 min
of stimulation. In one subject the volume changes prevailed even 15
min after the onset of exposure to the agonists.
NMDAR activity measurements in circulating RBCs. Changes in
the intracellular Ca2 levels in RBCs caused by exposure to the
NMDAR agonists or antagonists were monitored in L, M, and D
fractions by means of microfluorescent live imaging using fluo-4 AM
(Molecular Probes, Eugene, OR) as a marker (31). Loading of RBCs
with the fluorescent dye (1–5 M) was performed for 30 min at room
temperature in the darkness. During loading, the cells were resus-
pended in the incubation medium supplemented with 0.1% BSA and
2 mM CaCl2 to a density of 4  106 cells/ml. Thereafter, the cells
were placed in an imaging chamber and allowed to settle for 10 min.
In experiments in which kinetics of responses of individual cells to the
NMDA agonists and antagonists was monitored over time, the cov-
erslip serving as a bottom of the imaging chamber was coated with
polylysine to immobilize the cells. A series of images (bright field and
fluorescent images excited at center wavelength of 480 nm with a
half-width of 25 nm and a 510-nm longpass emission filter to reach
maximal detection efficiency) were taken with a100 objective using
Axiovert 200M microscope (Carl Zeiss, Jena, Germany). At least five
images were taken before the addition of agonists or antagonists and
used to calculate baseline levels of fluorescence. Solvent (incubation
medium) addition was performed in control samples.
Calibration was performed using cells resuspended in calcium
buffer containing 20–200 nM free Ca2 (a set of CaCl2-EGTA
mixtures) in the presence of Ca2 ionophore A23187 (10 M) and the
Ca2 pump blocker sodium orthovanadate (4 mM). These cells were
addressed to as calcium-clamped cells.
Analysis of the obtained images was performed using CellFinder
program developed by Dr. M. Makhinya (Computer Vision Lab; ETH
Zurich). This software was designed to detect the cell projection area
as an indicator of cell volume, the average fluorescent intensity within
this area corrected for the background fluorescence, and anisotropy (a
longest to shortest diameter ratio).
Radiolabeled antagonist binding assay was used as an alternative
approach to assess the number of active receptors per cell. [3H]MK-
801 is a specific NMDAR antagonist interacting with the channel pore
of active receptors exclusively (18). The number of [3H]MK-801
binding sites per cell in the absence or in the presence of a 200-fold
excess of nonlabeled MK-801 was assessed for evaluation of specific
and nonspecific binding.
Washed RBCs were incubated with [3H]MK-801 (20 Ci/mmol;
American Radiolabeled Chemicals) at a concentration of 5  107
mmol/ml (1 h, room temperature) in the presence of 300 M NMDA
and 100 M Gly. Thereafter the cells were fractioned according to
their density on 90% Percoll gradient (45,000 g, 30 min). L, M, and
D fractions were collected, washed three times in buffer 1 containing
the following (in mM): 145 NaCl, 5 KCl, 10 glucose, 0.1 EDTA, 10
Tris·HCl (pH 7.4 room temperature) supplemented with 0.1% BSA,
and lysed. One part of packed RBCs was mixed with 30 parts of lysis
buffer containing 25 mM NaH2PO4 and 1 mM EDTA (pH 7.0 at 0°C)
and incubated on ice for 30 min. Thereafter, RBC membranes were
precipitated (45,000 g for 30 min at 4°C) and the amount of [3H]MK-
801 bound to the membranes was assessed using Packard 1600 TR
liquid scintillation analyzer. The number of [3H]MK-801 binding sites
per cell was then calculated using the following equation:
NNR
Acells
AspMK 801  NA  Ncells
NNR is a number of NMDARs per cell, Acells denoted activity of bound
[3H]MK-801 after nonspecific binding is subtracted [Bq] and Asp
stands for specific activity of the [3H]MK-801 in [Bq/mmol], NA is the
Avogadro constant (6.022  1023 mol1), and Ncells are the amount
of cells in the sample.
Whole cell currents were measured using a NPC-16 Patchliner
(Nanion, Munich, Germany). The “pipette” solution contained the
following (in mM): 50 KCl, 10 NaCl, 60 KF, 20 EGTA, and 10
HEPES (pH adjusted to 7.2 by KOH), while the bath solution
contained the following (in mM): 140 NaCl, 4 KCl, 1 MgCl2, 2 CaCl2,
5 glucose, and 10 HEPES (pH adjusted to 7.4 by NaOH). NMDA,
glycine, and MK-801 were added as indicated in the experiments. The
pipette resistance was in the range of 3–5 M, and the seal resistance
was between 800 M and 5 G at a holding potential of 40 mV.
Measurements were performed with fresh RBC samples from three
healthy donors within 2–3 h after blood withdrawal.
pH measurements in RBCs and in RBC lysates. Shifts in the
intracellular pH were monitored over 10 min using microfluorescence
live imaging. RBC were washed three times in isotonic buffer con-
taining the following (in mM): 15 NaCl, 5 KCl, 10 glucose, 20
HEPES-imidazol buffer, 0.1 EDTA, and 0.1% BSA. The cells were
centrifuged and resuspended in the same buffer supplemented with 2
mM CaCl2 and 2 M of pH-sensitive fluorescent dye BCECF-AM
and incubated for 45 min at 37°C in the darkness to achieve optimal
dye loading. Some samples were supplemented with 50 M of MIA
during loading with the dye. The kinetics of the changes in BCECF
fluorescence in response to the treatment with 300 M of 1:1 NMDA-
glycine mixture were recorded at 488-nm excitation and 535-nm
emission wavelengths using Axiovert 200M fluorescent microscope
(Zeiss). The images were taken in time laps mode at 100 magnifi-
cation at a constant rate of 1 frame per min. The obtained data were
analyzed using CellFinder software. Fluorescent intensities were nor-
malized to those at time zero (first frame) and expressed as changes
compared with the readouts obtained for nontreated cells to correct for
the BCECF photobleaching.
Calcium-induced changes in pH were monitored in fresh hemo-
globin solution obtained by lysing 10 l of packed RBCs in 5 ml
of distilled water. Final hemoglobin concentration obtained that
way was 0.25 M. Sodium chloride concentration was then
adjusted to 150 mM, and 2,3-diphosphglycerate pentasodium salt
(2-mM final concentration; Sigma) was added to it. These solutions
were supplemented with various CaCl2 doses (0 –200 M), and pH
was measured at 37 0C using glass pH electrode of the ABL 700
blood analyzer (Radiometer). Thereafter, oxygen dissociation
curves were recorded from these cell lysates as described below.
Hemoglobin oxygen dissociation curves. Oxygen affinity of hemo-
globin was assessed using Hemox analyzer (TCS Scientific, New
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Hope, PA). Measurements were performed in Ca2-clamped cells, in
intact RBCs resuspended in buffer containing 2 mM CaCl2, and in
RBC lysates. Ten microliters of packed RBCs were added to 5 ml of
buffer in the presence or absence of NMDAR agonists NMDA (300
M) and glycine (100 M). Oxygen dissociation curves were re-
corded at 30 or 37°C and P50 calculated from them using Hemox
Analytical Software (HAS). Similar recordings were performed in
cell lysates [10 M of cells lysed in 5 ml H2O supplemented with
150 mM NaCl, 2 mM 2,3-diphosphoglycerate (2,3-DPG), and
various concentrations of CaCl2] obtained as stated above after pH
detection.
Statistical analysis. The obtained data were analyzed using
GraphPad Instat v.3.0 (GraphPad Software,) and presented as
means  SE. Statistical significant differences were assessed using
normality test followed by either one-way ANOVA test (when
distribution was normal) or Kruskal-Wallis test (when normality of
distribution cannot be confirmed) with the Bonferroni or Dunn’s
posttest correspondingly (accepted at P 	 0.05).
RESULTS
Expression of the NMDAR subunits in erythroid progenitors
during erythropoiesis. The number of functional NMDAR
heterotetramers in the immortalized human erythroid cell line
UT-7/Epo was estimated to be350,000 copies per cell (38).
We have then performed characterization of the expression
pattern of NMDAR subunits during ex vivo erythropoiesis
derived from peripheral stem cells and in circulating human
RBCs. Subunit speciation of the NMDARs in human EPCs
during their differentiation was monitored in the course of
transformation from pluripotent precursor (day 0) cells through
the proerythroblast (day 6) and basophilic and polychromatic
erythroblast (day 12) stages to normoblasts and enucleated
reticulocytes (day 18). Differentiation stages were verified
morphologically (Fig. 1, A–C) as well as by expression of
CD71 (Fig. 2). We have detected transcripts of the genes
Fig. 1. Peripheral blood-derived erythroid cultures express N-methyl-D-aspartate receptor (NMDAR) subunits. Representative cytospins of erythroid cells on day
6 (d6, A), 12 (d12, B), and 18 (d18, C). Cytospins were stained with May Grünwald Giemsa, and images were acquired with a Zeiss Axioskop2 microscope
equipped with a Zeiss Plan-Apochromat 63/1.4 oil immersion objective lens and a Zeiss AxioCam MRc digital camera. Images were recorded using Zeiss
AxioVision AC release 4.5.0 software. D: relative amounts of the GRIN gene transcripts in erythroid precursor cells (EPCs) harvested at day 6, 12, and 18
measured by TaqMan quantitative PCR. Values are represented as box plots of 9 erythroid cultures, each started with cells from a different donor. An overall
comparison indicated significant increase in expression of GRIN1 and GRIN2C between the days 6 and 18 in culture. *P 
 0.0391; **P 
 0.0078.
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Fig. 2. Changes of protein levels of NMDAR subunits
during erythropoiesis. Peripheral blood-derived erythroid
cultures were analyzed by flow cytometry on day 6 (d6),
12 (d12), and 18 (d18) after seeding. NMDAR subunit
expression at various EPC differentiation states was as-
sessed. Surface expression of CD71 (CD71 FITC) was
used as a marker of EPCs in the presented dot blots. The
number of cells expressing NMDAR subunits are shown as
histograms. Grey plots show the signal obtained from
staining with secondary APC-conjugated antibodies alone,
and black plots show specific anti-NR-APC signal. The
geometric mean fluorescence intensity (MFI) and the frac-
tion of cells showing specific anit-NR-APC signal were
analyzed from 60’000 cells each measurement and repre-
sented as box plots for the subunits NR2C (A), NR2D (B),
NR3A (C), and NR3B (D). Values are represented as box
plots of 9 erythroid cultures, each started with cells from a
different donor (n 
 9).
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GRIN1, GRIN2A, GRIN2C, GRIN2D, GRIN3A, and GRIN3B
encoding NMDAR subunits NR1, NR2A, 2C, and 2D and
NR3A and 3B in EPC at various stages of erythropoiesis (Fig.
1; Table 1). Relative expression of GRIN1 and GRIN2C
mRNA increased substantially from day 6 to day 18 in culture
(P 	 0.05; Fig. 1E). A tendency to increased expression of
GRIN2A, GRIN3A, and GRIN3B mRNA over 18 days in
culture was detected but was not statistically significant (Fig.
1E). Maximal expression of GRIN2D mRNA was found in
cells after 12 days in culture, whereas in 18-day-old cells the
expression levels dropped to the values similar to those de-
tected at day 6 (Fig. 1G). No transcripts of GRIN2B were
detected at any differentiation stage. In peripheral RBCs we
were not able to detect any GRIN transcripts, indicating that
those were eliminated during erythrocyte maturation (data not
shown).
Protein levels of subunits NR2C, 2D, 3A, and 3B were
measured using flow cytometry (Fig. 2). The number of ery-
throid cells in culture expressing NMDAR subunits varied
between 10 and 30%. The number of erythroid cells expressing
NR2C and NR2D increased during the basophilic and poly-
chromatic cell stages and decreased again once cells matured
towards normoblasts and reticulocytes (Fig. 2, A and B).
However, the number of copies for these subunits was rather
stable throughout the culture period as follows from the mean
fluorescence intensity levels (Fig. 2, A and B). The subunit
NR3A appeared to be expressed by an increasing proportion of
cells throughout erythropoiesis; however, its expression de-
creased slightly (Fig. 2C). The number of cells expressing
NR3B remained stable during the erythropoietic culture,
whereas its expression increased slightly (Fig. 2D). Specifi-
cally during ex vivo differentiation, the GRIN2D levels of the
median subunit per cell remained relatively unchanged from
day 6 (proerythroblast) with 186,000 (41,000–320,000) to day
12 (basophilic erythroblast) with 140,000 (18,300–540,000)
subunits per cell. Towards days 18–24 in culture (polychro-
matic- and normoblast, and also reticulocytes), expression of
the NR2D subunit dropped to 120,000 (4,100–240,000) sub-
units per cell. Thus the stable expression of GRIN2D mRNA
during differentiation from myeloid progenitor towards the
basophilic/polychromatic erythroblast was mirrored by a stable
expression in GRIN2D protein levels. During differentiation
towards erythrocytes the transcripts appear to become de-
graded, as they are not detected anymore, whereas NR2D
protein is retained although at much lower levels (data not
shown).
The importance of functional NMDARs in EPCs in the
course of differentiation was explored. The kinetics of changes
in the intracellular Ca2 levels in EPCs in response to stimu-
lation of the NMDARs with a mixture of NMDA and glycine
(300 M each) in the absence or presence of 50 M MK-801
were monitored using fluorescence microscopy. Administra-
tion of NMDA/glycine to the cells at day 12 resulted in acute
increase in the intracellular Ca2 levels as shown in Fig. 3A.
Table 1. Expression of NMDAR subunits in WBCs
Gene ID* Protein Ct
Ct (fold mRNA
expression compared with
EPCs)
GRIN1 2902 NR1 19.8 1.6 7.0
GRIN2A 2903 NR2A 15.8 1.9 11.2
GRIN2B 2904 NR2B 18.8 1.4 (Not expressed in EPCs)
GRIN2C 2905 NR2C 15.6 1.8 0.7
GRIN2D 2906 NR2D 12.0 0.9 11.0
GRIN3A 116443 NR3A 18.3 2.3 1.0
GRIN3B 116444 NR3B 17.3 1.6 10.8
Values are SE for 3 cultures, each started with cells from a different donor
(n 
 3). EPC, erythroid precursor cell. Relative amounts of transcripts of
N-methyl-D-aspartate receptor (NMDAR) subunits were detected by TaqMan
quantitative PCR. White blood cells (WBCs; predominantly monocytes) were
obtained from mononuclear cells in culture and separated from the hemato-
poietic stem cells (HSC) at day 3 of culturing as “adherent cell fraction.”
Individual values were normalized to GAPDH (Ct), and the individual fold
change compared with the median Ct values of erythropoiesis at day 6 was
calculated (expCt, fold change in mRNA expression). Comparison with the
values for mRNA expression in HSCs at day 3 was not possible as too few
cells were available at that time. GRIN2B expression in HSCs was fixed to 40
cycles. *NCBI gene ID.
Fig. 3. NMDAR function in EPCs. A: cells on day 12 were loaded with 3 M fluo-4 AM for 45 min at 37°C in cell culture medium and thereafter fluorescence
recordings were initiated using Axiovert 200M microscope in time-lapse mode at a frequency of one frame in 7 s. Cells were stimulated with 300 M of
NMDA/glycine 1 min after the onset of recordings and the changes in fluorescence followed for 10 min. Some cells were pretreated with 50 M of MK-801
for 45 min before the imaging procedure. The antagonist was present in the cell culture medium during the imaging. The number of cells analyzed was 542 for
control nontreated group (closed squares), 511 for the NMDA/Glycine-stimulated group (grey triangles), and 494 for the cells pretreated with MK-801 before
the stimulation with antagonists (open circles). B: cells at day 12 (closed circles) or at day 18 (open circles) were exposed to various concentrations of MK-801
for 24 h and cellular viability was assessed thereafter using flow cytometry (FacsCalibur; BD). Nuclear staining of propidium iodide was used as a marker of
cell death.
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Whenever MK-801 was present in the incubation medium
before the receptor activation, the response was biphasic. A
transient and incomplete Ca2 accumulation during the first 30
s upon NMDA/glycine addition was followed by a decrease in
the intracellular Ca2 significantly below the levels observed
in control nontreated cells. On day 18, EPCs lost their sensi-
tivity to NMDA/glycine and stimulation of the receptors did
not result in any acute significant changes in the intracellular
calcium along with higher intercellular variability in the intra-
cellular Ca2 levels and responsiveness to the stimulation (data
not shown). The effects of long-term exposure on the EPCs to
different concentrations of the pore blocking NMDAR antag-
onist MK-801 were explored. In line with the data on NMDA/
Gly-sensitivity of the intracellular Ca2 levels, exposure of
EPCs at day 12 to 50 M MK-801 for 24 h resulted in
significant increase of mortality whereas the cells at day 18
were antagonist resistant (Fig. 3B).
NMDAR expression pattern in WBCs. To evaluate the im-
pact of potential contaminations of myeloid progenitors in our
culture systems and that of WBCs in our RBCs preparations,
we used CD45 as a marker of myeloid and WBCs (45). We
were unable to detect myeloid cells in our culture system after
day 6. No WBCs were detected in purified RBCs, as shown
previously (3). We have assessed the expression GRIN tran-
scripts in adhesive WBCs separated at day 2 from our erythroid
culture. These cell preparations contained predominantly
monocytes. Expression of GRIN1 in this myeloid cell popula-
tion exceeded that in erythroid cells at day 6 of the erythro-
poietic culture by 4.4-fold, that of GRIN2A by 6.5-fold, and
that of GRIN2D by 9.8-fold whereas GRIN2C was 50% lower
in WBCs than in erythroid progenitors (Table 1). Compared
with erythropoietic cultures at day 18, WBCs expressed 0.6-
fold less GRIN1, 3.8-fold more GRIN2A, 0.06-fold less
GRIN2C, and 10.8-fold more GRIN2D compared with the
levels in basophilic and polychromatic erythroblasts (Table 1).
These findings provided further evidence for the absence of
myeloid cells or WBCs in erythroid cell culture. Expression
profiles for NMDAR subunits GRIN1, GRIN2C, and GRIN3A
in differentiated erythroid cells differed substantially from
those in WBCs. Furthermore, WBCs appeared to express
GRIN2B subunit whereas in erythroid cells the GRIN2B tran-
scripts remained below detection level at any time in culture
(Table 1).
NMDAR activity and intracellular Ca2concenrtation. In
the following set of experiments, the activity of NMDAR was
assessed in circulating RBCs. Changes in the intracellular
calcium levels in RBCs upon treatment with agonists NMDA,
glutamate, and HCA are shown in Fig. 4A. Increase in the
intracellular Ca2 levels, which was induced within minutes of
exposure to the agonists, could be blocked by the pore-block-
ing antagonist interacting with the open receptor channel MK-
801 (Fig. 4, A and B). Responses of individual cells to the
NMDAR stimulation varied substantially (Fig. 4C). However,
despite pronounced intercellular variability, the majority of
cells responded to the treatment with the NMDAR agonists
with acute Ca2 uptake.
NMDAR-induced whole cell currents in RBCs. Calcium
uptake following activation of the NMDAR was associated
with an increase in whole cell currents across the RBC plasma
membranes (Fig. 5). Changes in membrane conductance were
assessed using automated patch clamp platform Patchliner
(Nanion). Similar to the observations obtained using micro-
fluorescence live imaging (Fig. 4C), sensitivity of the cells to
agonists and antagonists varied markedly between individual
cells. An increase in currents associated with exposure to the
NMDA-glycine mixture was observed in 29.4% of cells. Cur-
rents induced by the treatment of cells with agonists could be
blocked by the treatment of cells with MK-801. Examples of the
NMDA-sensitive currents are shown in Fig. 5, A and C, and
statistical analysis of the findings in responding cells is given in
Fig. 5E. The appearance of the current-voltage (I-V) curves
changes when the NMDAR is activated (green line in Fig. 5D) or
when it is blocked (blue line in Fig. 5D). To relate the current
traces to the other data in the paper the slope of the I-V curves was
analyzed in the physiological relevant range between 30 and 0
mV (Fig. 5D). At stimulated NMDAR, the whole cell conduc-
tance is significantly increased compared with naïve RBCs (green
column vs. red column in Fig. 5E). When the RBCs with activated
NMDARs are treated with MK-801 to block NMDAR activity,
the whole cell conductance is significantly decreased (green col-
umn vs. blue column in Fig. 5E).
NMDAR abundance in RBC fractions of high medium and
low density. In the next sets of experiments RBCs were
separated into fractions according to their density using Percoll
density gradient centrifugation. D, M, and L fractions were
isolated as shown in Fig. 6A. The basal activity of the receptor
and total number of the functional NMDAR units was mea-
sured in each fraction using two independent approaches:
radioactive antagonist binding assay and agonists/antagonists-
induced changes in the intracellular calcium levels. Basal
receptor activity was evaluated as the cells were allowed to
interact with [3H]MK-801 in plasma and then fractioned on
Percoll gradient. The number of binding sites for radiolabeled
antagonist per cell obtained that way reflected the number of
NMDARs active in plasma-borne RBCs. The values for the
[3H]MK-801 binding to “activated” cells were obtained in the
presence of saturating concentrations of NMDA in plasma and
hence represented the total number of receptors. As shown in
the Fig. 6B, the number of active receptors interacting with
[3H]MK-801 was maximal in the L fraction enriched with
reticulocytes and young cells (see DESIGN AND METHODS). In this
fraction, no further activation of the receptor could be caused
by glutamate/NMDA supplementation of plasma. In contrast to
that, the receptors in M and D fractions, although significantly
lower in number, could be further activated by addition of
agonist to plasma (Fig. 6B).
These experimental settings could give rise to artefacts due
to the WBCs contamination (average of 5.6, 4.9, and 1.4 per
1,000 cells in the L, M, and D fractions; Ref. 45). To avoid the
overestimation of the receptor activity in RBCs, we have used
an alternative approach monitoring the agonist-induced Ca2
uptake in individual RBCs of L, M, and D fractions isolated
from blood of three healthy individuals by microfluorescence
live imaging. Receptor activity in RBCs of these donors was
assessed by [3H]MK-801 binding and presented in the right
panel of Fig. 6 (in red for donor 1, in green for donor 2, and in
blue for donor 3). The observations obtained by means of
microfluorescence imaging were in agreement with the ones
generated using radiolabeled antagonist binding assay. Maxi-
mal amount of “responding” RBCs of each individual donor
was present in the L fraction (Fig. 7A). Maximal amplitude of
NMDA-induced Ca2 uptake was recorded in the least dense
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Fig. 4. Changes in the intracellular Ca2 lev-
els in red blood cells (RBCs) exposed to
agonists and antagonist of NMDARs. A: an
increase in the intracellular Ca2 in response
to administration of 100 M NMDA, 100 M
NMDA  100 M glycine, 100 M gluta-
mate, or 50 M homocysteic acid (HCA) was
observed. Data are means of 34–80 single cell
recordings  SE. The orange bar on top of
each panel schematically indicates the dura-
tion of exposure to the agonists. B: sensitivity
of the HCA-induced Ca2 uptake by RBCs to
the NMDAR antagonist MK-801 (50 M).
Pretreatment with antagonist for 10 min abol-
ished the effects of subsequent exposure to
HCA. The green trace represents the average
Ca2-sensitive fluorescent signal recordings
for 444 unstimulated control HBA RBCs in
Tyrode’s solution. The red trace shows the
F/Fo ratio for RBCs stimulated with NMDAR
agonist HCA (100 M) 1 min after the start of
the recordings averaged from 776 single cell
recordings. Preincubation of the cells with
NMDAR antagonist MK-801 (100 M) ad-
ministered 10 min before the onset of the
recordings did not affect the basal intracellular
Ca2 levels during 20 min of exposure (blue
trace, average of 775 individual cell record-
ings), but effectively inhibited the HCA-sen-
sitive Ca2 influx, as depicted by the brown
trace (average of 742 individual cell record-
ings). Each curve shows data from 9 indepen-
dent measurements of 3 healthy donors  SE.
(C) A selection of traces from individual cells.
The images above the diagram exemplify the
original fluorescent images of cells at the time
points indicated by the dotted lines. The false
color coding scale is shown next to the origi-
nal tracks of the changes in fluorescence in-
tensity over time. The colors of traces corre-
spond to those of the circles marking the
individual cells in the leftmost image. The
tremendous cell-to-cell variation is obvious in
both the images and the traces.
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fraction of RBCs of donor 2. Transient Ca2 accumulation in
RBCs was associated with a transient shrinkage of cells that
could be caused by the activation of Gardos channel. Medium
density fraction of the donor 2 was also rich in responding
RBCs and showing a transient reduction in cell volume in
response to the NMDAR stimulation (Fig. 7B, middle).
We used Percoll density gradient to assess the amount of
cells changing their volume in response to the NMDAR stim-
ulation in the M fraction to which majority of RBCs belong
(Fig. 6A). The density of Percoll solution used in these exper-
iments was adjusted to resolve the changes in the M fraction.
As shown in Fig. 7D, most of the cells forming M fraction
migrated downwards in Percoll gradient 2 min after the onset
of stimulation with 300 M of 1:1 NMDA/glycine mixture.
This increase in RBC density was transient and could not be
detected 5 min after the onset of exposure to the NMDAR
agonists in four out of five donors. Cells of the fifth donor
remained dehydrated even after 15 min of exposure to the
agonists. No volume changes were observed in RBCs of all
donors suspended in nominally Ca2-free Percoll solution
containing 0.1 mM EDTA supplemented with NMDA and
glycine (data not shown).
In fraction D (Fig. 7C), the cells remained largely insensitive to
the agonist treatment and showing modest transient increase in the
intracellular Ca2. The obtained data revealed vast interindividual
and intercellular variation in the number of functional receptor
units and the amplitude of responses to the NMDAR agonists.
Among typical morphological characteristics of responding cells
are big volume (cell surface projection) and low density as L
fraction is enriched with responding cells. Medium fraction also
contains some of the responders, whereas D fraction is largely
deprived of them.
The impact of NMDAR activation state on Gardos channel
function. The following experiments were performed to assess
the possible influence of NMDA-sensitive Ca2 uptake on K
transport across the RBC membrane. Ouabain-resistant chlo-
ride-independent K (86Rb) influx was assessed at room tem-
perature, as was the case for Ca2 imaging presented in Fig. 7.
Fig. 5. Whole cell currents of RBC under
activation and blocking of the NMDARs.
Measurements as shown in A were per-
formed on 56 gigasealed RBCs. However,
for an observation period of 15–20 min only
34 cells were stable enough to allow analy-
sis. 29% of the analyzed RBCs were classi-
fied as “responders.” Similar in size fraction
of responding cells was obtained in Ca2
imaging experiments and when the number
of NR2D subunits was assessed using flow
cytometry. Responding cells were the RBCs
showing an increase in conductance with the
application of NMDA (100 M) and glycine
(300 M) and a decrease when MK-801 was
added. A: original current traces of an RBC
under the conditions presented above the traces
as a response to the voltage protocol given in
B. The current-time (I-t) diagram in C depicts
the temporal distribution of the currents at80
and 80 mV over the experimental course
starting with naïve RBC, application of
NMDA and glycine for NMDAR activation
and finally MK801 for NMDAR block as
indicated. The current traces in A correspond
to the time points at 2, 10, and 18 min,
respectively in C. D: current-voltage (I-V)
curves of the responding RBCs under the
conditions indicated (data are mean of 10
measurements). The slope of the curves in
the range between 30 and 0 mV was ana-
lyzed by linear regression and the results are
presented in E, revealing significant differ-
ences in the whole cell conductance at the
physiologically relevant membrane potential
for the different experimental conditions.
Significance was tested by comparing the
slopes using a 2-way ANOVA test and is
expressed as *P 	 0.05, **P 	 0.01, and
n.s., P  0.05.
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No density fractioning was performed before flux measure-
ments. As shown in Table 2, treatment of RBCs suspended in
Ca2-containing but not in nominally Ca2-free incubation
medium with 50 M memantine caused reduction in unidirec-
tional K influx. Administration of 100 M NMDA triggered
the activation of clotrimazol-sensitive Ca2-dependent K
influx. In nonactivated cells, Gardos channels remained quies-
cent.
Effect of the NMDAR activation on hemoglobin oxygen
affinity. The effect of the intracellular Ca2 on oxygen binding
to hemoglobin was tested. Intracellular free Ca2 concentra-
tion was clamped as cells were treated with Ca2 ionophore
A23187, and extracellular concentration of free calcium ions
was adjusted to 10–200 nM by using an EGTA-CaCl2 buffer
system. Oxygen dissociation curves were then measured and
PO2 required to achieve hemoglobin oxygen saturation of 50%,
P50, was assessed for the calcium-clamped RBCs. Calcium
levels in clamped RBCs were assessed using microfluores-
cence imaging. As shown in Fig. 8, the fluorescent signal
intensity of fluo-4 follows linearly the changes in the intracel-
lular Ca2 within the 10- to 200-nM interval (Fig. 8A). Intra-
erythrocytic Ca2 levels in intact and NMDA-stimulated cells
lies within this concentration range (triangle symbols). Oxygen
affinity of Ca2-clamped cells drops (P50 increases from
2.28  0.01 to 4.1  0.27 kPa) as intracellular Ca2 increased
from 20 to 200 nM (Fig. 8C). Exposure of RBCs in suspension
to 300 M NMDA-100 M glycine mixture was also associ-
ated with an increase in P50 (Fig. 8, B and D).
Acute transient RBC shrinkage triggered by exposure to the
NMDAR agonists results in transient increase in the intracel-
lular levels of 2,3-DPG and ATP due to the cytosolic water
loss. Additional experiments were performed to explore if this
factor contributed to a decrease in hemoglobin oxygen affinity.
Oxygen dissociation curves were monitored in RBCs sus-
pended in the medium containing 100 mM KCl/50 mM NaCl
medium or in the presence of clotrimazol. The effect of
NMDA/glycine on P50 was less pronounced but still preserved
in both conditions, (3.04 0.65 kPa in control vs. 3.16 0.04
kPa in depolarizing high KCl medium, P 
 0.011).
The effect of NMDAR agonists on the intracellular pH was
assessed microscopically using proton-sensitive fluorescent
dye BCECF-DA. Treatment of RBCs with NMDA/glycine
resulted in a modest transient decrease in pH-dependent
BCECF fluorescence indicating transient intracellular acidifi-
cation (Fig. 8F). The signal we reported was underestimated as
shrinkage following the NMDAR activation caused concentra-
tion of the fluorescent dye. This acidification reaction moni-
tored in bicarbonate-free medium was insensitive to the inhib-
itor of Na/H exchanger methyl isobutyl amiloride applied at
the concentration of 50 M. The ability of Ca2 to cause the
proton release from hemoglobin was explored as RBC lysates
(Hb concentration of 0.25 M, equilibrated with ambient air)
were exposed to various concentrations of Ca2. Cell lysates
prepared in 150 mM NaCl solution showed no changes in pH
in response to Ca2 administration. However, dose-dependent
acidification was observed if cell lysates were exposed to Ca2
Fig. 6. Activity and abundance of the NMDAR units in light (L), medium (M), and dense (D) RBC fractions. Cells were incubated with radiolabeled [3H]MK-801
in the absence or presence of saturating concentrations of NMDA (300 M) and glycine (100 M) added to plasma (activated cells, orange dots). Thereafter,
the cells were separated according to their density into L, M, and D fractions on Percoll gradient as shown in A. B: presents binding of radio-labeled MK-801
to the activated NMDARs was then determined in RBCs in L, M, and D fractions. Non-specific binding was assessed in the presence of 200-fold excess of
non-labeled MK-801 and subtracted from the obtained values. Thus the number of active NMDARs was obtained. Values obtained in plasma were shown as
“basal receptor activity” in nonstimulated RBCs. Upon stimulation with agonists all receptors in cells were activated and therefore binding of [3H]MK-801. Thus
the number of [3H]MK-801 binding sites within activated cells reflected total number of receptors in cells forming L, M, and D fractions. The measurements
were performed in blood samples per cell collected from 31 healthy human subjects. Data are presented as box and whisker plots in which each dot represent
a value obtained for an individual subject. Specifically marked in red (1), green (2), and blue (3) are the number of active receptors in blood samples of donors
blood of which was used to generate data shown in Fig. 7. In L, M, and D fractions distribution of values for individual donors did not show normal Gaussian
distribution and statistical analysis of the data was performed using nonparametric Kruskal-Wallis test with Dunn’s posttest (**P 	 0.01, and ***P 	 0.0001
compared with the basal activity of the NMDAR in corresponding fraction).
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Fig. 7. Kinetics of Ca2 uptake and volume changes in response to NMDAR activation in L, M, and D fractions. Intracellular calcium levels were assessed in
RBCs forming L (A), M (B), and D (C) fractions after their separation on Percoll density gradient using fluorescent live cell imaging. The experiments were
performed using blood of subjects 1 (red), 2 (green), and 3 (blue). The values of [3H]MK-801 binding obtained for RBCs of these subjects are highlighted in
corresponding colors in Fig. 6. Presented in the left panels are quantification of Fluo-4 fluorescence intensity F upon stimulation with glutamate (300 M) and
glycine (100 M) normalized to that at time zero in agonist-free medium (Fo). Middle: changes in cell projection area in the bright field images over the period
of stimulation with the NMDAR agonists. The numbers of cells used for analysis varied from 13 to 35. Data are presented as mean  SE. Right: representative
fluorescent images at 3 points in time (before, 1, and 6 min after the stimulation) for the cells in L, M, and D fractions obtained from blood of subject 2 (green
plots). Kruskal-Wallis test was performed to follow the changes in Ca2 levels and cell surface (a marker of volume) after the receptor activation. *P 	 0.05,
** and **P 	 0.01 and ***P 	 0.001 compared with time zero. D: shift of RBCs within the M fraction down the Percoll density gradient in response to 2 min
of stimulation with 300 M of 1:1 NMDA/glycine mixture in donors 1, 2, and 3.
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in the presence of 2 mM 2,3-DPG (Fig. 9). Exposure of
2,3-DPG alone to Ca2 did not result in the changes in pH (Fig.
9). Oxygen binding to hemoglobin within RBC lysates was
tested in the presence of 2,3-DPG and various concentrations
of Ca2. As shown in Fig. 9 Ca2-induced proton release was
associated with a dose-dependent rightward shift in oxygen
binding curve, the effect observed in Ca2-loaded or NMDA-
glycine stimulated RBCs (Fig. 8). Similar to that of pH, oxygen
binding to hemoglobin in lysates remained calcium-insensitive
in the absence of 2,3-DPG (data not shown).
DISCUSSION
Following up on our earlier observations on the presence of
NMDARs in rat RBCs and in human myeloid cell line differ-
entiating into erythroid progeny, UT-7/EPO (38), we have
demonstrated that NMDAR subunits are expressed in human
EPCs. Circulating human RBCs retain a limited number of
functional receptor units compared with the EPCs. Mammalian
RBCs may therefore be added to the list of cells possessing
NMDARs along with neurons and a number of nonneuronal
cells and tissues (22, 57). Expression of the GRIN transcripts
coding for the NMDAR subunits was changing dynamically
during erythropoiesis, as did the protein abundance. NMDARs
appear to be essential for survival, particularly at the early
stages of differentiation of precursor cells during erythropoie-
sis. Subunit composition of the erythroid receptors differed
substantially between the erythroid progeny and WBCs.
Calcium uptake was reported to be of key importance for
promoting differentiation and proliferation of EPCs at the
stages of burst-forming units erythroid (BFU-E) colony-form-
ing units erythroid (CFU-E; Refs. 43, 56). Increase in the
intracellular Ca2 is an integral part of signaling pathway
activated by binding of erythropoietin to its receptor (44). Our
data suggest that glutamate released from megakaryocytes (63)
Table 2. Effects of NMDA and memantine on the
unidirectional ouabain-insensitive Cl -independent K
(86Rb) influx in Ca2-containing and Ca2-free medium
Treatment
1.8 mM Ca2,
mmol·lcells1·h1
Ca2-free,
mmol·lcells1·h1
Control 0.0134 0.0017 0.0176 0.0029
Memantine 0.0056 0.0012* 0.0162 0.0015
Clotrimazol 0.0158 0.0016 NA
NMDA 0.0201 0.0017* 0.0160 0.0008
NMDA-memantine 0.0102 0.0059 0.0168 0.0028
NMDA-clotrimazol 0.0126 0.0023 NA
Values are means  SE. *P 	 0.05, in one-way ANOVA analysis with
Dunnett multiple comparison posttest; NA, not assessed.
Fig. 8. Ca2 sensitivity of hemoglobin oxygen affinity. Intracellular Ca2 concentration in RBCs was clamped using A23187 and EGTA-CaCl2 buffer to 5–200
nM. A: efficacy of clamping of intracellular Ca2, which was monitored as the change in fluorescence intensity of fluo-4 (open circles). Fluorescence intensity
measured in cells clamped at 50 nM Ca2 was chosen as Fo. Closed triangles show the fluorescence intensity of fluo-4 in native cells in the absence of presence
of 300 M NMDA/100 M glycine, which were resuspended in buffer containing 1.8 mM CaCl2. B: data on P50 detection obtained for the blood of one single
donor on four occasions. Before the P50 detection RBCs were loaded with various concentrations of calcium (clamping at 20 or 200 nM free Ca2). Oxygen
dissociation curves for calcium-clamped cells were recorded at 30°C. C: changes in P50 caused by exposing RBCs of 7 healthy donors to a mixture of NMDA
(300 M) and glycine (100 M). Intact RBCs were resuspended in the medium containing 2 mM Ca2 at 37°C and agonists added at the onset of oxygen
dissociation curve recording. Each point represents P50 of one donor (mean of triple recordings). Also presented are median values with variance shown as
whiskers. D: rightward shift in oxygen dissociation curve observed 1 min after the onset of stimulation with 300 M of 1:1 mixture of NMDA/glycine at 37°C.
E: opposite leftward shift in the same blood sample monitored between the 3d and 4th min of NMDAR stimulation. These reciprocal changes in P50 were
associated with the opposite shifts in the intracellular pH over shown in F. RBCs of 4 different donors were used for measurements of the intracellular pH by
means of microfluorescence live imaging. Due to the technical difficulties imaging was performed at room temperature. Shown are the differences in mean
fluorescence intensity between the unstipulated control and cells exposed to the 300 M of 1:1 mixture of NMDA/glycine. The number of cells analyzed at each
time point ranged between 343 and 412. P 	 0.05 resulting from Mann-Whitney test (normal distribution was not confirmed). ***P 
 0.0002, *P 	 0.05.
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may contribute to the regulation of Ca2 levels in EPCs at day
12 corresponding to the stage of basophilic and polychromatic
erythroblasts (Fig. 3A). The number of EPCs possessing NR2C,
2D, and 3A subunits is maximal at this stage (Fig. 2). Accord-
ingly, the cells display high sensitivity to treatment with NMDAR
agonists in our ex vivo erythropoietin system (Fig. 3A).
Ca2 uptake is inhibited and differentiation and survival of
EPCs is compromised in calcium-free medium (43, 56). Sim-
ilar to that, inhibition of Ca2 uptake by MK-801 in our ex
vivo erythropoiesis system resulted in 45.5  12.8% mortality
of cells at the stage of basophilic and polychromatic erythro-
blasts (Fig. 3B). Cells at later differentiation stages (normo-
blasts at day 18 and enucleated RBCs) are less or not at all
damaged by MK-801.
Transient receptor potential channels TRPC2, 3, and 6 were
suggested to mediate Ca2 currents in EPCs (23, 67). How-
ever, observations on the activation of the TRPC channels by
the downstream targets of erythropoietin [e.g., phospholipase
C (PLC), and protein kinase C (PKC)] were exclusively re-
ported in nonerythroid channel expressing systems (CHO and
HEK cells). Similar to TRPCs, NMDARs were shown to be
sensitive to the activation of PLC-inositol-3-phosphate kinase
signaling cascade and targets of regulatory PKC-induced phos-
phorylation (39, 73). Thus both types of ligand-gated channels
may coexist in membranes of EPCs (63).
Subunit composition of the erythroid NMDARs. From the
data shown in this study, we conclude that human erythroid
NMDARs are hetero-tetramers composed of NR1, NR2A, 2C,
and 2D and NR3A and 3B subunits. Subunit composition of
the erythroid NMDARs differs strikingly from that of the
neuronal receptors. As follows from our observations, NR2D
and NR2C are most abundant NMDAR subunits in EPCs and,
most likely, in circulating RBCs. In the mammalian brain, this
subunit shows particularly restricted temporal and spatial ex-
pression pattern. Very high levels of expression of NR2D in
some areas of embryonic rat brain (precocious midline dien-
cephalic structures and medial geniculate, anteroventral nu-
cleus, and periaqueductal grey zones) drop down dramatically
during postnatal period (49). In adult rodent brain, NR2D is
only detected in cerebellum and Golgi structures (9, 47) and is
highly expressed in motoneurons of the spinal cord (66). In
bone marrow and in megakaryoblasts derived from CD34
precursor cells, the NR2D subunit was found along with NR1
and NR2A (19, 24). Among the characteristic features reported
for the NR2D/NR1 heterodimers are reduced Mg2 block,
lower ion conductance and slow inactivation (15, 54). How-
ever, based on the available data obtained in transfected cells
by other groups, one can suggest that the erythroid-specific
receptor channels share at least some of these features, such as
slow inactivation, since glutamate-binding NR2D subunit is
highly abundant in these cells. Calcium accumulations ob-
served upon activation of the receptor activity with glutamate,
NMDA, and homocysteic acid that could be blocked by MK-
801 (Fig. 4) are in line with this hypothesis (33, 46, 48).
However, in erythroid precursors the glycine-binding NR3A
and B subunits were highly expressed, whereas the expression
of a common NR1 subunit was modest compared with that in
the brain (Figs. 1 and 2). These subunits are known as “inhib-
itory subunits” in the brain as they are glutamate-insensitive
but excited by glycine only (35). Currents induced by glycine
in NR1/NR3 diheteromers are insensitive to MK-801 or me-
mantine (58). This is not the case for the erythroid NMDARs,
as the receptors respond to the pore-targeting antagonists in
both EPCs and circulating RBCs. Thus the receptors are either
NR1/NR2 heterodimers or are built up of all three subunit
subtypes (NR1/NR2C, D/NR3 heterotetramers), although the
existence of the latter has been questioned (69). Any specula-
tions on the electrophysiological characteristics of erythroid
NMDARs require verification upon detailed investigation.
Receptor function in circulating RBCs of healthy human
subjects. NMDARs retained in circulating RBCs remain func-
tional and keep responding to stimulation with glutamate,
HCA, or NMDA as well as to the inhibition by MK-801 (Figs.
3–6). Calcium transport through the receptor is electrogenic,
putting NMDARs in line with other calcium-transporting ion
channels (Fig. 4). The number of such ion channels in RBC is
rather limited and their molecular identity often remains un-
known (28). Among the TRP channels, only TRPC6 is de-
scribed in RBC (17). Furthermore, there is biochemical and
functional evidence for a CaV2.1 channel (1, 71). There are
numerous electrophysiological reports of Ca2-permeable
channels that can be grouped in two categories: nonselective
voltage activated cation channels (NSVAC; e.g., Refs. 4, 29)
and receptor-mediated channels (e.g., Refs. 13, 25). Although
the I-V curve for NSVAC in whole cell conductance mode (55)
differs from that shown in Fig. 4D, NMDARs and NSVACs
have one common property. Both channels share the hysteresis
of whole cell current-voltage curves as their opening probabil-
ity depends on the direction in which membrane potential
changes occur (50).
The receptor-activated channels previously described in
RBCs share some conductance properties with the channel
described in Fig. 5 (13, 25). However, it is premature to make
any conclusions on the molecular identity of these channels.
Our findings strongly suggest that the currents presented in Fig.
5 are NMDAR mediated. Stimulation of RBCs with NMDA
induced an increase in conductance whereas administration of
the pore-blocking antagonist suppressed it. Asymmetrical al-
terations in conductance in response to NMDA treatment
Fig. 9. Dose-dependent Ca2-induced changes in pH and in P50 measured in
RBC lysates. Changes of pH and hemoglobin oxygen affinity in RBC lysates
in the presence of 2,3-diphosphoglycerate (2,3-DPG). RBCs were lysed in the
distilled water, and then NaCl was added to a final concentration of 150 mM
with the final hemoglobin concentration 0.25 M. 2,3-DPG (2 mM) and
various concentrations of CaCl2 were added and pH (closed circles) was
measured at 37 0C for each sample in prior to the P50 measurements (grey
diamonds). The impact of 2,3-DPG-Ca2 interactions into the observed shifts
in pH was assessed (open circles). Data shown are means of triplicate
measurements form one representative donor. The experiment was repeated
with blood of 3 different healthy individuals.
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suggest that is it may be channel mediated. The current mea-
sured is a superposition of NMDAR-channel current, currents
mediated by other ion channels (e.g., those reported elsewhere;
Refs. 11, 62), and a leak current. Channel-mediated compo-
nents show a slight outward rectification and a positive reversal
potential (Fig. 5D, blue I-V curve). Considering the composi-
tion of the bath and pipette solutions this could well be chloride
channel activity (61). The contribution of the NMDAR channel
can be estimated as the difference between putative fully
activated channels (Fig. 5D, green trace) and the corresponding
inhibited channels (Fig. 5D, blue trace). In the physiological
relevant range between30 and 0 mV, this difference amounts
to a conductance of 930 pS (Fig. 5E). The decreased current
at negative membrane potentials in the presence of Mg2 in the
bath solution is another indication for the NMDAR identity of
the channel (15).
So far channel-mediated Ca2 uptake by RBC was always
associated with pathophysiological conditions, such as clot
formation (30, 74) or Ca2-induced clearance (34). To our
knowledge, our study is the first one revealing possible phys-
iological role of controlled transient Ca2 uptake following the
activation of NMDARs, namely the regulation of oxygen
affinity of hemoglobin (Figs. 8 and 9).
Among endogenous regulators of the erythroid NMDAR
activity are plasma-borne glutamate, glycine, D-serine, homo-
cysteine, and HCA. The rodent NMDAR EC50 for glutamate is
96  20 M (26), being 10 M for HCA (53), and 40 M
for glycine (38, 58). These data were obtained for the receptors
in neurons and in artificial expression systems. These values
are close to the EC50 for glutamate (88.2 M) and homocysteic
acid (21 M) reported for the NMDARs in rat RBCs (38).
Glutamate concentrations in plasma of healthy human subjects
vary substantially depending on physical condition, exercises,
gender, diet, and age, making up from 7 1 M (14) to 255
26 M (32). Local glutamate and glycine availability in vicin-
ity of RBC membranes may exceed the bulk plasma levels due
to high abundance of these amino acids in the cytosol (32).
Homocysteine and HCA also contribute to the activation of
erythroid NMDARs. Plasma total homocysteine levels ranges
from 4.2 to 17.2 M in healthy human subjects to up to 470
M in patients with hyper-homocysteinemia (59).
Transient activation of the NMDARs by glutamate released
from the exercising muscle (14) or obtained with meal (27)
might also contribute to a transient increase in the intracellular
Ca2 promoting thereby oxygen release from hemoglobin (Fig.
8). The exact mechanism of a cross talk between calcium levels
in RBCs and hemoglobin oxygen affinity remains to be studied
in details.
Shrinkage (Fig. 8; Table 2) results in a rapid transient
increase in 2,3-DPG levels in the cytosol, which in turn could
stabilize hemoglobin in T state and promote oxygen release
(Fig. 7, B and D). However, a shift in oxygen affinity of
hemoglobin caused by the stimulation of the NMDARs was
preserved in the presence of clotrimazol or in high KCl
medium, conditions preventing Ca2-induced KCl and water
loss from RBCs. The obtained data reveal that changes in the
intracellular pH result from the shifts in protonation of hemo-
globin (Fig. 8). The latter result in the 2,3-DPG-dependent
alterations in P50 (Figs. 8 and 9). These observations are
consistent with earlier reports on an increase in free Ca2
concentration in the cytosol of RBCs undergoing deoxygen-
ation in which hemoglobin gets protonated (65). Conforma-
tional changes responsible for these Ca2-induced changes in
oxygen affinity of hemoglobin await further characterization.
Taken together, the obtained findings reveal the presence of
functional NMDARs in EPCs and, at much lower levels, in
circulating RBCs. The abundance and activity of these recep-
tors in plasma membrane of RBCs and their progenitors are
proportional to the intracellular Ca2 levels. Among the down-
stream targets of Ca2 accumulation are cell volume and
hemoglobin oxygen affinity.
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Hänggi P, Telezhkin V, Kemp PJ, Schmugge M, Gassmann M,
Goede JS, Speer O, Bogdanova A. Functional plasticity of the
N-methyl-D-aspartate receptor in differentiating human erythroid pre-
cursor cells. Am J Physiol Cell Physiol 308: C993–C1007, 2015. First
published March 18, 2015; doi:10.1152/ajpcell.00395.2014.—Cal-
cium signaling is essential to support erythroid proliferation and
differentiation. Precise control of the intracellular Ca2 levels in
erythroid precursor cells (EPCs) is afforded by coordinated expression
and function of several cation channels, including the recently iden-
tified N-methyl-D-aspartate receptor (NMDAR). Here, we character-
ized the changes in Ca2 uptake and electric currents mediated by the
NMDARs occurring during EPC differentiation using flow cytometry
and patch clamp. During erythropoietic maturation, subunit composi-
tion and properties of the receptor changed; in proerythroblasts and
basophilic erythroblasts, fast deactivating currents with high ampli-
tudes were mediated by the GluN2A subunit-dominated receptors,
while at the polychromatic and orthochromatic erythroblast stages, the
GluN2C subunit was getting more abundant, overriding the expres-
sion of GluN2A. At these stages, the currents mediated by the
NMDARs carried the features characteristic of the GluN2C-contain-
ing receptors, such as prolonged decay time and lower conductance.
Kinetics of this switch in NMDAR properties and abundance varied
markedly from donor to donor. Despite this variability, NMDARs
were essential for survival of EPCs in any subject tested. Our findings
indicate that NMDARs have a dual role during erythropoiesis, sup-
porting survival of polychromatic erythroblasts and contributing to the
Ca2 homeostasis from the orthochromatic erythroblast stage to
circulating red blood cells.
calcium; differentiation; erythropoiesis; NMDA receptor
EVERY HOUR, APPROXIMATELY 1010 new erythrocytes are released
into the circulation in an adult human after having undergone
a tremendous variety of critical transformations during eryth-
ropoiesis. These sequential transformations occur within sev-
eral days and are controlled by numerous intracellular and
extracellular regulatory factors. Erythropoietin (Epo) and Ca2
ions are two of the essential players in signaling cascades that
support cell survival, proliferation, and differentiation of EPCs
through stages from burst-forming units-erythroid (BFUe) to
red blood cells (RBCs) (9, 30, 53, 61). The key role of
stage-specific alterations in intracellular Ca2 levels and the
underlying changes in activity of Ca2 transport pathways in
the EPCs have been reported previously (21, 42, 53). Omission
of extracellular Ca2 completely inhibits erythopoietic matu-
ration (44). Given its importance, the molecular identity of ion
channels mediating Ca2 uptake by EPCs during the early
stages of maturation has been a subject of intensive investiga-
tion (11, 15, 42). In human and mouse EPCs, Ca2 influx that
is mediated by transient receptor potential channels (TRPCs)
contributes to the Epo-Epo receptor (EpoR)-mediated signaling
(10, 11, 15, 42, 58). Indeed, Epo regulates, in a concentration-
dependent manner, Ca2 influx into already hemoglobinized
BFUe-derived EPCs, but not in EPCs at earlier stages of
differentiation (24). However, Cheung et al. (8) have reported
that Ca2 influx induced by Epo was insufficient to activate
Ca2-sensitive K channels (Gardos channel). This strongly
indicates the presence of multiple Ca2 uptake pathways in
EPCs during differentiation (52). We have recently reported
the presence of N-methyl-D-aspartate receptors (NMDARs) in
human progenitor cells and have shown that these nonselec-
tive, ligand-gated cation channels mediate Ca2 uptake in
EPCs (18, 35).
NMDARs are best characterized in neurons, but are not
limited to the central and peripheral nervous system alone.
Indeed, these receptors have been reported in a variety of cells
and tissues, including osteoclasts, megakaryocytes, leucocytes,
and RBCs (28, 35, 37, 39, 41). NMDARs are formed of
glycine-binding subunits GluN1 and GluN3A/3B, and gluta-
mate-binding subunits GluN2A/2B/2C/2D (12, 46, 59). For
full activation, the heteromeric ion channel requires glutamate
and the cotransmitters glycine (in the brain) or D-serine (in the
spinal cord) (12). Depending on the subunit composition,
cation selectivity, deactivation time, conductance, sensitivity to
Mg2 inhibition, and pharmacology of the NMDARs vary
greatly (6, 46, 50). NMDARs containing GluN2C/2D have a
lower conductance and a prolonged decay time (45, 47).
Combination of these subunits with GluN3A/B results in a
further decrease in the current amplitude, distinct channel
properties, and altered pharmacology (6, 7, 34). In contrast,
NMDAR containing the GluN2A subunit has a fast decay time
and higher conductance (55). Recently, we have shown that
expression of the GRIN2C (GluN2C) and GRIN3B (GluN3B)
mRNA levels increased progressively from proerythroblast to
orthochromatic erythroblast stage, whereas GRIN2A gene, cod-
ing for the GluN2A subunit, exhibited a high interindividual
variability during maturation (35). This study was designed to
characterize the function of the NMDARs expressed in EPCs at
various stages of differentiation. Using an ex vivo erythropoi-
etic maturation system, we monitored Ca2 uptake and ionic
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currents induced by NMDAR agonists in human basophilic,
polychromatic, and orthochromatic erythroblasts derived from
isolated mononuclear cells to determine the stage-dependent
alterations in NMDAR channel properties which mirrored the
switch in subunit expression pattern observed at the transcrip-
tional level (18, 35). Our new findings demonstrate the impor-
tance of the NMDAR in protecting the EPCs against apoptosis.
MATERIALS AND METHODS
Human blood samples and isolation of CD34 and erythropoietic
precursor cells. Blood samples were obtained at the University
Children’s Hospital Zurich, Switzerland, or mononuclear cells were
bought as a product from the Welsh blood bank in Cardiff, UK. All
blood donors (n  16 donors, both sexes, ages between 18 and 49 yr,
Caucasian) provided written informed consent in accordance with the
Declaration of Helsinki. Mononuclear cells were isolated from hepa-
rinized venous blood on a Ficoll-Paque PLUS gradient according to
the protocol provided by GE-Healthcare (Dietikon, Switzerland).
Ex vivo hematopoiesis. Freshly isolated mononuclear cells were
cultured in a two-phase liquid system as described elsewhere (35, 40).
During the first phase, cells were maintained in StemSpan Serum-Free
Medium for expansion of Hematopoietic Cells (SFEM) containing
0.51 mM L-glutamic acid and 0.4 mM glycine supplemented with
StemSpan CC100 Cytokine mixture (StemCell Technologies,
Grenoble, France) and 2% of penicillin-streptomycin (Sigma-Al-
drich). After 4 days in culture, nonadherent cells were reseeded in
StemSpan SFEM containing 20 ng/ml stem cell factor, 5 ng/ml
interleukin-3, 1 unit Epo (all provided by ProSpec-Tany Techno-
Gene, Ness-Ziona, Israel) and 2% of penicillin-streptomycin (Sigma-
Aldrich).
Morphological characterization. Cell morphology was assessed
microscopically after cytocentrifugation (Cytospin 4 Cytocentrifuge,
Thermo Fisher Scientific, Reinach, Switzerland) and May-Grünwald-
Giemsa staining as described elsewhere (40). Differentiation state of
the erythropoietic precursor cells (EPCs) was evaluated with the Axio
Imager 2 Research Microscope (Carl Zeiss, Feldbach, Switzerland).
Standard morphological appearance of basophilic, polychromatic,
orthochromatic erythroblasts and reticulocytes is represented in mul-
tiple sources (e.g., Ref. 1).
Flow cytometry. To measure the changes in intracellular Ca2
levels, cells were loaded with 3 M FLUO-4 AM for 30 min,
followed by a further 30 min of treatment with the following anti-
human monoclonal antibodies: CD34, (eFluor 450 conjugated, clone
4H11, Ref. 48-0349-42), CD71, (APC conjugated, clone OKT9, Ref.
17-0719) both from eBiosciences (San Diego, CA), and CD117 (PC7
conjugated, clone 104D2D1, PN IM3698), CD235a (APC-Alexa
Fluor 750 conjugated, clone KC16, PN A89314), and CD45 (Krome
Orangeconjugated, clone J.33, PN A96416) all from Beckman
Coulter. Loading with both the fluorescent probe and the antibodies
was performed in StemSpan SFEM medium (containing 0.51 mM
glutamate and 0.4 mM glycine). Preincubation with the receptor
antagonist MK-801 (80 M) for 30 min also occurred in the cell
culture medium in a humidified atmosphere with 5% CO2 at 37°C.
Incubation with FLUO-4 AM, antibodies against the surface markers,
and antagonist was performed in cell culture medium to mimic the
“physiological conditions” in which basal level of NMDAR activation
was maintained. Furthermore, MK-801 can only bind to activated
NMDAR. Cell culture medium was replaced by the FACS solution in
which cells were washed twice and resuspended before the assessment
of fluorescence intensity. FACS solution contained (in mM) 135
NaCl, 5 KCl, 5 HEPES, 10 D-glucose, 2 CaCl2 and was adjusted to pH
7.35 with NaOH. Agonist-induced Ca2 uptake was recorded as
response to the administration of 150 M NMDA and 50 M glycine
(NMDA/GLY) to the cell-containing FACS medium. In a separate set
of experiments, apoptotic markers were detected in EPCs pretreated
with 500 M MK-801 or memantine for 12 h in glutamic acid- and
glycine-containing StemSpan SFEM. Those markers included
caspases 3, 8, 9 and phosphatidylserine. Unstained (blank, red histo-
grams) and unstimulated (control, green histograms) cells were used
as controls. All experiments have been performed in triplicate, and
15,000 to 35,000 cells had been analyzed at each occasion. Galios
Flow Cytometer software was used for data acquisition and Kaluza
1.2 software (Beckman Coulter) was applied for analysis.
Electrophysiology. Electrophysiological experiments were per-
formed using EPCs obtained from eight donors between day 7 and 20
of erythropoietic maturation. Nonadherent EPCs were plated down on
coverglasses coated with poly-L-lysine solution (0.01% vol/wt in
H2O). Cells were voltage clamped during continuous perfusion at
room temperature.
Protocols used elsewhere (14) to record NMDA-induced whole cell
currents were adapted for detection of NMDAR activity in EPCs with
some modification. The internal solution contained (in mM) 115
N-methyl-D-glucamine (NMDG)-HCl, 40 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES), 10 ethylene glycol-bis(-
aminoethyl ether)-N,N,N=,N=-tetraacetic acid (EGTA), 2 Na2ATP, and
0.2 Na3GTP and pH was adjusted to 7.2–7.25 by HCl titration and
osmolality to 280–285 mosmol/kgH2O. The external solution con-
tained (in mM) 127 NaCl, 20 CsCl, 12 D-glucose, 10 HEPES, 5 BaCl2,
2 CaCl2, with pH adjusted to 7.35 and osmolality to 300–305
mosmol/kgH2O. Cs and Ba2 were used to reduce K conductance.
High concentration of EGTA was applied to bind the residual free
Ca2 after depolarization. To record passive membrane currents,
standard intracellular solution containing (in mM) 117 KCl, 11
HEPES, 11 EGTA, 10 NaCl, 2 MgCl2, 2 Na2ATP, 1 CaCl2 adjusted
to pH 7.2 with KOH was used. The standard extracellular solution
consisted of (in mM) 135 NaCl, 5 KCl, 5 HEPES, 10 D-glucose, 1.5
CaCl2, adjusted to pH 7.35 with NaOH. Junction potential was
Fig. 1. Stage-dependent N-methyl-D-aspartate receptor (NMDAR) subunit expression during ex vivo erythropoietic maturation. A: differentiation stages of
erythroid precursor cells (EPCs) in culture derived from peripheral blood-borne CD34 cells were analyzed morphologically and by the presence of the
differentiation markers (CD34, CD117, CD71, and CD235a) assessed by flow cytometry (56) and matched with the -globin, GRIN2C, and GRIN3B transcript
abundance during ex vivo erythropoietic maturation (36). EpoR, erythropoietin (Epo)-Epo receptor; BFUe, burst-forming units-erythroid; CFUe, colony-forming
units- erythroid. B: green histograms (control, unstimulated) showing CD34, CD117, CD71, and CD235a abundance in the EPCs at days 8 (basophilic
erythroblasts) and 16 (orthochromatic erythroblasts) in culture. Horizontal bars indicate the A gate selection. Shown in red are the histograms for the unstained
cells (blank). CD45 was used to assess the fraction of white blood cells in erythroid cultures (quantification of the data and statistics are presented in Table 1).
Table 1. Characterization of erythropoietic maturation with specific surface marker
Day of Maturation CD34 Cells (Gate A) CD117 Cells (Gate A) CD71 Cells (Gate A) CD235a Cells (Gate A) CD45 Cells (Gate A)
Day 8 2.30 1.83% 62.72 14.89% 80.04 9.53% 50.06  11.21% 0.08 0.34%
Day 16 0.00 0.01% 0.77 1.45% 83.12 10.12% 69.69  19.63% 0.00 0.01%
The percentage of cells in gate A (see Fig. 1B) presented as mean  SD (n  9 different donors).
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adjusted after seal formation. For single recordings, high-resistance
seals (G seals) were formed, and cells were stable for 2–10 min.
External and pipette solution (in mM: 117 KCl, 11 HEPES, 10 NaCl,
10 D-glucose, and 1.5 CaCl2) was used to record single-channel
activity. The pH was adjusted with NaOH to 7.35. Currents were
normalized to the cell capacitance (pA/pF). Patch pipettes were pulled
from borosilicate glass (GC100F-15, Harvard Apparatus, Holliston,
MA) and fire polished. When filled with this pipette solution, they had
tip resistances of between 9 and 12 M in the bath solution. Axopatch
200B amplifier, Digidata 1440A, and pClamp 10.3 were used to
acquire and filter (5 kHz) data (Axon CNS, Molecular Devices,
Downingtown, PA). Leak current in whole cell recordings was sub-
tracted manually. The electrophysiological properties of the EPC
membranes were assessed using a voltage-step protocol, which held
the voltage at 	70 mV and stepped for 200 ms from 	120 mV to
60 mV, in 10-mV increments. Agonist-evoked currents were re-
corded while holding the membrane at 	60 mV. A voltage-step
protocol described elsewhere (48) with a sequence of a hyperpolar-
izing step (	100 mV) and two depolarizing steps (30 mV and 80
mV) was applied to liberate Mg2 from the pore receptor prior to
testing of the effects of pore-targeting NMDA antagonists MK-801
and memantine (48). NMDAR modulators were added at the holding
potential of 	60 mV. The recordings were performed at the depolar-
izing step (100 mV). To ensure fast drug application, a Rapid
Solution Changer System was used, which allowed solution changes
within 20 ms. All chemicals were purchased from Sigma-Aldrich.
Statistical analysis. Data are presented as means  SD. Statistical
analysis was performed using one-way ANOVA with Bonferroni’s
multiple comparison test, Kruskal-Wallis with Dunn’s post test, or
Student’s paired t-test, as appropriate. For all tests, significance was
set at P 
 0.05.
RESULTS
Ex vivo erythropoietic maturation. Characteristic changes in
differentiating EPC cultures were monitored by morphological
examination (Fig. 1A). In addition, hemoglobin accumulation
and the expression of stage-specific markers such as CD34,
CD117, CD71, and CD235a were assessed. These differentia-
tion steps were associated with the alteration in the levels of
transcripts for the GRIN genes (Fig. 1B) and corresponding
protein abundance of NMDAR subunits (Fig. 1A) (18, 35).
EPCs are referred to as the dominant (80%) cell type at the
specific day as the cell population has never been completely
homogeneous. On day 8 of erythropoietic maturation, 2.3%
still expressed CD34, the rest of the EPCs had differentiated to
proerythroblasts. White blood cells (CD45) could not be
traced. In all experiments, the proportion of CD45 cells was

0.01%. After 8 days in culture, the majority of EPCs had
differentiated into basophilic erythroblasts with characteristic
morphology (large cells with large nuclei with clumped chro-
matin, no nucleoli seen) and the onset of CD117 expression.
On day 12, the majority of the EPCs were smaller in size with
further progressing chromatin condensation in the nucleus and
low hemoglobinization (Fig. 1A). The EPCs expressed CD71
and CD235a and were CD117 negative. These characteristics
indicated that at day 12 the polychromatic erythroblast stage
was dominant. On day 16, most of the EPCs appeared to be
smaller, with highly condensed nuclear and strongly hemoglo-
binized and expressing CD71 and CD235a and defined as
orthochromatic erythroblasts (Fig. 1 and Table 1). Enucleation
and reticulocyte formation occurred intensively after day 17 in
culture, with 90% of all EPCs losing nucleus by day 20 as
shown in Fig. 1A.
NMDA-induced whole cell currents and Ca2 influx in EPCs
during differentiation stages. Activity of NMDARs in baso-
philic, polychromatic, and orthochromatic erythroblasts was
determined by monitoring whole cell currents and Ca2 uptake
Fig. 2. Stage-dependent Ca2 influx into the EPCs upon stimulation with NMDA and glycine (GLY) in the absence or absence of MK-801. The size of cell
population responding to the stimulation with NMDA/GLY (150 M/50 M) with Ca2 uptake was tested in the EPCs derived from nine different donors at
days 8, 12, and 16 in culture. Changes in intracellular Ca2 were evaluated with Ca2 indicator FLUO-4. A: representative histograms showing fluorescence
intensity in unstimulated cells (control, shown in green), cells stimulated with NMDA (150 M) and glycine (50 M) (NMDA/GLY, in blue), and stimulated
cells in the presence (MK-801  NMDA/GLY, in yellow) of antagonist MK-801 (60 M). Blank (unstained) readouts from the cells free from fluorophore are
shown in red. At day 8 of maturation one population of cells with high FLUO-4 intensity (gate A) and one with low FLUO-4 intensity (gate B) were present.
At later stages only one population was present (gate A). Quantification of the data is presented in Table 2. B: dot plots illustrating relative change of intracellular
Ca2 levels in CD71 cells (gate A- and gate A). Presented are the representative readouts from the EPCs at day 12 in culture in which Ca2-sensitive
fluorescence of FLUO-4 was recorded in unstimulated cells (control), in stimulated (NMDA/GLY) cells, and in stimulated cells in the presence of antagonist
(MK-801  NMDA/GLY). Quantification of the data is presented in Table 3. C: Ca2 uptake by the EPCs upon the stimulation with NMDA/GLY on average
decreased during maturation from day 8 to day 16 in culture (##P 
 0.01 compared with values for day 8). Inhibition of NMDAR by MK-801 resulted in
significant reduction of intracellular Ca2 at all stages of maturation (*P 
 0.05 and **P 
 0.01 compared with the antagonist-free cells). All experiments were
performed in triplicate for each of nine donors used in these experiments. The amount of cells analyzed for each single recording ranged from 15,000 to 35,000.
Data were normalized to the values obtained for unstimulated EPCs (dashed line). Box plots show the median and 95% confidence interval.
Table 2. Ca2 influx upon stimulation with NMDA/GLY in the absence or presence of MK-801 at various
differentiation stages
Treatment
Day of Maturation (Gate)
Day 8 (Gate A) Day 8 (Gate B) Day 12 (Gate A) Day 16 (Gate A)
FLUO-4 Intensity
(Gated Cells) GMF
FLUO-4 Intensity
(Gated Cells) GMF
FLUO-4 Intensity
(Gated Cells) GMF
FLUO-4 Intensity
(Gated Cells) GMF
Control 18.17 8.19% 11.46 14.66 6.21% 9.25 30.97 7.27% 11.70 59.95 9.73% 4.08
NMDA/GLY 56.06 6.14% 30.83 18.01 2.69% 9.88 60.79 5.88% 21.07 64.71 6.17% 4.46
MK-801  NMDA/GLY 37.89 7.08% 17.82 16.68 4.82% 9.23 38.94 8.53% 13.39 37.37 7.41% 2.36
Measurements were performed in repetitive erythroid precursor cell EPCs) cultures (n  3) from the same donor. Gating conditions are exemplified in Fig
2A and are presented in the table as the mean percentage of cells in the gate SD and geometric mean fluorescence (GMF). NMDA, N-methyl-D-aspartate; GLY,
glycine.
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in a group of healthy human donors that were involved in
previous molecular characterization of the receptor (18, 35).
Since NMDARs, but not the other ionotropic glutamate recep-
tors, are highly sensitive to N-methyl-D-aspartate, we mainly
used NMDA for the receptor stimulation. Nonetheless, similar
currents were induced by 250 M glutamate and 50 M
glycine (data not shown).
Ca2 uptake via the NMDAR was recorded in the cells,
which were transferred from the glutamate and glycine-con-
taining culture medium to agonist-free culture medium. There-
after the cells were stimulated with the agonists (NMDA/
GLY). The number of EPCs responding to the stimulation with
induction of Ca2 uptake (NMDA/GLY) (exemplified in Fig.
2A and Table 2) decreased with differentiation of basophilic
erythroblasts to polychromatic and orthochromatic erythro-
blasts (24.9  17.9%, 14.4  9.6%, and 7.8  8.5% of
“responding cells” in the population, respectively) (Fig. 2C).
All cells responded to stimulation with the NMDAR agonists
with an increase in the intracellular Ca2-expressed CD71
(gate A in Fig. 2B and Table 3). The amplitude of Ca2
uptake in erythroid precursor cells caused by the stimulation
with NMDA/GLY reduced with differentiation from basophilic
(day 8) to orthochromatic (day 16) erythroblasts (Fig. 2C). In
orthochromatic erythroblasts (day 16), MK-801 treatment re-
sulted in a modest, but significant decrease in intracellular
Ca2 levels (2.5  9.1%) compared with the unstimulated
EPCs (dotted line in Fig. 2C). Whole cell voltage-clamp
recordings were used to verify the data obtained by flow
cytometry. At a holding potential of	60 mV, coadministration
of NMDA and GLY for 500 ms resulted in induction of
currents with characteristics depending on the differentiation
stage of the EPCs, as illustrated in Fig. 3A. Stimulation of the
EPCs in whole cell and single-channel configuration with
-amino butyric acid (GABA) used as a negative control was
without an effect (data not shown).
In basophilic erythroblasts (Fig. 3A, day 8), stimulation with
agonists immediately induced currents with a density of
77.41  31.81 pA/pF (Fig. 3B) and a deactivation time of
332.0  149.4 ms (Fig. 3C). Desensitization of the channels
was observed upon repetitive stimulation with the agonists
(Fig. 3D). Maturation to polychromatic erythroblasts (Fig. 3A,
day 12) was associated with a decrease in current density to
40.96  25.13 pA/pF (Fig. 3B) and prolongation of deactiva-
tion to 591.3  206.2 ms (Fig. 3C). This tendency persisted
with differentiation to orthochromatic erythroblasts (Fig. 3A,
day 16) in which current density declined further to 16.01 
7.81 pA/pF (Fig. 3B) while deactivation time increased to
1,139.1  382.9 ms (Fig. 3C). The number of cells, which
were sensitive to agonist stimulation, declined during matura-
tion, from 24.9  13.3% in basophilic erythroblasts to 18.6 
9.3% of polychromatic erythroblasts, making up only 8.4 
8.6% in orthochromatic erythroblasts. The number of cells
responding to the stimulation of NMDARs at various dif-
ferentiation stages was identical no matter what technique
(electrophysiology or flow cytometry) was used for detec-
tion of the NMDAR activation (Fig. 3E).
Sensitivity of agonist-induced currents to MK-801 and
memantine. We have explored the sensitivity of currents in-
duced by the receptor agonists to the potent and selective
NMDAR channel blockers MK-801 (60 M) and memantine
(80 M). As shown in Fig. 3F, these noncompetitive antago-
nists reduced the agonist-sensitive current density significantly.
The application of MK-801 decreased the current density
mediated by the NMDARs from 62.77  10.42 pA/pF to
42.12  8.51 pA/pF and memantine suppressed the mean
current density to 46.82 10.29 pA/pF. Long-term application
of NMDA and glycine and repetitive performance of the
voltage-step protocol induced deactivation (Fig. 3, D and G).
Further inhibition of current density could be mediated by
MK-801 supplementation (Fig. 3G).
Activation of single channels after application of NMDA and
glycine. The effects of NMDAR activation and the concomi-
tant Ca2 uptake on the activity of ion channels is consistent
with the properties of Ca2-activated K channels and were
determined in the cell-attached configuration. The single Ca2-
sensitive K channel currents (Fig. 4A) had a current-voltage
(I–V) relationship resembling the characteristics of Gardos
channels (13). The conductance of 23 pS of the channels was
determined from the slope of the regression line. This value
was similar to the conductance of 18–22 pS reported for the
Gardos channels in mature red blood cells (16, 17, 27). Stim-
ulation of reticulocytes with the NMDAR agonists induced a
6.7-fold increase in the product of open state probability
(Popen) and number (N) of open channels (NPopen) (0.64 0.19
vs. 0.09  0.16 in nonstimulated cells) in 8.6  7.4% of cells
between day 17 and day 20 in culture (Fig. 4, B and C). The
single-channel activity decreased after 30 s of stimulation
with agonists. Removal of the agonists resulted in recovery of
the basal channel activity within 2 min. The spontaneous
activity of these channels has been previously described by
Dyrda et al. (13), and attributed to pressure activation. Further
characterization of the Ca2-sensitive K current was outside
the scope of the study.
Interindividual variability of NMDAR activity correlates
with the changes in GluN subunit expression levels during
maturation. We have monitored interindividual variability in
the relative mRNA expression of GRIN2A at day 8 and the
relative change of intracellular Ca2 concentration after
NMDAR activation that was recorded as a shift in geometric
mean fluorescence (GMF). GRIN2A expression of individ-
ual donors correlated with the amplitude of changes in
Table 3. Reduction of NMDAR-mediated Ca2 influx after pretreatment with MK-801 in CD71 cells
Treatment Gate A		 (Gated Cells) Gate A	 (Gated Cells) Gate A	 (Gated Cells) Gate A (Gated Cells)
Control 24.53 4.55% 1.01  0.85% 67.82  7.41% 6.64 5.00%
NMDA/GLY 25.77 3.89% 2.42  1.19% 38.65  4.02%* 33.16 5.03%*
MK-801  NMDA/GLY 29.02 3.81% 1.63  2.25% 60.72  4.49% 8.63 4.83%
The distribution of cells between the quadrants (see Fig. 2A) presented as mean % SD. *P
 0.01, compared with the unstimulated control (Student’s paired
t-test).
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the intracellular Ca2 levels after NMDAR stimulation
(Fig. 5A).
In basophilic erythroblasts, low levels of the GRIN2C and
GRIN3B transcripts were associated with a prominent increase
in the intracellular Ca2 upon NMDAR activation (Fig. 6A).
Inverse correlation was observed between the upregulation of
the GRIN2C and GRIN3B genes and the amplitude of Ca2
uptake in the EPCs stimulated with the NMDAR agonists
during the transformation into polychromatic and orthochro-
matic erythroblasts (Fig. 6B).
Further correlations were detected between the type of
NMDA-induced current and the subunit expression pattern.
Deactivation time correlated inversely with the relative
GRIN2A expression levels of individual donors (Fig. 5C).
A switch in NMDAR properties from channels with high
amplitude and fast decay currents, characteristic of the baso-
philic erythroblasts, to currents of smaller amplitude and lon-
ger deactivation time from polychromatic erythroblast stage
onwards, mirrored a switch from the GluN2A to GluN2C/3B in
all nine donors (Fig. 6, B and C).
Alteration in electrophysiological properties during enucle-
ation of erythropoietic cells. Besides the above-mentioned
stage-dependent switch in NMDAR properties and the basal
intracellular Ca2 levels, alterations in basal electrophysiolog-
ical properties of the EPC membranes exhibited during enu-
cleation.
Current-voltage relationship within the 	120 to 60 mV
potential range showed no substantial changes until day 15 of
differentiation. A representative I–V curve (current type A)
recorded from basophilic and polychromatic erythroblasts
showed characteristic lack of voltage dependence within the
range of potentials from 	90 mV to 30 mV resembling the
I–V relationship reported for chloride channels reported to be
present in RBCs (26, 57) (Fig. 7, A and D). During enucleation
(between day 16 and 18), a switch from voltage-independent to
two types of voltage-dependent behavior occurred in 82.8 
1.01% of cells (Fig. 7, B–E). The majority of cells (70.8 
3.01%) exhibited a steep increase in conductance during de-
polarization from 	20 mV to 50 mV (current type B), a
feature characteristic of certain potassium channel types (25,
26, 57) (Fig. 7, B and D). In 12.0  2.01% of EPCs a
bell-shaped I–V relation (type C current) with maximal current
density monitored at 30 mV was observed (Fig. 7, C and D).
At day 18 of differentiation, in 17.2  1.0% of cells the I–V
relationship (type A current) remained essentially voltage in-
sensitive (Fig. 5E). Further in-depth studies are required for
detailed characterization and molecular identification of all ion
channels contributing to these basal electrophysiological prop-
erties.
Treatment of the EPCs with high doses of NMDAR channel
pore blockers induces apoptosis. Earlier on, we have shown
that high doses of memantine or MK-801 (above 100 or 50
M, respectively) resulted in cell death, which was particularly
pronounced for the early differentiation stages (18, 35). Herein
we have extended this observation by analyzing the mechanism
of cell death induced by high doses of pore-targeting NMDAR
blockers. Incubation of basophilic erythroblasts with 500 M
MK-801 or memantine (the dose toxic for both blockers) for 12
h in the SFEM culture medium induced activation of caspase 3,
caspase 8, and caspase 9 in the majority of cells (Fig. 8 and
Table 4). Phosphatidylserine exposure was enhanced in EPCs
exposed to both NMDAR antagonists (Fig. 8 and Table 5).
Hyperactivation of the receptors by additional supplementation
of NMDA (500 M) and glycine (100 M) to the culture
medium caused only modest adverse effects (Table 5).
DISCUSSION
Plasticity of NMDAR and whole cell currents during
erythropoiesis. The functional plasticity of the NMDAR during
EPC differentiation is the most striking finding of this study. A
dynamic switch in the subunit expression patterns was pre-
cisely mirrored by changes in the NMDAR channel function.
These events contributed to the general remodeling of the
membrane reflected by the changes in shape of the I–V curves
observed in the course of EPC differentiation.
During differentiation from basophilic to polychromatic
erythroblasts, the GluN2A subunit of the NMDAR in the cells
was substituted by the GluN2C subunit, whereas the expres-
sion and abundance of the other subunits, of which GluN2D
and 3B subunits were dominating, remained unchanged. The
electrophysiological properties of NMDAR in EPCs at any of
the stages tested exhibited high similarity to those in their
counterparts in neurons (49). Namely, proerythroblasts and
basophilic erythroblasts exhibited an NMDAR subtype with
high amplitude and fast deactivation kinetics reported for the
GluN2A-containing receptors (49). These receptors enable
efficient glutamate-induced changes in transmembrane poten-
tial and massive short-term Ca2 uptake. At these stages of
maturation, EPCs were reported to be particularly dependent
on Ca2-driven signaling. The latter is activated upon binding
of erythropoietin to its receptors (42, 43) and engaged in
control of a number of other processes of which iron process-
ing in erythroblasts is one of the most important (20). The peak
of Epo receptor expression is associated with the highest
NMDA-evoked Ca2 influx, fast deactivation time, and high
conductance (Fig. 3, A–C) (11, 15, 42). Our findings indicate
that prolonged exposure to high antagonist concentration en-
Fig. 3. Whole cell currents induced by EPC stimulation with NMDA and glycine. NMDA-induced currents were recorded in whole cell configuration at holding
potential 	60 mV. A: original recordings for the cells exposed to NMDA (150 M) and GLY (50 M) at day 8 (top, n  64 cells), day 12 (center, n  59
cells), day 16 (bottom, n  47 cells). B: alteration of current density of whole cell currents during erythropoietic maturation (***P 
 0.001 compared with day
8). C: alteration of deactivation time during maturation (***P 
 0.001 compared with day 8). D: deactivation of whole cell currents upon repetitive application
of NMDA and GLY in EPCs at day 12 in culture. E: no significant deviation in percentage of EPCs responding to NMDAR activation recorded using flow
cytometry and electrophysiology (P  0.05). EPCs from four different donors were analyzed for patch-clamp techniques (day 8, n  486 cells; day 12, n  458
cells; day 16, n  487 cells) and from nine different donors for flow cytometry. F: application of the 60 M MK-801 or 80 M memantine reduced the current
density significantly immediately after induction of NMDA currents (**P 
 0.01 and ***P 
 0.001). G: reduced current density after MK-801 (60 M)
application during repetitive voltage steps were applied. Black trace shows current density without antagonist application after NMDAR activation and gray trace
shows current density with MK-801 application after NMDAR activation. All data are means  SD and were recorded at 100 mV.
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hances phosphatidylserine exposure (Fig. 8). This supports the
hypothesis that the maintenance of NMDAR function is crucial
for protection against apoptosis in proerythroblasts and baso-
philic erythroblasts. These observations are in agreement with
the earlier studies in which requirement of the extracellular
Ca2 for survival and further differentiation of the EPC was
postulated (42). Detailed investigation of the molecular mech-
anisms of involvement of NMDAR in protection of the EPCs
from apoptosis was outside the scope of this study. In neural
progenitor cells, activation of NMDARs causes transient re-
cruitment of activator protein-1 (AP-1) to the DNA, followed
with suppression in proliferation and induction of differentia-
1 pA
1 pA
1 pA
1 pA
+40 mV
0 mV
-20 mV
-40 mV
***
1 s 1 s
2 pA 2 pA
Extracellular Solution NMDA/GLY
A
B
C
G = 23.1   2.4 pS+-
Fig. 4. Activation and deactivation of single channels after NMDAR activation. Single-channel recordings were performed in cell-attached configuration to
monitor spontaneous single-channel activity and its alteration in response to the stimulation with 150 M NMDA and 50 M glycine. A: mean single-channel
conductance (G) was 23.1  2.4 pS (n  4). V, voltage; I, current. B: single-channel recording before (left) and after (right) NMDA/GLY application. Holding
potential was fixed at 	40 mV. C: change in open probability and number of open channels (NPopen) upon NMDA/GLY application (n  96 cells). ECS,
extracellular solution. Data are means  SD (***P 
 0.001).
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tion (29). In erythroid cells, AP-1 is known to be involved in
regulation of proliferation and survival in Epo-dependent ery-
throid cells via controlling the activity of c-Jun and JunB
transcription factors (23, 33).
Our results suggest that NMDARs may contribute to Epo-
driven Ca2 signaling along with TRP channels described
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Fig. 5. Donor dependence of Ca2 influx, receptor properties, and GRIN2A
expression during hematopoiesis. mRNA expression was normalized to
GAPDH. A: correlation between GRIN2A mRNA expression and relative
change in geometric mean fluorescence (GMF) in the stimulated EPCs.
Correlation coefficient was calculated by the change in GMF triggered by the
agonists and the relative mRNA expression from six donors. B: correlation of
current density and relative GRIN2A mRNA expression (n 4). C: correlation
of deactivation time and relative GRIN2A mRNA expression from four donors.
Data are means  SD; linear (A and B) and exponential (C) functions were
used for curve fitting.
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Fig. 6. Stage dependence of Ca2 influx, receptor properties, and GRIN2C/3B
expression during hematopoiesis. mRNA expression was normalized to
GAPDH. A: correlation of relative GRIN2C and GRIN3B mRNA expression
(n  9) and relative change in GMF after NMDAR activation (n  9). B:
correlation of current density and relative GRIN2C/3B mRNA expression
during erythropoietic maturation (n  6). C: correlation of deactivation time
and relative GRIN2C/3B mRNA expression during erythropoietic maturation
(n  6). Data are means  SD (correlation coefficients see Table 4).
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earlier (15, 42, 44). Each of these channels mediating Ca2
uptake respond to its own set of stimuli supporting a complex
cross-talk between multiple receptors which drive the EPC
differentiation process. Further studies are required to charac-
terize the functional and possible physical interaction between
these two types of channels.
Maturation to polychromatic and orthochromatic erythroblasts
and finally to reticulocytes and RBCs is associated with a gradual
replacement of this NMDAR type with the one mediating slowly
decaying currents of smaller amplitude (Figs. 3 and 6, B and C).
Induction of expression of the GluN2C subunit, which replaces
GluN2A in receptors also containing the GluN2D and GluN3B
subunits, coincides with the onset of hemoglobinization [day 10 in
culture according to Wickrema et al. (60) and Fig. 1]. Regulation
of exocytosis of transferrin, its receptor recycling, and that of iron
uptake by the EPCs in mice, rats, and rabbits is controlled by
Ca2/calmodulin and is bound to sense the changes in Ca2
uptake mediated by the NMDARs (20). Apart from their possible
involvement in iron handling at the later stages of EPC differen-
tiation, “slow” NMDARs are best suited for the regulation of
basal Ca2 levels. Together with other Ca2-permeable ion chan-
nels, such as voltage-dependent anion channels and voltage-gated
calcium channel Cav2.1, which have been characterized in RBCs
(25), these channels contribute to the regulation of cell volume,
redox balance control, proteolysis, and O2 affinity for hemoglobin
(5, 18, 35).
Glutamate signaling in the microenvironment of EPCs.
Fluctuations of glutamate levels in peripheral blood are mir-
Current type A
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Current type C
40 mV
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C
D
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Mean current density
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Current type C
Fig. 7. Alteration in electrophysiological
properties during hematopoiesis. Cells were
voltage clamped in whole cell configuration
during hematopoiesis, and voltage steps
(10-mV increments) from 	120 mV to 60
mV were applied for 200 ms. Current was
normalized to cell capacitance (pA/pF) A:
frequently observed whole cell currents (type
A current, 86 cells) from early and interme-
diate stages of hematopoiesis (until day 15).
B: frequently observed whole cell currents
(type B current, 79 cells) from late stage of
erythropoietic maturation (from day 16 on).
C: infrequently observed type of whole cell
currents (type C current, 8 cells) from late
stage (day 18). D: voltage-step protocol and
three examples for the three whole cell cur-
rent types. E: analysis of voltage-current re-
lationship from four different donors at day
18 of differentiation. Data are means  SD
(n  76 cells).
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rored by alterations in the activity of erythroid NMDARs.
Recently, we have shown that NMDARs in RBCs show a high
degree of basal activity when in the circulation (18). Addition-
ally, glutamate levels within the bone marrow may be regu-
lated by controlled secretion of this amino acid from mega-
karyocytes and macrophages (3, 22, 32, 39). The close asso-
ciation of bone marrow and glutamatergic nerve endings may
further contribute to the alterations in glutamate levels promot-
ing erythropoiesis and increasing RBC production. However,
the exact range of glutamate levels therein has never been
measured. We have shown that hyperactivation of NMDARs in
young and mature RBCs, particularly those in sickle cell
disease patients, was associated with a transient increase in
Ca2, cell shrinkage, and oxidative burst (18). Prolonged
chronic activation of NMDARs in EPCs causes receptor de-
sensitization (Fig. 3D) but does not induce apoptosis in pre-
cursor cells (Fig. 8). We suggest that the desensitization is
essential for cytoprotection as it controls Ca2 uptake. Further-
more, Ca2 oscillations mediated during the activation-deacti-
vation cycles are used for signal transduction by a majority of
cells (2, 51). The regulatory mechanisms and the physiological
role of NMDARs expressed in EPCs as well as in other
hematopoietic progenitors giving rise to leucocytes, and plate-
lets require further investigation (28, 41). The pronounced
toxic effect of NMDAR inhibition may be attributed to the
importance of these receptors and Ca2 fluxes they mediate for
sustaining the EPCs’ survival (42), but it more likely represents
the off-target action of the receptor blockers at high concen-
trations (31).
In several studies, the receptors containing GluN2C/2D and
GluN3B subunits were shown to have lower sensitivity to the
channel pore blockers MK-801 and memantine and to Mg2
block (7, 38, 54). Thus, the reduced efficiency of the pore-
targeting MK-801 to inhibit NMDA currents is most likely
associated with the unusual subunit compositions of erythroid
NMDAR in which GluN1 is underrepresented, whereas
GluN3B and 2D were most abundant. The low conductance
and slow deactivation time we have observed for NMDARs in
polychromatic erythroblasts were shown to be characteristic
for the receptor formed by the GluN2C/D and GluN3B sub-
units (49). Currents mediated by the NMDAR in proerythro-
blasts showed no plateau phase as it was reported for the
NMDAR currents in neuronal cells (4). These findings indicate
that an atypical subunit composition and functional pattern of
NMDAR in erythroid cells resemble the properties of the
receptors described for other nonneuronal tissues (7, 28, 39).
Interindividual variability in quantity and quality of red
blood cell production. We have observed marked intercellular
and interindividual variability in the expression pattern and
abundance of NMDAR subunits in EPCs of healthy humans
(Fig. 5, B and C). However, repetitive measurements per-
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Fig. 8. Downstream activation of caspases and enhanced phosphatidylserine
(PS) exposure after long-term blockage of NMDAR in differentiating EPCs.
EPCs obtained from three donors and cultured for 12 days were incubated for
12 h at 37°C in the presence of 500 M MK-801 or memantine or were
supplemented with NMDA in addition to the medium-borne agonists (510 M
glutamate and 400 M glycine). Cells were stained with caspase activity
marker or FITC-labeled annexin-V antibody. Caspases 3, 8, and 9 were all
upregulated (gate A) after long-term incubation (shown in yellow) with
MK-801 and memantine (only MK-801 shown). High concentration of NMDA
did not affect caspase activity (data not shown). PS exposure was increased
(gate A) after long-term inhibition of NMDAR (only memantine shown).
Overactivation of NMDAR (NMDA/GLY) with 500 M NMDA and 100 M
glycine did not influence annexin-V binding (blue histogram) significantly.
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formed for NMDARs in EPCs derived from CD34 cells of
the same donor were highly reproducible. Interindividual vari-
ability of the GRIN gene transcript levels could represent
individual genetic, epigenetic, and signaling profiles (19). In-
tercellular heterogeneity in part reflects heterogeneity of the
EPC maturation stages in culture. However, this heterogeneity
in NMDAR abundance is persistent in circulating RBCs inde-
pendent of cell age, suggesting that, despite similar morphol-
ogy, several subpopulations of RBCs and EPCs are produced
representing “glutamate-sensitive” and “glutamate-resistant”
cells (18, 35). Expression patterns of GRIN2A and GRIN2C
define the properties of the NMDARs as the levels in GRIN2A
transcripts in the individual donors are proportional to the peak
amplitudes of glutamate-sensitive currents and Ca2 uptake,
and are inversely proportional to the deactivation time duration
(Figs. 5 and 6).
Based on the finding that enhanced Ca2 influx is a trigger
for increased terminal erythropoiesis (15, 42) we have sug-
gested that GluN2A-containing NMDAR contributes to this
essential Ca2 uptake. This would imply that the interindi-
vidual variability in number of receptors per cell and its subunit
composition might have an influence on red blood cell produc-
tion, properties, and clearance (5). These observations concur
with previous reports on the interindividual and inter-cellular
variability in sensitivity to NMDAR agonists such as glutamate
or homocysteine. The degree of glutamate-sensitivity of RBCs
of healthy human individuals may contribute to the quality of
stored blood products and the outcome of transfusion (35).
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Summary
Recently we showed that N-methyl D-aspartate receptors (NMDARs) are
expressed in erythroid precursors (EPCs) and present in the circulating red
blood cells (RBCs) of healthy humans, regulating intracellular Ca2+ in these
cells. This study focuses on investigating the possible role of NMDARs in
abnormally high Ca2+ permeability in the RBCs of patients with sickle cell
disease (SCD). Protein levels of the NMDAR subunits in the EPCs of SCD
patients did not differ from those in EPCs of healthy humans. However,
the number and activity of the NMDARs in circulating SCD-RBCs was
substantially up-regulated, being particularly high during haemolytic crises.
The number of active NMDARs correlated negatively with haematocrit and
haemoglobin levels in the blood of SCD patients. Calcium uptake via these
non-selective cation channels was induced by RBC treatment with glycine,
glutamate and homocysteine and was facilitated by de-oxygenation of
SCD-RBCs. Oxidative stress and RBC dehydration followed receptor stimu-
lation and Ca2+ uptake. Inhibition of the NMDARs with an antagonist me-
mantine caused re-hydration and largely prevented hypoxia-induced
sickling. The EPCs of SCD patients showed higher tolerance to memantine
than those of healthy subjects. Consequently, NMDARs in the RBCs of
SCD patients appear to be an attractive target for pharmacological inter-
vention.
Keywords: red blood cells, calcium, sickle cell disease, N-methyl
D-aspartate receptors, memantine.
Sickle cell disease (SCD) is a well-known one-gene disease. A
point mutation in position 6 of the beta-globin chain gives
rise to polymerization of deoxyhaemoglobin S (HbS), loss of
deformability and increase in cell adhesion. Haemolysis,
vaso-occlusive and pain crises are hallmarks of this disease.
Gene therapy and bone marrow transplantation are the opti-
mal, but rarely available and very expensive treatment strate-
gies for this group of patients (Locatelli et al, 2013;
Chandrakasan & Malik, 2014). Treatment with hydroxycar-
bamide (HC), which aims to increase haemoglobin F levels
in RBCs, is part of the current standard care (Manwani &
Frenette, 2013). This therapy significantly decreases the inci-
dence and severity of pain crises and can be combined with
regular blood transfusions. Further management includes
symptomatic care, such as iron chelation, antibiotic treat-
ment and psycho-social support. However, not all patients
respond equally well to HC treatment. Thus, there is a stand-
ing need for novel treatment strategies.
Extensive experimental efforts have resulted in the sugges-
tion of a number of novel potential targets for pharmacologi-
cal intervention. Inhibition of the Gardos channel with the
selective blocker Senicapoc (ICA-17043; Neusentis, Cam-
bridge, UK) was used in a clinical trial aiming to reduce
dehydration, which promotes haemoglobin S (HbS) polymer-
ization. (Eaton & Hofrichter, 1990). This strategy alone sup-
pressed haemolysis but failed to decrease the incidence of
pain and vaso-occlusive crises (Ataga & Stocker, 2009). Inhi-
bition of the calcium-dependent cysteine protease l-calpain,
was recently suggested as an attractive clinical strategy to
reduce proteolysis and thereby suppress premature clearance
and lysis of RBCs carrying human haemoglobin S (De
Franceschi et al, 2013). Further suggestions include protec-
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tion of RBCs from oxidative stress by blocking NADPH ox-
idases (NOXes) which generate superoxide anions and are
particularly abundant in the RBCs of SCD patients (George
et al, 2013). Pathological hyperactivation of Gardos channels,
l-calpain and NOXes in diseased RBCs are not directly trig-
gered by mutated HbS expression. However, all three pro-
teins are known to respond to the up-regulation of the
intracellular Ca2+ levels which were reported in the RBCs of
SCD patients (Bogdanova et al, 2013). Furthermore, calcium
overload is known to increase the adherence of RBCs to
vascular endothelium in SCD patients (Hebbel et al, 1980;
Mohandas & Evans, 1985). The steady-state passive channel-
mediated permeability of red cell membranes for Ca2+ in
healthy humans is very low (c. 50 lmol/(lpacked cells•h)).
Thus, even a minor increase in Ca2+ uptake due to the acti-
vation of one or several types of ion channels is associated
with a substantial transient increase in intracellular Ca2+. In
SCD-RBCs abnormally high Ca2+ uptake is mediated by a
conductive transport pathway known as Psickle. This pathway
is activated by deoxygenation, shear stress and a number of
other stimuli (Bookchin & Lew, 1981) and, when activated,
results in a 6- to 10-fold increase in intracellular free Ca2+
levels (Tiffert et al, 2003). The molecular identity of ion
channel(s) mediating Psickle remains unknown. Identification
and characterization of these channel(s) is of key importance.
Inhibition of the Psickle pathway and the consecutive decrease
in intracellular Ca2+ levels will cause inhibition of Gardos
channels, l-calpain, and NOXes. We have recently shown
that N-methyl D-aspartate receptors (NMDARs) are involved
in Ca2+ uptake by the RBCs of healthy humans (Makhro
et al, 2013). These ionotropic glutamate receptors are non-
selective cation channels requiring glutamate and glycine for
their activation. They are known to mediate synaptic Ca2+
uptake in the brain (Paoletti et al, 2013). This study focuses
on the involvement of NMDARs in the control of intracellu-
lar Ca2+ levels in SCD-RBCs. We have been able to follow
the abundance and activity of NMDARs in erythroid
precursor cells and in the circulating RBCs of SCD patients.
Pathological hyperactivation of the NMDARs monitored in
SCD-RBCs resulted in an increase in membrane permeability
for Ca2+. Haemolytic crises were associated with further up-
regulation in receptor activity. Correlation of NMDAR activ-
ity with red cell number and C-reactive protein levels in
plasma suggests that NMDAR is an active player in regulat-
ing red cell properties and life span in SCD patients.
Subjects and methods
A detailed description of materials and methods is available
as a supplementary file.
Patients and healthy subjects
Our subject pool consisted of 16 adult patients (21–44 years
old) with symptomatic SCD and 31 age-matched healthy
adult subjects with no history of SCD. The group of 16 SCD
patients consisted of 9 subjects with HbS/HbS, 3 patients
with HbS/HbC, 3 with HbS/b-thalassaemia and one patient
with HbS/HbD genotype. All patients experience mild and
severe SCD crises, and show chronic haemolytic anaemia and
persisting reticulocytosis. Blood samples were collected after
obtaining informed consent from the subjects. The study was
approved by the Ethics Commission of the Canton of Zurich
and was performed in accordance with the declaration of
Helsinki. General information on the patients is presented in
Table I.
Protein abundance of the GluN1 subunit of the NMDAR
in SCD-RBC membranes
Immunoblotting was used to explore the alterations in pro-
tein abundance of the GluN1 subunit in membrane fractions
obtained from the SCD-RBCs and cells of healthy donors
after centrifugation on 90% isotonic Percoll gradient (Lutz
et al, 1992). Blood or pre-filtered RBC suspension was used
for fractionation, and membrane preparation from cells
forming the light (L), medium (M) and dense (D) fractions
of RBCs was obtained (see Fig 1A). Immunoblotting was
performed using mouse monoclonal antibodies against the
GluN1 subunit on the NMDAR (#MAB1586 Millipore,
Temecula, CA) as well as rabbit polyclonal antibodies against
total actin (#A2066, Sigma-Aldrich, St. Louis, MO, USA).
Rat cortex lysate was used as a positive control, and total
actin as a loading control.
NMDAR activity in SCD-RBCs
The number of active receptors per cell was detected using
radiolabelled antagonist binding assay as described earlier
(Makhro et al, 2013). Blood samples were incubated with
[3H]MK-801 (740 GBq/mmol, Perkin Elmer, Boston, MA)
with subsequent fractionation on Percoll gradient. The
potential impact of white blood cells (WBCs) on the [3H]
MK-801 binding assay in RBCs in fractions was assessed, as
binding of the radiolabelled antagonist was tested in blood
samples with and without filtration through a cellulose col-
umn. As filtration resulted in a substantial increase in the
number of [3H]MK-801 binding sites due to the shear stress
filtration step, it was avoided in cases when basal activity of
the erythrocytic NMDARs in plasma was determined. Micro-
fluorescence live imaging was used to confirm the data on
receptor activity and abundance obtained using [3H]MK-801
binding assay.
Ca2+ uptake through NMDARs as a function of
oxygenation of SCD-RBCs
Changes in the intracellular Ca2+ levels in RBCs upon treat-
ment with agonists (300 lmol/l of NMDA, glutamate or hom-
ocysteine mixed with 100 lmol/l glycine) and/or antagonist
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(memantine, 50 lmol/l) of the NMDARs were monitored
using the fluo-4 AM dye, as described elsewhere (Makhro et al,
2013). RBCs were loaded with 5 lmol/l of the dye for
30 min at room temperature. Incubation medium con-
tained 145 mmol/l NaCl, 5 mmol/l KCl, 1 mmol/l CaCl2,
015 mmol/l MgCl2,10 mmol/l Tris-HCl (pH 74), 10 mmol/l
glucose and 01% bovine serum albumin. The effect of hypoxia
on cell shape and Ca2+ content was tested in the RBCs of SCD
patients. The cells were loaded with fluo-4 AM and exposed to
15% O2 (normoxia) or 05% O2 (hypoxia), 5% CO2, balanced
with N2 for 10 min, with or without supplementation of the
NMDAR antagonist memantine (100 lmol/l) and/or
300 lmol/l NMDA/100 lmol/l glycine mixture. Calcium
uptake, cell surface projection and anisotropy as markers of
cell volume and sickle cell transformation were then measured
microscopically and analysed using CellFinder (Dr. M. Mak-
hinya, Computer Vision Laboratory, Z€urich, Switzerland) as
described (Makhro et al, 2013).
NMDARs in control of SCD-RBC density, K+ content
and intracellular reduced (GSH) and oxidized (GSSG)
glutathione levels
The changes in red cell density upon activation or inhibition
of the NMDARs were measured in blood from four selected
SCD patients using centrifugation in Percoll density gradient
in the presence or absence of NMDA or memantine.
Together with mean cell volume (MCV), haematocrit and
cell water content, distribution in Percoll gradient was used
as an indication of dehydration-rehydration. Changes in the
intracellular K+ content in oxygenated and deoxygenated
SCD-RBCs were monitored using flame photometry, and
unidirectional chloride-independent K+ influx was measured
using 86Rb as a tracer, as described elsewhere (Makhro et al,
2013). The effects of an NMDA/glycine mixture and meman-
tine on the intraerythrocytic GSH:GSSG balance was tested
using Ellman’s reagent (5,50-dithio-bis-[2-nitrobenzoic acid]).
Proteins were precipitated with 5% trichloroacetic acid and
removed; non-protein reduced thiols assessed with or with-
out pre-treatment with glutathione reductase and NADPH,
as described elsewhere (Tietze, 1969; Bogdanova et al, 2003).
Ex vivo erythropoiesis and expression of NMDARs in
erythroid precursor cells
Mononuclear cells were isolated from the peripheral blood of
healthy people and SCD patients and cultured ex vivo, using
a 2-phase StemSpan liquid system. After seeding in serum-
free expansion medium (SFEM) supplemented with a cyto-
kine mix and penicillin/streptomycin the cells were cultured
in it for 5 d. Thereafter non-adherent cells were reseeded
and maintained for up to 21 d in StemSpan SFEM with 2%
penicillin/streptomycin, 20 ng/ml stem cell factor, 1 u/ml
erythropoietin and 5 ng/ml interleukin 3. At day 5, 2 lmol/l
dexamethasone and 1 lmol/l b-estradiol were added. DuringTa
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that time the cells progressed from pluripotent cells to pro-
erythroblasts, to basophilic and polychromatic erythroblasts
and finally, to normoblasts and enucleated reticulocytes
(Makhro et al, 2013). High performance liquid chromatogra-
phy (HPLC) was used to verify globin synthesis in fully dif-
ferentiated cells. The preferential production of HbA/A2 or
HbS in reticulocytes was measured in cells derived from the
CD34+ cells using HPLC (Figure S1). Expression of GRIN
genes was monitored in the course of differentiation of EPCs
(at days 6, 12 and 18 in culture) using TaqMan Gene
Expression Kits containing specific primers. Protein levels of
NMDAR subunits were assessed in EPCs using flow cytome-
try. CD45 (Anti-CD45 peridinin chlorophyll [PerCP], clone
2D1, BD, San Jose, CA, USA) was used as a WBC marker
and CD71 (clone M-A712 fluorescein isothiocyanate [FITC]-
conjugated, BD, San Jose, USA) as reticulocyte marker.
Abundance of the NMDAR subunits GluN2C (anti-NMDAe3
(NR2C), goat polyclonal IgG, sc-1470); GluN2D (anti-
NMDAe4 (NR2D), mouse monoclonal IgG, sc-178221);
GluN3A (anti-NR3A (NR3A), goat polyclonal IgG sc-51160)
was measured in EPCs at various stages of differentiation.
Stained cells were fixed with 1% formaldehyde and fluores-
cence intensity was measured using the BD Biosciences FAC-
SCalibur flow cytometer (BD Biosciences, San Jose, USA).
Memantine toxicity was probed for the EPCs of healthy
donors and SCD patients after 6, 12 or 18 d in culture. Cells
were exposed to 001–1 mmol/l memantine for 24 h and cell
mortality monitored by flow cytometry, using propidium
iodide (PI) nuclear staining.
Statistical analysis
The data obtained were analysed using GraphPad Instat v.30
(GraphPad Software, Inc., La Jolla, CA) and presented as
means  standard error of the mean (SEM) if not stated
otherwise. Statistically significant differences were assessed
using a one-way analysis of variance (ANOVA) test with the
Bonferroni post-test, when a normal distribution test was
passed, or, if normal distribution was not confirmed, with a
Kruskal Wallis test with Dunn’s post-test and accepted at
P < 005. Pearson product-moment correlation coefficients
were used to assess covariance between the NMDAR activity
in RBC fractions and the appearance of blood markers of
haemolytic events.
Results
Presence and activity of NMDARs in circulating RBCs of
SCD patients during stable periods and in crises
Immunoblotting was used to assess the protein levels of the
obligatory GluN1 subunit in membrane fractions prepared
from light (L), medium (M) and dense (D) fractions of
RBCs of healthy people and SCD patients (Fig 1A). The L
fractions of both healthy and SCD-RBCs were enriched with
young cells and reticulocytes as follows from cytological
estimation using Sysmex (182  82& reticulocytes
(mean  standard deviation [SD]) in healthy human sam-
ples and 243& in the SCD sample shown in Fig 1B) and the
(A) (B)
(C)
Fig 1. The abundance and activity of NMDARs is altered in the RBCs of SCD patients compared to that in the cells of healthy humans. (A) Sep-
aration of RBCs from a healthy donor (HbA) and SCD patient (HbS) into the light (L), medium (M) and dense (D) fractions on Percoll gradient
and protein 41a/b ratio in cells forming the L, M and D fraction of the SCD patient. (B) Relative abundance of GluN1 subunit protein in the
membranes of RBCs forming the L, M and D fraction of a healthy subject (HbA) and a SCD patient (HbS) with or without pre-treatment with
memantine (100 lmol/l, 1 h) and in rat cerebellar protein extract. (C) The number of active NMDARs per cell in RBCs of L, M and D fractions
of SCD patients during asymptomatic periods and during crises. The means  SEM for 9 patients are shown. Circles denote individual values.
NMDAR, N-methyl D-aspartate receptor; SCD, sickle cell disease; RBCs, red blood cells.
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band 41a/b ratio (Fig 1A). For SCD-RBCs the L fraction
was highly enriched with GluN1 and showed higher receptor
activity per cell in RBCs (Fig 1B and Table II). The receptor
activity in all fractions of the RBCs of asymptomatic SCD
patients exceeded that in cells of healthy donors by 50% and
more (Table II). Notably, HC treatment had no effect on the
receptor function in SCD-RBCs (Table II). The number of
active receptors per cell was similar in RBCs of homozygous
HbSS patients and those presented with compound HbS-b
thalassaemia (data not shown). Activity of the NMDARs in
the L-fraction of SCD-RBCs increased substantially during
the crises compared to the asymptomatic values (Fig 1C).
Furthermore, the activity of NMDARs in SCD-RBCs
appears to be intimately related to the severity of patients’
condition. Up-regulation of the NMDAR activity of mature
SCD-RBCs forming the M fraction correlated negatively with
haemoglobin and haematocrit levels and positively with
plasma lactate dehydrogenase (LDH) and C-reactive protein
content (Fig 2). These observations suggest that hyper-activa-
tion of NMDARs was associated with onsets of haemolytic
events. Furthermore, receptor activity in cells forming frac-
tions L (younger cells) and D (terminally dehydrated cells)
correlated positively with neutrophil counts in blood (data
not shown). It is noteworthy that all patients studied showed
only mild neutrophilia and neutrophil counts did not exceed
12–14 9 109/l.
Effect of NMDAR agonists and antagonists on
intracellular Ca2+ levels, cell volume and ion content
The role of the NMDAR activation state in the maintenance
of intracellular Ca2+ levels, RBC volume and redox state was
explored ex vivo.
RBCs of SCD patients loaded with the calcium-sensitive
dye fluo-4 AM responded to treatment with the agonists
NMDA and glycine (300 and 100 lm respectively), with an
acute temporary increase in intracellular Ca2+. Exposure of
the SCD-RBCs to memantine (50 lmol/l) caused a modest
decrease in Ca2+-sensitive fluorescence (Fig 3A,C, Figures S2
and Supplementary Animated Figures S3-S8). Uptake of Ca2+
triggered the activation of Ca2+-sensitive Gardos channels,
K+ loss, and cell shrinkage. Passive K+ flux through the
membranes of SCD-RBCs substantially exceeding that in
the RBCs of healthy humans could be further facilitated by
the NMDAR agonists, and partially suppressed by the recep-
tor antagonist memantine (Fig 3B). Inhibition or stimulation
Table II. NMDAR activity in light, medium and dense fractions of RBCs of healthy people and SCD patients off or on hydroxycarbamide
treatment.
Fraction Healthy subjects (n = 31) SCD patients Off-HC (n = 11) SCD patients On-HC (n = 6)
Light (L) 349  75 69  11** 72  17**
Medium (M) 41  07 22  6*** 16  3***
Dense (D) 43  06 30  11*** 12  2***
NMDAR, N-methyl D-aspartate receptor; SCD, sickle cell disease; HC, hydroxycarbamide.
**Denotes P < 001 and ***stands for P < 0001 when compared with healthy control subjects.
(A) (B)
(C) (D)
Fig 2. Correlation between the NMDAR
activity in the M fraction of SCD-RBCs and
markers of haemolysis [haemoglobin (A),
haematocrit (B) and lactate dehydrogenase in
plasma (C) and inflammation [C-reactive
protein (D)]]. Covariance analysis of the
receptor activity and the markers of haemolysis
and inflammation was performed using
Pearson product-moment correlation coeffi-
cients for the 34 blood samples taken from 16
patients on different occasions during
asymptomatic periods and during haemolytic
crises. HB, haemoglobin, Hct, haematocrit;
LDH, lactate dehydrogenase; CRP, C-reactive
protein.
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of the NMDARs resulted in the re-distribution of RBCs in
Percoll gradient. Interestingly, the cells containing more
receptors underwent dehydration as soon as they were
exposed to shear stress while passing through the Percoll, as
follows from Fig 1B. These GluN1-enriched cells moved
down the Percoll gradient to the D fraction. In line with this
observation, filtration of RBCs through the cellulose column
was associated with an increase in the NMDAR activity
detected using 3H-MK-801 binding assay (data not shown).
Dehydration induced by passing through the Percoll gradient
could be abolished by the pre-treatment of blood samples
with memantine prior to the separation. Memantine-treated
cells showed a maximum of GluN1 levels associated with the
L fraction, whereas the D fraction was almost deprived of
GluN1 (Fig 1B).
Incubation of whole blood from asymptomatic SCD
patients with NMDA resulted in further dehydration of cells,
which were then shifted down the gradient (Fig 3D). Treat-
ment of blood with memantine, on the other hand, induced
re-hydration and a corresponding upward shift within the
Percoll gradients (Fig 3D). Monitoring of the kinetics of the
morphological responses to the stimulation of the NMDARs
in SCD-RBCs in the absence or presence of memantine was
performed microscopically. The cells were pre-incubated with
saturating concentrations of glutamate and glycine with or
without memantine in a Ca2+-free medium. During the
recording, Ca2+ (final concentration 1.8 mM) was adminis-
tered to the medium and the changes in cellular morphology
monitored over 12 min. The corresponding Supplementary
Animated Figures S3-S8, can be viewed online in the supple-
mentary section. These video files show substantial reduction
or complete abolishment of echinocytic transformation in
the cells pre-treated with memantine before exposure to cal-
cium.
The oxidative stress characteristic of SCD-RBCs was moni-
tored as a four-fold increase in the intracellular oxidized glu-
tathione (GSSG) levels over the GSSG content of RBCs in
healthy human subjects. Further accumulation of GSSG was
observed upon stimulation of NMDARs in SCD-RBCs with
NMDA. Inhibition of the NMDARs with memantine pre-
vented an oxidative burst triggered by NMDA (Fig 3E).
NMDARs and sickle cell transformation caused by
deoxygenation
Polymerization of deoxygenated HbS was induced ex vivo by
equilibration of SCD-RBCs with a humidified gas phase con-
taining 5% CO2 and 05% O2 in Eschweiler tonometers.
These oxygen levels have been recorded in some areas in the
brain (Erecinska & Silver, 2001). Cells exposed to a gas phase
supplemented with 15% O2 served as the normoxic control,
mimicking pO2 in human lungs under normoxic conditions
(133 kPa). At the onset of deoxygenation, the NMDARs in
SCD-RBCs were either stimulated with NMDA (300 lmol/l)
and glycine (100 lmol/l) or suppressed with memantine
(50 lmol/l). Following 2 min of equilibration with the gas
phase, the cells were incubated under normoxic or hypoxic
conditions for 15 min. Thereafter RBC morphology (Fig 4A–
D,F,G and Figure S2), intracellular Ca2+ (Fig 4E) and the
intracellular ion content (Fig 4H) were assessed.
Deoxygenation of SCD-RBCs resulted in characteristic
alterations in cell morphology, including the formation of
drepanocytes (indicated with arrows in Fig 4B,C), “holy leaf”,
and “granular” cells (Figure S2C) and echinocytes (Fig 4 and
Figure S2C). Quantitatively, these changes were assessed as an
increase in anisotropy (Fig 4G, Figure S2A). Intracellular Ca2+
accumulation was induced by deoxygenation, as exemplified
in Fig 4B–D and quantified in Fig 4E. Intake of Ca2+ trig-
gered loss of K+ (Fig 4H) and a decrease in cellular projection
areas, signifying dehydration and shrinkage (Fig 4F, Fig S2B).
The presence of extracellular Ca2+ was critical for initiating
Ca2+-driven dehydration which in turn facilitated polymeriza-
tion of deoxy-HbS (Figure S2A). Chelation of the intracellular
Ca2+ with 1,2-bis(o-aminophenoxy)ethane-N,N,N0,N0-
tetraacetic acid (BAPTA) in addition to omission of the extra-
cellular Ca2+ further reduced sickling and shrinking of hyp-
oxic SCD-RBCs (Figure S2A).
Polymerization rate of deoxy-HbS is inversely related to
the Hb concentration to an extremely high power (Hebbel,
2009). Stimulation of the NMDARs with NMDA and glycine
aggravated the morphological changes induced by deoxygen-
ation, including impressive induction of echinocytosis and
RBC fragmentation (Fig 4D). Potassium loss from the oxy-
genated agonists’-treated SCD-RBCs reached its maximum
and could not be further stimulated by hypoxia (Fig 4H).
Some of the cells were showing signs of irreversible HbS
polymerization (“holy leaf” appearance) even under normox-
ic conditions (Figure S2C). Memantine administration effec-
tively prevented hypoxia-induced sickling and echinocytosis
(Fig 4C,G). A decrease in Ca2+ uptake by deoxygenated cells
was observed upon memantine treatment followed by the
suppression of hypoxia-induced K+ loss and dehydration
(Fig 4H and F respectively).
Subunit composition of NMDARs and their expression in
erythroid precursor cells of patients (SCD-EPCs)
Previously we explored the expression profile of GRIN genes
in EPCs derived from healthy human blood (Makhro et al,
2013). A similar approach was used to monitor the presence
of transcripts of GRIN genes and changes in protein levels of
all subunits of the NMDARs in SCD-EPCs. Pluripotent
mononuclear cells were isolated from the peripheral blood of
healthy subjects and patients. These cells were cultured to
obtain pro-erythroblasts (day 6), basophilic and polychro-
matic erythroblasts (day 12) or normoblasts and enucleated
reticulocytes (day 18). Expression profiles obtained for the
transcripts of GRIN1, GRIN2A, GRIN2C, GRIN2D, GRIN3A
and GRIN3B in SCD-EPCs at each differentiation stage are
shown in Fig 5. The expression of GRIN1 and GRIN2C tran-
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(A)
(C)
(D) (E)
(B)
Fig 3. Intracellular Ca2+ and oxidized glutathione levels, cell density, and residual K+ flux in SCD-RBCs upon activation (300 lmol/l glutamate
and 100 lmol/l glycine) or inhibition (100 lmol/l memantine) of the NMDARs. (A) Kinetics of changes in the intracellular Ca2+ in SCD-RBCs
(fluorescence intensity at each time-point (F) normalized to the average signal intensity at time zero (Fo)). Number of cells analysed per time
point ranges from 24 to 42. * denotes P < 005 and ** stands for P < 001 when compared to the signal at time zero. (B) Chloride-independent
ouabain-insensitive unidirectional K+ influx into the RBCs of healthy humans and SCD patients. ** indicates P < 001 when fluxes were com-
pared between the HbA and HbS-RBCs under the same conditions. Data are means of six independent experiments  SD. ## denotes P < 001
for the K+ fluxes in SCD-RBCs treated with either memantine or NMDA/Gly. (C) Representative experiments showing the alterations in Ca2+-
sensitive fluo-4 fluorescent signal intensity in response to NMDA/Gly or memantine treatment quantified in panel A. (D) Distribution of SCD-
RBCs in Percoll gradient after pre-treatment of whole blood with either 300 lmol/l NMDA or 100 lmol/l memantine. Numbers below the
images indicate the corresponding haematocrit values. (E) Oxidized glutathione (GSSG) content of RBCs exposed to agonists in the presence or
absence of memantine for 30 min. # denotes P < 005 compared to the values in the RBCs of healthy humans (HbA-control). *stands for
P < 005 compared to control levels in SCD-RBCs (HbS-control). NMDA, N-methyl D-aspartate; SCD, sickle cell disease; RBCs, red blood cells;
Gly, glycine.
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scripts in healthy subjects increased progressively during ex
vivo differentiation. Peak levels of GRIN2D transcripts were
found at the stage of basophilic and polychromatic
erythroblasts (12 d). In SCD-EPCs these stage-dependent
variations in expression levels of all GRIN genes were
blunted. No significant changes in NMDAR transcript levels
were detected during differentiation. Compared to healthy
controls, relative expression of GRIN3B was significantly
higher in SCD throughout erythropoiesis. Similar to those in
EPCs of healthy humans (Makhro et al, 2013), transcripts of
GRIN2B in EPCs obtained from SCD patients were below
the detection threshold at any differentiation stage.
(A) (A)
(E)
(F)
(G)
(H)
(B)
(C) (C)
(D) (D)
(B)
Fig 4. Responses of SCD-RBCs to deoxygenation in the presence of the NMDAR agonists (300 lmol/l NMDA/100 lmol/l glycine) and antagonist
(50 lmol/l memantine). RBCs in suspension were exposed to either 15% or 05% O2 in gas phase in Eschweiler tonometers (15 min, 37°C).
Shown are (A-D) the representative images of erythrocytes in different conditions, cell morphology and intracellular Ca2+ levels; (E) quantifica-
tion of the changes in the intracellular Ca2+ levels; (F) alterations in RBC projection area; (G) changes in anisotropy as a marker of sickle cell
transformation in deoxygenated SCD-RBCs and (H) changes in the intracellular K+ concentration. NMDA, N-methyl D-aspartate; SCD, sickle cell
disease; RBCs, red blood cells; Gly, glycine.
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Protein levels per cell and the number of cells expressing
GluN2C, 2D, 3A and 3B were assessed in EPCs during differ-
entiation. On average, the percentage of cells expressing the
NMDA subunits varied from c. 10% for pro-erythroblasts to
20–40% at the later differentiation stages, independent of the
presence of the HBB E6V mutation (HbS gene) (Fig 6A,C,D,
and E). The number of copies of the dominant GluN2D and
3B subunits per cell, expressed as the mean fluorescence inten-
sity, were the highest at the normoblastic stage (Figs 6D and
3B). A tendency towards an increased number of cells express-
ing GluN3A and 3B subunit in the EPCs of SCD patients was
observed at the stage of basophilic and polychromatic erythro-
blasts (Fig 6E and G). However, this tendency did not reach
statistical significance and was not preserved at the normoblas-
tic stage. All in all, the protein levels for all subunits at each
differentiation stage tested did not differ between the EPCs of
healthy humans and those of SCD patients. This observation
suggests that the striking enrichment of the circulating SCD-
RBCs with NMDARs resulted from the disturbed clearance of
the receptors from reticulocytes.
Sensitivity of the EPCs to memantine exposure was tested
as a function of antagonist concentration. As shown in Fig 7,
memantine was well-tolerated by both the EPCs of control
subjects and those of SCD patents within a pharmacologi-
cally relevant concentration range (1–50 lmol/l). At higher
concentrations (01–1 mmol/l) the highest mortality rate was
observed in control EPCs at the pro-erythroblast stage (6 d
in culture, Fig 7A). The EPCs of SCD patients showed maxi-
mal sensitivity to high doses of memantine only at the stage
of polychromatic erythroblasts (12 d in culture, Fig 7B),
being generally more tolerant to memantine than the cells of
healthy humans. Cell death was accompanied by characteris-
tic changes in morphology, including a high degree of vacuo-
lization and vesiculation (Fig 7C).
Discussion
The present study indicates that an abnormally great abun-
dance of functional NMDARs is characteristic of the circulat-
ing RBCs of SCD patients (Fig 1, Table II). Hyperactivation
of the NMDARs in RBCs was associated with the severity of
haemolytic events, as the number of active receptors in the
majority of cells forming M fraction correlated negatively
with haemoglobin/haematocrit levels and positively with
plasma LDH (Fig 2). Induction of HbS polymerization in
vitro by exposing the RBCs of SCD patients to low oxygen
(A) (B)
(C) (D)
(E) (F)
Fig 5. Expression of NMDAR subunits during
erythropoiesis. (A-F) relative amounts of the
different NMDAR isotypes (as indicated). Cells
were harvested and analysed at days 6, 12 and
18, transcripts were measured by TaqMan real
time polymerase chain reaction. Values are rep-
resented as box plots of 9 erythroid cultures
from healthy subjects (open boxes, n = 9) and
10 erythroid cultures from SCD (grey boxes,
n = 10), each started with cells from a different
donor. An overall comparison indicated signifi-
cant differences between days of culture only
for the expression of GRIN2C (P < 005) and
GRIN1 (P < 005).
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levels revealed that hypoxia-induced Ca2+ uptake, dehydra-
tion and the polymerization rate itself could be substantially
slowed down in the presence of the NMDAR antagonist me-
mantine (Fig 4). Activation of the NMDARs with NMDA
and glycine, on the other hand, could induce a complex cell
response resembling that occurring during crises, including
some sickle cell transformation Ca2+ uptake, K+ and water
loss and oxidative stress (Fig 3).
Taken together, all these findings suggest that inhibition
of the NMDARs may be beneficial as it hits multiple cal-
cium-sensitive targets, preventing the dehydration, sickling
and oxidation associated with haemolytic crises in SCD
patients (Bogdanova et al, 2013). The design of the present
ex vivo study did not allow testing for the long-term effects
of memantine supplementation on SCD-RBCs, such as
changes in calpain activity, or changes in the adherence of
SCD-RBCs to the endothelial layer. The lack of active
NMDARs in the circulating C57B6 mouse red blood cells
was documented by using [3H]MK-801 binding assay (A.
Makhro and A. Bogdanova, unpublished observations). This
observation limits us to the use of human cells in the future,
making mouse models of SCD useless for such a long-term
study.
We have previously shown that the number of NMDARs
and the amplitude of response to the stimulation of
NMDARs in the RBCs of healthy humans is particularly high
in the light fraction enriched with reticulocytes and young
cells (Makhro et al, 2013). Similarly, the number of copies of
GluN1 and the number of active receptors assessed as the
[3H]MK-801 binding sites per cell is maximal in the upper
light fraction of SCD-RBCs (Table II, Fig 1B, C). As reported
by Bookchin et al (1991), the reticulocytes of SCD patients
(A) (B)
(D)
(E)
(c)
(F)
(G) (H)
Fig 6. Protein levels of GluN2C, 2D, 3A and
3B in EPCs at various differentiation stages.
Shown are the numbers of cells in which fluo-
rescent signal from the corresponding antibod-
ies was detected by means of flow cytometry
(A, C, E, G) and the mean intensity of this sig-
nal per cell (B, D, F, H). Numbers above boxes
represent medians of the corresponding signal
in EPC cultures obtained from healthy control
subjects. Cells were harvested and analysed at
day 6, 12 and 18. Data were obtained from
cultures grown from CD34+ cells of four differ-
ent SCD patients (open boxes) and six healthy
subjects (grey boxes). EPCs, erythroid precur-
sors; AU, arbitrary units.
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show maximal susceptibility to dehydration and sickling.
This paradoxic predisposition of young cells to premature
clearance may be caused at least in part by higher susceptibil-
ity to calcium overload resulting from hyperactivation of
NMDARs.
Substantial up-regulation of NMDAR abundance and
activity in SCD-RBCs was observed in all RBC fractions,
being particularly high in the L fraction (Table II). A fur-
ther increase in the number of active receptors in the L
fraction of SCD-RBCs was detected in patients showing
symptoms of haemolytic crises manifested as a decrease in
haematocrit, and the onset of a pain crisis (Fig 1C). These
observations suggest that the greater abundance and activity
of NMDARs may be associated with the onset of crises.
Dissection of the factors involved in hyperactivation of the
NMDARs in RBCs of patients with SCD during the crisis is
of key importance. Plasma glutamate and glycine levels are
determinants of NMDAR activity in RBCs. Increased levels
of glycine and a c. 35-fold increase in the intraerythrocytic
levels of both agonists have been reported for SCD patients
during asymptomatic periods (Kiessling et al, 2000). No
data for plasma amino acid composition during crises are
currently available. One can expect that haemolysis would
be associated with the release of these excitatory amino
acids, resulting in progressive activation of the receptors in
RBCs.
Mechanisms that control NMDAR abundance in the RBCs
of SCD patients await further in-depth characterization,
which is beyond the scope of this study. Although relatively
high, the number of receptors per cell in circulating SCD-
RBCs is within the 102 range and is thus not comparable
with that in EPCs, which range from 105 to 103 receptor
copies per cell (Makhro et al, 2010, 2013). Terminal stages of
EPC differentiation are clearly associated with massive clear-
ance of the receptors from the plasma membrane. Even a
slight disturbance in clearance efficiency would result in sig-
nificant up-regulation of the number of NMDARs remaining
in membranes of circulating RBCs. The mechanisms involved
in clearance of NMDARs in EPCs have not yet been studied.
Unusually high levels of membrane-bound haemoglobin
resulting from its higher affinity to the cytosolic domain of
band 3 protein may at least partly explain the inclmplete
clearance of the receptors (Rotter et al, 2010).
The conductive pathway involved in the increased perme-
ability of the membranes of SCD-RBCs to cations, including
calcium ions, is known as Psickle. Analysis of the properties
and pharmacological profile of Psickle suggests that the current
is mediated by more than one channel type. Among the
hallmarks of Psickle are activation upon deoxygenation
(Browning et al, 2007; Vandorpe et al, 2010) and filtration
(shear stress) (Brain et al, 2004), permeability for K+, Na+
and Ca2+ (Bookchin & Lew, 1981), sensitivity to Zn2+ and
(A)
(C)
(B)
Fig 7. Memantine and MK-801 toxicity studies
performed for healthy human-derived EPCs
and SCD-EPCs at days 6, 12 and 18 in culture.
The EPCs were exposed to memantine added
to the culturing medium at concentrations of
10 lmol/l-1 mmol/l for 24 h (A,B). Thereafter
the cells were harvested and mortality assessed
using propidium iodide staining. Data are the
means of four cultures obtained from four
independent healthy subjects or HbSS
patients  SD. (C) SCD-EPCs were treated
with 05 mmol/l MK-801 for 12 h at the vari-
ous differentiation stages. Vacuolization is
present at days 14 and 19 and indicates apop-
tosis. Cells at the early stage of erythropoiesis
(day 10) are less sensitive to MK-801 treatment
and mature RBCs (day 21) are completely
resistant. SCD, sickle cell disease; EPCs,
erythroid precursors.
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stilbene disulfonate (DIDS) (Joiner, 1990; Browning et al,
2007), voltage- and pH-dependence (Joiner et al, 1993).
These properties are shared by NMDARs. We have demon-
strated that NMDAR function in the RBCs of SCD patients
is oxygen-dependent (Fig 4). Sensitivity to 4,40- diisothiocy-
anostilbene-2,20-disulfonic acid (DIDS) (Tauskela et al, 2003)
and voltage-dependence were demonstrated in the NMDARs
in neurons. Sensitivity of NMDARs to Zn2+ appears to be
particularly interesting in view of reports that 1 year of zinc
sulphate supplementation was found to reduce the incidence
of pain crises and infections in SCD patients in several clini-
cal trials (Swe et al, 2013). Whether this beneficial action of
Zn2+ is, at least in part, mediated by suppression of the
NMDARs remains to be confirmed.
We have demonstrated the sensitivity of NMDARs in
SCD-RBCs to filtration as a manifestation of shear stress
(Fig 1B, and text). These receptors have been shown to be
mechano-sensitive (Paoletti & Ascher, 1994; Singh et al,
2012). Other features of Psickle, such as sensitivity to Gd
3+,
CO and to a toxin produced by the tarantula spider GsMTx-
4 (Vandorpe et al, 2010) have not been tested for NMDARs.
NMDAR function is known to be highly sensitive to changes
in pH, but the optimal pH range for the NMDARs in the
brain differs from that of Psickle. These are the indications
that Cav21 channels and voltage-dependent anion channels
(VDACs) may contribute to Psickle along with NMDARs, each
responding to a characteristic set of stimuli related to stress
and inflammation (Kaestner, 2011).
Our observations clearly show that the inhibition of
NMDARs hits multiple targets in RBCs. In addition, meman-
tine has recently been reported to effectively suppress neuro-
pathic pain after surgery (Morel et al, 2013). Failure to
reduce the number and severity of acute pain episodes was
the reason for the negative outcome of several trials in which
a Gardos channel blocker, the anti-adhesion drug poloxamer
188, and inhaled nitric oxide were used in treatment of
patients with SCD (Gee, 2013). A combination of the pre-
vention of haemolytic crises and reduction in vaso-occlusive
events with potential effective pain management makes
memantine an attractive candidate for therapy of SCD.
The number of patients with SCD is growing rapidly in Swit-
zerland and other European countries due to the increasing
flow of migrants from Africa and Asia to Europe (Schmugge
et al, 2008). Currently, most of the SCD patients in Switzerland
are children. Moreover, when proven efficient in treatment of
SCD, calcium-lowering therapy could be extended for treat-
ment of other types of rare hereditary forms of anaemia associ-
ated with abnormal intracellular Ca2+ levels, such as
thalassaemia, phosphofructokinase deficiency and others.
Authorship
P.H. and O.S. performed research shown in Figs 5–7; A.M.
produced data for the Figs 1 and 3A,C,D and Table II; A.B.
generated data for Figs 3C, 4, and Figures S2 and animation
figures; J.S.G. and M.S. provided blood and information on
the SCD patients. J.S.G. produced the data shown in Fig 2.
All authors contributed to data analysis, discussion and writ-
ing of the manuscript.
Acknowledgements
This study was supported by a ZIHP cooperative grant (to
J.S.G, O.S. and A.B.), funded by the European Community’s
Seventh Framework Programme (FP7/2007-2013) under Grant
Agreement No. 602121, the CTI/Lyfjos GmbH grant and the
Vontobel Foundation (to A.B.), and supported by the Hart-
mann M€uller-Stiftung (to O.S.). The authors state that there is
no conflict of interests to disclose. We gratefully acknowledge
technical assistance of Nikolay Bogdanov and cordially thank
Dr Heather Murray for careful proof-reading and language
editing.
Supporting Information
Additional Supporting Information may be found in the
online version of this article:
Data S1. Subject and methods.
Fig S1. Quantification of HbA, HbF, HbA1C, HbA2 and
HbS of the total haemoglobin at reticulocyte stage of eryth-
ropoietic maturation (day 21).
Fig S2. The role of intra- and extracellular Ca2+ in facili-
tation of HbS polymerisation and SCD-RBC shrinkage.
Fig S3. Experiment 1 Control: HbSS control 1 BF (bright
field)/HbSS control 1 Ca (green channel).
Fig S4. Experiment 2 Control: HbSS control 2 BF (bright
field)/HbSS control 2 Ca (green channel).
Fig S5. Experiment 3 Control HbSS control 3 BF (bright
field)/HbSS control 3 Ca (green channel).
Fig S6. Experiment 1 Memantine-pretreated cells: HbSS
memantine 1 BF (bright field)/HbSS memantine 1 Ca (green
channel).
Fig S7. Experiment 2 Memantine-pretreated cells: HbSS
memantine 2 BF (bright field)/HbSS memantine 2 Ca (green
channel).
Fig S8. Experiment 3 Memantine-pretreated cells: HbSS
memantine 3 BF (bright field)/HbSS memantine 3 Ca (green
channel).
References
Ataga, K.I. & Stocker, J. (2009) Senicapoc (ICA-
17043): a potential therapy for the prevention
and treatment of hemolysis-associated complica-
tions in sickle cell anemia. Expert Opinion on
Investigational Drugs, 18, 231–239.
Bogdanova, A.Y., Ogunshola, O.O., Bauer, C. &
Gassmann, M. (2003) Pivotal role of reduced glu-
tathione in oxygen-induced regulation of the Na
(+)/K(+) pump in mouse erythrocyte membranes.
Journal of Membrane Biology, 195, 33–42.
Bogdanova, A., Makhro, A., Wang, J., Lipp, P. &
Kaestner, L. (2013) Calcium in red blood cells-a
NMDA Receptors in RBCs of Sickle Cell Disease Patients
ª 2014 The Authors. British Journal of Haematology published by John Wiley & Sons Ltd. 263
British Journal of Haematology, 2014, 167, 252–264
perilous balance. International Journal of Molecu-
lar Sciences, 14, 9848–9872.
Bookchin, R.M. & Lew, V.L. (1981) Effect of a
‘sickling pulse’ on calcium and potassium trans-
port in sickle cell trait red cells. Journal of Physi-
ology, 312, 265–280.
Bookchin, R.M., Ortiz, O.E. & Lew, V.L. (1991)
Evidence for a direct reticulocyte origin of dense
red cells in sickle cell anemia. Journal of Clinical
Investigation, 87, 113–124.
Brain, M.C., Pihl, C., Robertson, L. & Brown, C.B.
(2004) Evidence for a mechanosensitive calcium
influx into red cells. Blood Cells, Molecules, &
Diseases, 32, 349–352.
Browning, J.A., Staines, H.M., Robinson, H.C.,
Powell, T., Ellory, J.C. & Gibson, J.S. (2007) The
effect of deoxygenation on whole-cell conduc-
tance of red blood cells from healthy individuals
and patients with sickle cell disease. Blood, 109,
2622–2629.
Chandrakasan, S. & Malik, P. (2014) Gene Ther-
apy for Hemoglobinopathies: the State of the
Field and the Future. Hematology/oncology Clin-
ics of North America, 28, 199–216.
De Franceschi, L., Franco, R.S., Bertoldi, M.,
Brugnara, C., Matte, A., Siciliano, A., Wiesch-
haus, A.J., Chishti, A.H. & Joiner, C.H. (2013)
Pharmacological inhibition of calpain-1 prevents
red cell dehydration and reduces Gardos channel
activity in a mouse model of sickle cell disease.
FASEB Journal, 27, 750–759.
Eaton, W.A. & Hofrichter, J. (1990) Sickle cell
hemoglobin polymerization. Advances in Protein
Chemistry, 40, 63–279.
Erecinska, M. & Silver, I. (2001) Tissue oxygen
tension and brain sensitivity to hypoxia. Respira-
tion Physiology, 128, 263–276.
Gee, B.E. (2013) Biologic complexity in sickle cell
disease: implications for developing targeted ther-
apeutics. ScientificWorldJournal, 2013, 694146.
George, A., Pushkaran, S., Konstantinidis, D.G.,
Koochaki, S., Malik, P., Mohandas, N., Zheng,
Y., Joiner, C.H. & Kalfa, T.A. (2013) Erythrocyte
NADPH oxidase activity modulated by Rac
GTPases, PKC, and plasma cytokines contributes
to oxidative stress in sickle cell disease. Blood,
121, 2099–2107.
Hebbel, R.P. (2009) Chapter 42 Pathobiology of
sickle cell disease. In: Hematology. Basic Princi-
ples and Practice. (ed. by Hoffma, R., Benz, E.J.,
Shattil, S.J., Furie, B., Silberstein, L.E., McGlave,
P. & Heslop, H.), pp. 565–576. Churchill Living-
stone Elsevier, Philadelphia, PA.
Hebbel, R.P., Yamada, O., Moldow, C.F., Jacob,
H.S., White, J.G. & Eaton, J.W. (1980) Abnor-
mal adherence of sickle erythrocytes to cultured
vascular endothelium: possible mechanism for
microvascular occlusion in sickle cell disease.
Journal of Clinical Investigation, 65, 154–160.
Joiner, C.H. (1990) Deoxygenation-induced cation
fluxes in sickle cells: II. Inhibition by stilbene di-
sulfonates. Blood, 76, 212–220.
Joiner, C.H., Morris, C.L. & Cooper, E.S. (1993)
Deoxygenation-induced cation fluxes in sickle
cells. III. Cation selectivity and response to pH
and membrane potential. American Journal of
Physiology, 264, C734–C744.
Kaestner, L. (2011) Cation channels in erythrocytes -
historical and future perspective. The Open
Biology Journal, 4, 27–34.
Kiessling, K., Roberts, N., Gibson, J.S. & Ellory,
J.C. (2000) A comparison in normal individuals
and sickle cell patients of reduced glutathione
precursors and their transport between plasma
and red cells. Hematology Journal, 1, 243–249.
Locatelli, F., Kabbara, N., Ruggeri, A., Ghavam-
zadeh, A., Roberts, I., Li, C.K., Bernaudin, F.,
Vermylen, C., Dalle, J.H., Stein, J., Wynn, R.,
Cordonnier, C., Pinto, F., Angelucci, E., Socie,
G., Gluckman, E., Walters, M.C., Rocha, V. &
Eurocord, European, B. & Marrow Transplanta-
tion, g. (2013) Outcome of patients with hemo-
globinopathies given either cord blood or bone
marrow transplantation from an HLA-identical
sibling. Blood, 122, 1072–1078.
Lutz, H.U., Stammler, P., Fasler, S., Ingold, M. &
Fehr, J. (1992) Density separation of human red
blood cells on self forming Percoll gradients:
correlation with cell age. Biochimica et Biophysi-
ca Acta, 1116, 1–10.
Makhro, A., Wang, J., Vogel, J., Boldyrev, A.A.,
Gassmann, M., Kaestner, L. & Bogdanova, A.
(2010) Functional NMDA receptors in rat ery-
throcytes. American Journal of Physiology. Cell
Physiology, 298, C1315–C1325.
Makhro, A., Hanggi, P., Goede, J.S., Wang, J., Bru-
ggemann, A., Gassmann, M., Schmugge, M., Ka-
estner, L., Speer, O. & Bogdanova, A. (2013) N-
methyl D-aspartate (NMDA) receptors in
human erythroid precursor cells and in circulat-
ing red blood cells contribute to the intracellular
calcium regulation. American Journal of Physiol-
ogy. Cell Physiology, 305, C1123–C1138.
Manwani, D. & Frenette, P.S. (2013) Vaso-occlu-
sion in sickle cell disease: pathophysiology and
novel targeted therapies. Blood, 122, 3892–3898.
Mohandas, N. & Evans, E. (1985) Sickle erythro-
cyte adherence to vascular endothelium. Mor-
phologic correlates and the requirement for
divalent cations and collagen-binding plasma
proteins. Journal of Clinical Investigation, 76,
1605–1612.
Morel, V., Etienne, M., Wattiez, A.S., Dupuis, A.,
Privat, A.M., Chalus, M., Eschalier, A., Daulhac,
L. & Pickering, G. (2013) Memantine, a promis-
ing drug for the prevention of neuropathic pain
in rat. European Journal of Pharmacology, 721,
382–390.
Paoletti, P. & Ascher, P. (1994) Mechanosensitivity
of NMDA receptors in cultured mouse central
neurons. Neuron, 13, 645–655.
Paoletti, P., Bellone, C. & Zhou, Q. (2013) NMDA
receptor subunit diversity: impact on receptor
properties, synaptic plasticity and disease. Nat-
ure Reviews Neuroscience, 14, 383–400.
Rotter, M.A., Chu, H., Low, P.S. & Ferrone, F.A.
(2010) Band 3 catalyzes sickle hemoglobin poly-
merization. Biophysical Chemistry, 146, 55–59.
Schmugge, M., Speer, O., Ozsahin, A.H. & Martin,
G. (2008) Die Sichelzellerkrankung in der
Schweiz. Teil 1: pathophysiologie, Klinik.
Schweiz Med Forum, 8, 582–586.
Singh, P., Doshi, S., Spaethling, J.M., Hockenberry,
A.J., Patel, T.P., Geddes-Klein, D.M., Lynch,
D.R. & Meaney, D.F. (2012) N-methyl-D-aspar-
tate receptor mechanosensitivity is governed by
C terminus of NR2B subunit. Journal of Biologi-
cal Chemistry, 287, 4348–4359.
Swe, K.M., Abas, A.B., Bhardwaj, A., Barua, A. &
Nair, N.S. (2013) Zinc supplements for treating
thalassaemia and sickle cell disease. Cochrane
Database Systematic Review, 6, CD009415.
Tauskela, J.S., Mealing, G., Comas, T., Brunette,
E., Monette, R., Small, D.L. & Morley, P. (2003)
Protection of cortical neurons against oxygen-
glucose deprivation and N-methyl-D-aspartate
by DIDS and SITS. European Journal of Pharma-
cology, 464, 17–25.
Tietze, F. (1969) Enzymic method for quantitative
determination of nanogram amounts of total
and oxidized glutathione: applications to mam-
malian blood and other tissues. Analytical Bio-
chemistry, 27, 502–522.
Tiffert, T., Bookchin, R.M. & Lew, W.L. (2003)
Calcium homeostasis in normal and abnormal
human red cells. In: Red Cell Membrane trans-
port in Health and Disease (eds by Bernhardt, I.
& Ellory, J.C.), pp. 373–405. Springer, Berlin.
Vandorpe, D.H., Xu, C., Shmukler, B.E., Otterbein,
L.E., Trudel, M., Sachs, F., Gottlieb, P.A.,
Brugnara, C. & Alper, S.L. (2010) Hypoxia acti-
vates a Ca2+-permeable cation conductance sen-
sitive to carbon monoxide and to GsMTx-4 in
human and mouse sickle erythrocytes. PLoS
ONE, 5, e8732.
P. H€anggi et al
264 ª 2014 The Authors. British Journal of Haematology published by John Wiley & Sons Ltd.
British Journal of Haematology, 2014, 167, 252–264
88 
 
6. Discussion 
6.1. More than memory formation - Plasticity of NMDAR in 
erythroid cells 
We have shown the expression of NMDARs in EPCs and their presence in RBCs of 
healthy human subjects. During erythropoietic maturation, the number of functional 
receptors decreased from several hundred thousand to 15-30 per cell in fully 
differentiated RBCs. 3 These findings strongly suggest that NMDARs are not only 
essential for memory formation and synaptic plasticity in neurons, but also important 
for hematopoietic cells, along with platelets, leucocytes, megakaryocytes, and 
osteoclasts. 172,174,274,275,348-350 
The data obtained for mRNA and protein expression of the different GluN subunits 
indicate that the subunit composition of the erythroid NMDAR differs strongly from that 
in neurons. The mRNA expression patterns showed the presence of GRIN genes` 
transcripts for each known NMDAR subunit, except for GRIN2B. Maximal expression 
levels were observed for the GRIN2C and GRIN2D transcripts. The expression of 
GluN1, GluN2C, GluN2D, GluN3A and GluN3B could be confirmed on protein level by 
means of flow cytometry and western blotting. The expression pattern suggests that 
the EPCs, from the stage of polychromatic erythroblasts, possess a slow deactivating 
receptor with low conductance. These characteristics would even be enhanced by the 
co-expression of the dominant negative subunits GluN3A and Glu3B. 215,219 
Nonetheless, the characterization at the molecular level is not sufficient to clarify the 
subunit composition and the functional properties of the NMDARs in erythroid cells. 
The relatively low expression levels of GRIN1 and GluN1 respectively, indicates a 
structure with only one instead of the two “obligatory” GluN1 subunits. 196 Furthermore, 
the sensitivity to channel blockers, including magnesium, MK-801, and Memantine, is 
expected to be low compared to the “classic” neuronal NMDARs. 231 Therefore, studies 
on the functional level were required to investigate the properties of those receptors. 
We were able to demonstrate the presence of functional receptors in EPCs and 
circulating RBC. Our studies showed that NMDAR activation caused enhanced Ca2+ 
influx in erythroid cells. Even more substantial was the finding of the functional plasticity 
of NMDAR during erythropoietic maturation. The alteration of the functional properties 
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(conductance, deactivation time, and Ca2+ uptake) reflected the changes in the mRNA 
expression pattern (Figure 9). 351 
 
Figure 9: Schematic summary on the functional plasticity of the NMDAR during human 
erythropoietic maturation. GluN2A-containing NMDAR (red) is involved together with EpoR and TRPC 
in the regulation of cell survival and differentiation of early stage erythropoietic precursor cells 
(proerythroblasts and basophilic erythroblasts). During further maturation, the alteration of the 
expression pattern, the current properties and the reduced Ca2+ influx indicate a switch from a GluN2A-
containing receptor to a GluN2C/3B-containing receptor (green). In orthochromatic erythroblasts and 
reticulocytes, GluN2C/3B-containing receptor is more likely to participate in the final part of 
differentiation and the regulation of Ca2+ homeostasis. 351 
 
Proerythroblasts and basophilic erythroblasts with the highest GRIN2A expression 
exhibited typical current properties of the GluN2A containing receptor. 221 At this stage 
of maturation, the Epo-driven Ca2+ signaling is essential for cell survival and 
differentiation. This suggests the existence of a complex interplay between EpoR, 
TRPC, and NMDAR for the mandatory enhanced Ca2+ influx in proerythroblasts and 
basophilic erythroblasts. 18,165,352 During ongoing differentiation with increasing 
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GRIN2C expression, the NMDA current properties changed to a GluN2C containing 
receptor. The switch to reduced conductance in polychromatic and orthochromatic 
erythroblasts correlated with the decrease in NMDA mediated Ca2+ influx, onset of 
hemoglobinization, iron kinetics, and the general remodeling of the membrane during 
differentiation. 201,353,354 Along the possible role of the NMDAR with low conductance 
in maturation, these receptors, together with VDACs, non-selective cation channel, and 
Cav2.1, presumably take part in the regulation of basal intracellular Ca2+. Especially 
the presence and the contribution of these channels to the regulation of cell volume, 
proteolysis, and redox balance control in circulating RBCs supports this 
hypothesis. 3,5,351,355 
Furthermore, complete blocking of the NMDAR resulted in apoptosis of nearly all 
proerythroblasts and basophilic erythroblasts. Polychromatic erythroblasts and 
orthochromatic erythroblasts with the “slow” NMDAR subtypes were significantly less 
sensitive to the inhibition. This further supports the hypothesis that a “fast” GluN2A 
containing receptor is participating in the regulation of cell survival of CFU-e cells, 
proerythroblasts, and basophilic erythroblasts.  
Experiments performed with erythroid cells of the same donor during repetitive blood 
sampling revealed a high degree of reproducibility in the expression patterns and 
functional properties of the erythroid NMDAR. However, within a group of donors, 
considerable inter-individual variability that presumably was driven by genetic and 
epigenetic variation was observed. Substantial inter-cellular heterogeneity was 
monitored in orthochromatic erythroblasts and reticulocytes. Inter-cellular and inter-
individual heterogeneity persisted when an assessment of glutamate sensitivity was 
performed in the sub-populations of the circulating RBCs. 3,5,351 These observations 
are of potential clinical significance for the prediction of the quality of blood conserves 
and the outcome of blood transfusion, as well as for analysis of abnormalities in 
erythropoiesis and RBC clearance. 355 The molecular mechanisms and the 
consequences of the inter-cellular and inter-individual variability in RBCs require 
further investigations. 
We have shown the presence of NMDARs in erythroid cells and their contribution to 
the regulation of intracellular Ca2+. 351 The functional plasticity of NMDAR in erythroid 
cells and the alteration of passive electrophysiological properties imply that ion 
channels and ion homeostasis are very dynamic processes during erythropoietic 
maturation. The interplay of all the different receptors and ion channels during 
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differentiation is probably highly complex and more detailed studies are required. The 
change from prevalent chloride currents to potassium and calcium currents during 
enuclation would be of special interest. Two main questions that remained unanswered 
are (i) the role of NDMARs in the control of EPC proliferation, survival and 
differentiation, and (ii) the molecular mechanisms in control of GRIN genes’ expression 
in these cells during their maturation into reticulocytes. 
The observed alterations in the expression levels of the GluN2A and 2C subunits are 
a part of complex and precisely controlled changes occurring in EPCs during 
differentiation. Unfortunately, our knowledge of the mechanism in control of the protein 
expression in differentiating EPCs is incomplete. Little information is available in the 
literature on the possible involvement of the key regulators of erythropoiesis at the 
stages from BFU-e onward, such as GATA1, SCL and FOG, in management of GRIN 
genes expression in any cell type. 356,357 However, analysis of the promoter region of 
the GRIN genes (using TESS, Transcriptional Element Search System, Perelman 
School of Medicine, University of Pennsylvania, US) indicate the existence of potential 
binding sites for several transcription factors that are essential to the survival of EPCs 
and the differentiation, including GATA-2, GATA-1, LMO2, p300, Pu.1, Sp1, and 
STAT5. Further studies are needed to clarify the contribution of these transcription 
factors to the regulation of NMDAR subunits in erythroid cells.  
Besides the transcriptional and posttranscriptional regulation, the detailed downstream 
signaling mechanisms of NMDAR activation was outside of the scope of this study. 
Nevertheless, independent from the cell type, EpoR and NMDAR have similar targets, 
including PLC and PKC. 358,359 The regulation of the survival of the EPCs at the early 
differentiation stages is mediated by ERK1/2, Bcl-xL, and Epo-driven signaling. 360 In 
neuronal cells, ERK1/2 are downstream targets of the NMDAR. 361 This suggests that 
the regulation of cell survival and apoptosis is co-regulated by Epo signaling and 
GluN2A containing NMDARs at the early stages EPC differentiation. 
In addition to the regulation of the NMDARs and their downstream targets, another 
important aspect is the role of glutamate signaling for hematopoiesis. Glutamate is not 
only the most abundant excitatory neurotransmitter; it is also an important signaling 
molecule in the bone marrow. 173,174,274,362,363 This implies that transient fluctuation in 
serum glutamate levels influences erythropoiesis. We have shown that erythroid 
NMDAR gets deactivated after repetitive activation, and prolonged chronic activation 
did not induce apoptosis. The erythroid NMDAR is therefore protected against hyper-
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activation under physiological conditions. In contrast to this, circulating RBCs of SCD 
patients responded to hyper-activation with transient increase in Ca2+, cell shrinkage, 
and oxidative burst, which indicates the role of NMDAR in the pathophysiology of the 
anemic disorder. 5 
 
 
6.2. An old drug for young kids – the potential of Memantine 
for the treatment of sickle cell anemia 
Our studies indicated that sickle cell anemia patients have an abnormally high 
abundance of functional NMDARs in circulating RBCs. 5 This higher abundance in 
circulating erythrocytes was associated with hemolytic events. Furthermore, we 
showed ex vivo that activation of NMDARs induces massive transient Ca2+ uptake into 
the SCD-RBCs. These enhanced intracellular Ca2+ levels trigger openings of the 
Gardos channels, the loss of K+-Cl-, and dehydration. Additionally, the inhibition of the 
NMDARs by Memantine suppressed the formation of terminally sickled cells upon 
deoxygenation. These findings suggest that the inhibition of NMDARs in RBCs has 
beneficial effects on the pathophysiology of SCD and indicate that the receptor is a 
promising novel target for the treatment of several other rare anemias.  
We have shown that reticulocytes contain a higher number of NMDAR copies per cell 
and are more sensitive to the stimulation with agonists (NMDA or glutamate) than 
mature and senescent cells. These findings are consistent with higher susceptibility of 
young RBCs of SCD patients to dehydration. 3,364 The number of transcripts, the 
protein abundance of the GluN subunits, the conductance and the Ca2+ uptake 
mediated by the activation of the NMDARs decreased steadily during the final stages 
of EPC maturation. The higher number of functional receptor copies in reticulocytes 
and the disturbed clearance during differentiation might contribute to the predisposition 
of young cells and to premature removal from the circulation. 364 In all RBC fractions of 
SCD patients, the abundance and activity of the NMDARs was up-regulated. 
Particularly in the “light” fraction and within in hemolytic crises those parameters were 
further enhanced. This observation supports our hypothesis of the important role of 
NMDARs in the pathophysiology of sickle cell anemia.  
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Although GRIN3B mRNA expression was highly up-regulated in EPCs from SCD 
patients, this finding could not be confirmed on the protein level. However, SCD-EPCs 
exhibited lower sensitivity to the inhibition than EPCs from healthy subjects. An 
unpublished observation (Hänggi, 2014) indicates that higher abundance of the 
GluN3B rather than the number of receptor units per cell in EPCs of patients, may be 
the cause of this change in the receptors’ pharmacological properties. The discrepancy 
between the higher abundance of NMDAR in SCD patients’ RBCs, and the lack of 
difference in their abundance in the EPCs of healthy and diseased subjects is more 
likely to be attributed to the clearance of receptors than the higher number of receptors 
in EPCs. To clarify this hypothesis, voltage-clamp recordings are required. 
Our studies strongly suggest that erythroid NMDARs are a promising novel target for 
pharmacological intervention. The inhibition of the ion channel hits multiple 
downstream Ca2+-sensitive targets in RBCs. Due to the lack of any major side effects, 
low toxicity, and excellent pharmacological properties Memantine would be the best 
candidate for a first clinical trial, which is currently in preparation at the Clinic of 
Hematology at the University Hospital Zurich (USZ). The combination therapy of the 
non-competitive channel blocker with the allosteric modulator zinc might lead to 
significant improvements in the treatment of SCD progression. As evoked Ca2+ uptake 
in RBCs is one of the first and major steps in the pathophysiology, our new therapy 
approach is very promising (Figure 10). 
Moreover, if the clinical trial is successful, Memantine has the potential to be a 
therapeutic option for several other rare hereditary forms of anemia, including 
thalassemia and spherocytosis, in which an abnormally high number of NMDAR copies 
per RBC was detected (Makhro, Hänggi, Bogdanova unpublished observations). 
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Figure 10: Hypothetical mechanism of Memantine for the treatment of sickle cell anemia 
(Copyright of RBC images by Georgia Regents University, 2013). The open-channel blocker Memantine 
binds to the transmembrane loop of the NMDAR in RBC. Thereby, enhanced and pathological Ca2+ 
influx should be avoided. Without the critically high intracellular Ca2+ levels, the loss of K+-Cl-, 
dehydration, and irreversible sickle would be reduced. 
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7. Outlook 
The focus of the ongoing work will be on the approval of Memantine for the treatment 
of sickle cell anemia (Figure 11). We have shown the presence of NMDARs in 
circulating RBCs of healthy subjects and SCD patients and the clinical trial approval 
(CTA) was submitted to the Swiss health authorities (Swissmedic). 
 
Figure 11: Development plan for Memantine. Schematic overview of the development plan for 
Memantine as a novel treatment for sickle cell anemia. After the proof of concept (PoC) in a small 
number of patients (n ≤ 15), the effectiveness will be evaluated in a higher number of patients (n > 100). 
Exit point would be the out-licensing of Memantine after the successful completion of clinical phase IIb. 
 
After receiving the CTA for a combined CT phase I and IIa, we will evaluate the 
therapeutic potential of Memantine in a small number of patients (n ≤ 15 SCD patients). 
As the drug is already approved by Swissmedic for Alzheimer’s disease, it is possible 
to combine clinical trial phase I (first use in man) and phase IIa (first use in patient). 
Depending on whether, the proof of concept (safe and efficient drug) was shown in the 
small SCD patient cohort; this could be a first exit point for out-licensing. Nevertheless, 
the preferred exit point would be after successful completion of clinical trial phase IIb 
with a higher number of patients (n > 100) and therefore a substantial derisk for 
possible investors and out-licensing. Independent from the exit point, we would plan 
and organize the proof of effectiveness in patients (CT phase IIb) in Europe, either 
Great Britain and/or France.  
Besides the clinical trial, there are be several follow-up projects in the field of ion 
channels, hematopoiesis, and rare hereditary blood disorders. The focus of the first 
work package (listed in left panel of Figure 12) would be on NMDARs in erythroid cells. 
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To study the NMDARs on single channel level the replacement for several components 
of the patch clamp setup is required, including the air table, the microscope, and the 
pipette puller. The appropriate modifications allow detailed studies of the different 
NMDAR subtypes and their role in erythroid cells. Investigation of the downstream 
signaling cascade and the transcrtional regulation would be the part of the first work 
package as well. Furthermore, the validation of GluN2C/2D specific antagonist, might 
lead to a new therapeutic approach to target NMDRs highly specific in mature 
erythrocytes only. 
 
  
 
Figure 12: Work packages for follow-up studies. The follow-up studies/work packages of the PhD 
project would be in the field of NMDARs in erythroid cells, NMDARs in hereditary blood disorders, and 
erythropoietic maturation. 
 
The second work package (listed in middle panel of Figure 12) would be more related 
to SCD and other rare anemic disorder including α- and β-Thalassemia, and 
spherocytosis. The main deliverable from the second work package would be the 
validation of Memantine as a treatment for other hereditary rare anemic disorders.  
The third work package (listed in right panel of Figure 12) would focus on ion channels, 
the microenvironment of erythropoiesis, and their influence on hematopoiesis. Before 
the investigation of the glutamate signaling in ex vivo co-culture systems, the focus of 
this work package would be on the identification and role of the different ion channels 
during enucleation.  
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